
<html lang="en"     class="pb-page"  data-request-id="6d39ba24-2954-4784-99e4-9c9c00498fd5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2014.57.issue-15;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/jm500413g;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Development and Biological Evaluation of Potent and Selective c-KITD816V Inhibitors" /></meta><meta name="dc.Creator" content="Soyoung  Lee" /></meta><meta name="dc.Creator" content="Hyunseung  Lee" /></meta><meta name="dc.Creator" content="Jinhee  Kim" /></meta><meta name="dc.Creator" content="Suhyun  Lee" /></meta><meta name="dc.Creator" content="Soo Jung  Kim" /></meta><meta name="dc.Creator" content="Byong-Seok  Choi" /></meta><meta name="dc.Creator" content="Soon-Sun  Hong" /></meta><meta name="dc.Creator" content="Sungwoo  Hong" /></meta><meta name="dc.Description" content="The c-KIT tyrosine kinase has emerged as a potential therapeutic target for an array of diseases. However, there exists a drug resistance that is caused by mutations in c-KIT; therefore, c-KIT rema..." /></meta><meta name="Description" content="The c-KIT tyrosine kinase has emerged as a potential therapeutic target for an array of diseases. However, there exists a drug resistance that is caused by mutations in c-KIT; therefore, c-KIT rema..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 16, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm500413g" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm500413g" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm500413g" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm500413g" /></link>
        
    
    

<title>Development and Biological Evaluation of Potent and Selective c-KITD816V Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm500413g" /></meta><meta property="og:title" content="Development and Biological Evaluation of Potent and Selective c-KITD816V Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0019.jpeg" /></meta><meta property="og:description" content="The c-KIT tyrosine kinase has emerged as a potential therapeutic target for an array of diseases. However, there exists a drug resistance that is caused by mutations in c-KIT; therefore, c-KIT remains as a clinical challenge due to limited effective treatment options for therapies. For example, the acquired activating point mutation D816V significantly impairs the efficacy of targeted cancer therapies. Understanding the mechanisms of drug resistance at the molecular level will aid in designing and developing particular inhibitors with the potential to overcome these resistance mutations. We undertake a structure-based de novo design of 7-azaindole as the molecular core using the modified scoring function. This approach led to an identification of new c-KIT inhibitors over 100-fold specific for the D816V mutant relative to the wild-type c-KIT with nanomolar inhibitory activity. More importantly, these compounds potently inhibit clinically relevant D816V mutations of c-KIT in biochemical and cellular studies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm500413g"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm500413g">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm500413g&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm500413g&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm500413g&amp;href=/doi/10.1021/jm500413g" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 6428-6443</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm500390g" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm500434q" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Development and Biological Evaluation of Potent and Selective c-KIT<sup>D816V</sup> Inhibitors</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Soyoung++Lee">Soyoung Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hyunseung++Lee">Hyunseung Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jinhee++Kim">Jinhee Kim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Suhyun++Lee">Suhyun Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Soo+Jung++Kim">Soo Jung Kim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Byong-Seok++Choi">Byong-Seok Choi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Soon-Sun++Hong">Soon-Sun Hong</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sungwoo++Hong">Sungwoo Hong</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">â </span> <span class="aff-text">Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), Yuseong-gu, E6-4, Daejeon 305-701, Korea</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">â¡</span> <span class="aff-text">Center for Catalytic Hydrocarbon Functionalizations, Institute for Basic Science (IBS), Daejeon 305-701, Korea</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">Â§</span> <span class="aff-text">Department of Biomedical Sciences, College of Medicine, Inha University, Incheon, 400-712, Korea</span></div><div class="corresp-info"><strong>*</strong>For S.H.: phone, (+82) 42-350-2811; fax, (+82) 42-350-2810; E-mail, <a href="/cdn-cgi/l/email-protection#0b6364656c64796c4b606a62787f256a68256079"><span class="__cf_email__" data-cfemail="cba3a4a5aca4b9ac8ba0aaa2b8bfe5aaa8e5a0b9">[emailÂ protected]</span></a></div><div class="corresp-info"><strong>*</strong>For S.-S.-H.: phone, (+82) 32-890-3683; fax, (+82) 32-890-2462; E-mail, <a href="/cdn-cgi/l/email-protection#70181f1e170330191e18115e11135e1b02"><span class="__cf_email__" data-cfemail="690106070e1a290007010847080a47021b">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm500413g&amp;href=/doi/10.1021%2Fjm500413g" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 6428â6443</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 8, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 March 2014</li><li><span class="item_label"><b>Published</b> online</span>16 July 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 August 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm500413g" title="DOI URL">https://doi.org/10.1021/jm500413g</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6428%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSoyoung%2BLee%252C%2BHyunseung%2BLee%252C%2BJinhee%2BKim%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D15%26contentID%3Djm500413g%26title%3DDevelopment%2Band%2BBiological%2BEvaluation%2Bof%2BPotent%2Band%2BSelective%2Bc-KITD816V%2BInhibitors%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6443%26publicationDate%3DAugust%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm500413g"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1777</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">15</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm500413g" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Development and Biological Evaluation of Potent and Selective c-KITD816V Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Soyoung&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Hyunseung&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Jinhee&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Suhyun&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Soo&quot;,&quot;last_name&quot;:&quot;Jung Kim&quot;},{&quot;first_name&quot;:&quot;Byong-Seok&quot;,&quot;last_name&quot;:&quot;Choi&quot;},{&quot;first_name&quot;:&quot;Soon-Sun&quot;,&quot;last_name&quot;:&quot;Hong&quot;},{&quot;first_name&quot;:&quot;Sungwoo&quot;,&quot;last_name&quot;:&quot;Hong&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;6428-6443&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm500413g&quot;},&quot;abstract&quot;:&quot;The c-KIT tyrosine kinase has emerged as a potential therapeutic target for an array of diseases. However, there exists a drug resistance that is caused by mutations in c-KIT; therefore, c-KIT remains as a clinical challenge due to limited effective treatment options for therapies. For example, the acquired activating point mutation D816V significantly impairs the efficacy of targeted cancer therapies. Understanding the mechanisms of drug resistance at the molecular level will aid in designing and developing particular inhibitors with the potential to overcome these resistance mutations. We undertake a structure-based de novo design of 7-azaindole as the molecular core using the modified scoring function. This approach led to an identification of new c-KIT inhibitors over 100-fold specific for the D816V mutant relative to the wild-type c-KIT with nanomolar inhibitory activity. More importantly, these compounds potently inhibit clinically relevant D816V mutations of c-KIT in biochemical and cellular studies.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500413g&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500413g" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500413g&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500413g" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm500413g&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500413g" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm500413g&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm500413g&amp;href=/doi/10.1021/jm500413g" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm500413g" /></input><a href="/doi/pdf/10.1021/jm500413g" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm500413g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm500413g%26sid%3Dliteratum%253Aachs%26pmid%3D25004409%26genre%3Darticle%26aulast%3DLee%26date%3D2014%26atitle%3DDevelopment%2Band%2BBiological%2BEvaluation%2Bof%2BPotent%2Band%2BSelective%2Bc-KITD816V%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D15%26spage%3D6428%26epage%3D6443%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291763" title="Noncovalent interactions">Noncovalent interactions</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jmcmar.2014.57.issue-15/production/jmcmar.2014.57.issue-15.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The c-KIT tyrosine kinase has emerged as a potential therapeutic target for an array of diseases. However, there exists a drug resistance that is caused by mutations in c-KIT; therefore, c-KIT remains as a clinical challenge due to limited effective treatment options for therapies. For example, the acquired activating point mutation D816V significantly impairs the efficacy of targeted cancer therapies. Understanding the mechanisms of drug resistance at the molecular level will aid in designing and developing particular inhibitors with the potential to overcome these resistance mutations. We undertake a structure-based de novo design of 7-azaindole as the molecular core using the modified scoring function. This approach led to an identification of new c-KIT inhibitors over 100-fold specific for the D816V mutant relative to the wild-type c-KIT with nanomolar inhibitory activity. More importantly, these compounds potently inhibit clinically relevant D816V mutations of c-KIT in biochemical and cellular studies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54664" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54664" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The c-KIT tyrosine kinase belongs to a family of type III receptor tyrosine kinase and is a transmembrane receptor that mediates the pleiotropic biological effects through its ligand stem cell factor (SCF, also known as mast cell growth factor).<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Once SCF binds to an extracellular immunoglobulin-like domain of c-KIT, two monomeric c-KIT receptors become dimerized, resulting in an activation of downstream intracellular signal transduction, including phophatidylinositol-3-kinase (PI3K)/Akt pathway, mitogen-activated protein kinase (MAPK), and signal transducer and activator of transcription (STAT), which are involved in cell proliferation, differentiation, and survival<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> Deregulated c-KIT kinase activity can be variably detected in multiple different types of pathogenesis, including small cell lung carcinoma, acute myeloid leukemia (AML), neuroblastoma, malignant melanomas, colorectal cancer, systemic mastocytosis (SM), and gastrointestinal stromal tumors (GISTs).<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> The activation loop of the wild-type c-KIT exists in a dynamic equilibrium between the active and inactive conformations. Impairing c-KIT activity with tyrosine kinase inhibitors, such as imatinib, has yielded good responses in some c-KIT-dependent cancers.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> Imatinib is effective against the wild-type c-KIT by stabilizing the inactive conformation of the c-KIT kinase domain and then preventing the inactive form from switching to the active conformation of c-KIT.<a onclick="showRef(event, 'ref5 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref7">(5, 7)</a></div><div class="NLM_p">Chemotherapy of cancers with first-line drugs often leads to resistance of the cancers.<a onclick="showRef(event, 'ref5 ref8'); return false;" href="javascript:void(0);" class="ref ref5 ref8">(5, 8)</a> Gain-of-function point mutations in the c-KIT kinase domain result in a ligand-independent constitutive activation of c-KIT signaling, which leads to an uncontrolled mast cell proliferation and apoptosis resistance.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9-11)</a> Systemic mastocytosis patients have a gain-of-function mutation (c-KIT<sup>D816V</sup>) in many cases<a onclick="showRef(event, 'ref9 ref12'); return false;" href="javascript:void(0);" class="ref ref9 ref12">(9, 12)</a> Introduction of the D816V point mutation disrupts the inactive conformation and impedes the binding process of first-line drugs, including imatinib, to the ATP-binding site of c-KIT.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> To date, only a few multikinase inhibitors, such as dasatinib<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and ponatinib,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> sufficiently block the activity of c-KIT<sup>D816V</sup>.</div><div class="NLM_p last">Simultaneously inhibiting off-targets can result in a target-related toxicity because many individual biological targets are involved in important cellular functions. In this way, many multikinase inhibitors in clinical use might lead to possible side effects because off-target kinase inhibition can cause toxicity to normal cells.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Recently, an interest has been growing in an effort to discover an approach to only inhibit the mutant therapeutic target, thereby minimizing the risk of potential side effects associated with the inhibition of normal function. The structural similarity has made the search for selective c-KIT<sup>D816V</sup> inhibitors a challenging process. In this regard, it would be worthwhile to identify c-KIT<sup>D816V</sup> inhibitors in a specific manner over the wild-type c-KIT without normal SCF/KIT signaling pathway disruption. This strategy would potentially provide an effective treatment option as a special type of cancer treatment. Herein we describe our efforts to develop a new series of 7-azaindole-based inhibitors that may be effective and specific against c-KIT<sup>D816V</sup> and demonstrate the biological activities of these compounds against imatinib-resistant HMC-1.2 cell lines.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71351" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71351" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Identification of New c-KIT<sup>D816V</sup> Inhibitors</h3><div class="NLM_p">We began our study by cross-screening our compound collection in search of c-KIT<sup>D816V</sup> inhibitors. This led to an identification of a 7-azaindole-based derivative, combined with 3,4-dimethoxybenzene group at C3, and pyridylsulfonamide group at C5 as a c-KIT<sup>D816V</sup> inhibitor (<b>1</b>, IC<sub>50</sub> = 346 nM) (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The synthesized inhibitor compound <b>1</b> may impair c-KIT<sup>D816V</sup> catalytic activity by specifically binding to the ATP binding site as illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>. Because 7-azaindole scaffold has been used for PI3KÎ± inhibitors,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> we proceeded to screen this series of compounds against PI3KÎ±. Indeed, the newly identified c-KIT<sup>D816V</sup> inhibitor <b>1</b> exhibited an inhibitory activity against PI3KÎ± (IC<sub>50</sub> = 12 nM). Because the initial hit <b>1</b> was found to have a higher affinity for PI3KÎ±, our first design efforts were focused on improving the selectivity against PI3KÎ± while maintaining potent c-KIT<sup>D816V</sup> inhibition.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Initial hit for c-KIT<sup>D816V</sup> inhibitors. Compounds were tested against c-KIT<sup>D816V</sup> and PI3KÎ±.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of new scaffolds as c-KIT<sup>D816V</sup> inhibitors and opportunities for modification in the schematic active site of c-KIT<sup>D816V</sup>. (A) Predicted binding mode of <b>1</b> in PI3KÎ±. (B) Predicted binding mode of <b>1</b> in c-KIT<sup>D816V</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The recent design of selective kinase inhibitors has been facilitated by the availability of substantial three-dimensional structural information regarding various kinaseâinhibitor complexes. The predicted hydrogen bonding network with Tyr836, Asp810, and the inhibitor in PI3KÎ± (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A) was based on previous studies using X-ray crystallography.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Our experience also confirmed the importance of a water-mediated hydrogen bond with residues in the active site of PI3KÎ±.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Although hydrogen bonds appeared to form between pyridyl nitrogen at the 5 position of <b>1</b> and bound water molecule in PI3K, this key hydrogen bonding interaction was not expected in c-KIT<sup>D816V</sup> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B). We speculated that these structural differences can possibly provide a guideline for improving the selectivity via inhibitor modifications in this region of accessing specific spaces of the gatekeeper. With this agenda, our initial survey of the disruption of the key intermolecular hydrogen bonding network in PI3KÎ± via C5 group modifications was conducted, probing the structural differences affecting the binding pockets of PI3KÎ± and c-KIT<sup>D816V</sup> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).</div><div class="NLM_p">Indeed, modification of the C5 group was essential for enhancing the selectivity over PI3KÎ±, as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. Of particular significance was the observation that the binding affinity of <b>2</b> over PI3KÎ± was dramatically reduced (IC<sub>50</sub> = 1.6 Î¼M for PI3KÎ±) when the pyridyl group at the C5 position was replaced with a phenyl group, probably due to the disruption of the key hydrogen bond with a bound water molecule in PI3KÎ±. We also noted that the sulfonyl group of aniline at the C5 position was allocated to generate further stabilizing interactions through the formation of hydrogen bond with Lys802 in PI3KÎ±. With the binding mode set in this way, the sulfonyl group appeared to be unnecessary for producing an inhibitory activity over c-KIT<sup>D816V</sup>. To verify this assumption, we then removed the sulfonyl group and assessed their inhibitory potencies over PI3KÎ± and c-KIT<sup>D816V</sup>. Subsequently, compound <b>4</b> exhibited excellent selectivity over PI3KÎ± while retaining the lowest POC number for c-KIT<sup>D816V</sup> (IC<sub>50</sub> = 6.3 nM for c-KIT<sup>D816V</sup>, IC<sub>50</sub> > 10000 nM for PI3KÎ±). Compound <b>3</b> was prepared as the control to investigate the role of the pyridyl group. Next, a second set of data was obtained for compounds in which C-5 aryl ring was substituted with a variety of patterns of groups. From these results, it was evident that either a removal of the sulfonamide group or a replacement of the pyridyl group with a phenyl group at C5 led to a dramatic loss in the inhibitory activity over PI3KÎ±. Remarkably, this strategy has served well without compromising the c-KIT<sup>D816V</sup> affinity, and most of 3,4-dimethoxybenzene derivatized compounds are found to have a greater binding affinity for c-KIT<sup>D816V</sup> than PI3KÎ± (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). We also examined the significance of the <i>meta</i>-substituents at the C5-aryl ring and observed that the binding affinity for c-KIT<sup>D816V</sup> was dramatically reduced when the <i>meta</i>-amino group of compound <b>4</b> was moved to the <i>ortho</i>-position (<b>13</b>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Exploration of Groups at the C5 Position of Azaindole Core<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0013.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0014.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Compounds were tested against c-KIT<sup>D816V</sup> and PI3KÎ±.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> De Novo Design</h3><div class="NLM_p">On the basis of the preliminary data, compound <b>4</b> was selected as an initial hit compound to allow for additional interactions to be identified. We explored the space at 3- and 5- positions of 7-azaindole to identify the derivatives with enhanced potency through the structure-based de novo design, as summarized in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>. Thus, we prepared two receptor models to perform the de novo design of 7-azaindole derivatives: one is the homology modeling for the structure of c-KIT<sup>D816V</sup> constructed by the MODELER program on the basis of wild-type c-KIT in the active conformation,<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> and the other is the autoinhibited form of the wild-type (PDB entry: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T45">1T45</a>)<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> as for the wild-type c-KIT model. First, a variety of 7-azaindole derivatives were generated with the LigBuilder program<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> based on the structure of the D816V mutantâazaindole complex obtained from docking simulations. To score the generated derivatives with consideration of their binding affinity for c-KIT and c-KIT<sup>D816V</sup>, the program employed an empirical binding free energy function.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> As the starting point for generating 7-azaindole derivatives, we analyzed the binding pocket in the ATP-binding site of the D816V mutant using the POCKET module. The structure of c-KIT<sup>D816V</sup> in complex with 7-azaindole was used as the input to identify key interacting residues in the ATP-binding site. From this information, it could be possible to define a binding model of 7-azaindole inhibitors at the ATP biding site. A variety of 7-azaindole derivatives were then generated via an application of genetic algorithm, whereby the structures evolved as the chemical groups modified at the substitution positions of the 7-azaindole core, and these derivatives were rescored with the modified scoring function (see the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). The generated 7-azaindole derivatives were then selected according to the calculated binding free energy to maximize the affinity for the D816V mutant and minimize the affinity for wild-type c-KIT.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Flowchart for the discovery process of potent and selective inhibitors of D816V mutant of c-KIT through the structure-based de novo design.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The de novo design studies identified a variety of functional groups to introduce the 7-azaindole core at the 3- and 5- positions. For the synthesized derivatives, IC<sub>50</sub> (50% inhibitory concentration) values were determined against the wild-type c-KIT and D816V mutant.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> To determine whether or not the 3,4-dimethoxy phenyl group at the C3 position of initial hit <b>4</b> was optimal, the effects of its replacement with other groups were explored, and a series of (hetero)aryl groups were installed (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Because the 3-aniline group at the C5 position of <b>4</b> proved to be effective for high inhibitory activity, we tentatively fixed the 3-aniline group in this region, then screened various groups at the C3 position. We observed that the binding affinity and potency were reduced when the 3,4-dimethoxy group was replaced with the 3,5-dimethoxy group (<b>27</b>) or the monomethoxy group (<b>25</b> and <b>26</b>), indicating that the orientation of the dimethoxy group is critical in sustaining potency. The enzyme potency of the derivatives was also decreased when the trimethoxy group was introduced (<b>21</b>), demonstrating that the 3,4-dimethoxy phenyl group at the C3 position group is the maximum size that is suitable for this position in the 7-azaindole core. A comparison of the IC<sub>50</sub> values of <b>4</b> (IC<sub>50</sub> = 6.3 nM) to that of <b>22</b> (IC<sub>50</sub> = 104 nM) clearly reveals that substitutions of other chemical groups for the 3,4-dimethoxybenzene moiety lead to a large decrease in the inhibitory activity against c-KIT<sup>D816V</sup>. From the first round of C3 array exploration, derivatives bearing 3,4-dimethoxybenzene appeared to be the superior inhibitors, suggesting that this group is an effective substituent for the potent activity against c-KIT<sup>D816V</sup>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Exploration of Groups at the C3 Position of Azaindole Core<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0015.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0016.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> (50% inhibitory concentration) values were determined against the D816V mutant.</p></div></div><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Enhancement of Selectivity for the D816V mutant</h3><div class="NLM_p">The aniline <b>4</b> proved to be a potent c-KIT<sup>D816V</sup> inhibitor (IC<sub>50</sub> = 6.3 nM) and represented a potent hit in our c-KIT<sup>D816V</sup> program. To address the structural and mechanistic aspects that are relevant to the selective inhibition of the D816V mutant by these newly identified inhibitors, we carried out docking studies for c-KIT<sup>D816V</sup> in complex with <b>4</b>. Previous molecular modeling and dynamics simulation studies revealed that the activating D816V mutation triggers spontaneous detachment of the juxtamembrane domain from the c-KIT domain, which stabilizes the activation loop (A-loop) in the extended conformation.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> This conformational change in c-KIT<sup>D816V</sup> results in maintaining the active form, which enables constitutive oncogenic activation. Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a> displays representative MD trajectory snapshots of the D816V mutantâ<b>4</b> complexes. The binding modes of <b>4</b> with the D816V mutant shows that the 7-azaindole skeleton fully maintains the bidentate hydrogen bonding pattern with the backbone groups of Cys673, which reveal that the strengths and dynamic stabilities of the bidentate hydrogen bonds with Cys673 serve as critical factors that affect the potency and selectivity of c-KIT<sup>D816V</sup> inhibitors. Compound <b>4</b> appears to be stabilized through the hydrophobic interactions with side chains Leu595, Val603, Ala621, Tyr672, and Leu799. Another feature in the binding modes of <b>4</b> is that the terminal 3,4-dimethoxybenzene group appears to be exposed to the bulk solvent in the c-KITâ<b>4</b> complex and stabilized through interactions with the protein groups at the entrance of the ATP-binding site of c-KIT<sup>D816V</sup>.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Representative MD trajectory snapshots of the hydrophobic pocket constructed by phosphate-binding loop and activation loop in the ATP-binding sites of (A) c-KIT<sup>D816V</sup> and (B) wild-type c-KIT. (C) Predicted binding mode of <b>4</b> with the D816V mutant of c-KIT. Carbon atoms of c-KIT and <b>4</b> are indicated in gray and green, respectively. Asp810 and Phe811 of DFG motif are indicated in magenta. Each navy dotted line indicates a hydrogen bond.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Having identified the significance of the 3,4-dimethoxyphenyl group at the C3 position of 7-azaindole, we carried out a broader exploration of analogues which incorporated this key functional group (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). In general, the synthesized derivatives appear to maintain the bidentate hydrogen bonding with the backbone groups of Cys673 in both c-KIT and c-KIT<sup>D816V</sup>. The aromatic ring system of these analogues is further stabilized through hydrophobic interactions with nonpolar residues, including Leu595, Val603, Ala621, Leu799, Tyr672, and Cys674. The third hydrogen bond in the P-loop appears to be established in a different fashion in complex of wild-type c-KIT and the D816V mutant. The molecular modeling study indicated that Asp-Phe-Gly (D810-F8111-G812) motif in the A-loop and the glycine-rich phosphate-binding loop (P-loop) form a deep hydrophobic pocket in c-KIT<sup>D816V</sup>. In contrast, the p-loop in the wild-type is away from 7-azaindole, as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B. The 3-aminophenyl group at C5 faced into the hydrophobic pocket constructed by phosphate-binding loop and activation loop in the ATP-binding sites of c-KIT<sup>D816V</sup>. This suggests that there exists a possibility of further elaboration of the substituents of C5 aryl ring (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Influence of C5 Groups on Selectivity</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0017.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0018.gif" alt="" id="fx6" /></img><div></div></div><div class="NLM_p">With this agenda, a diverse set of substituents were investigated to expand the structureâactivity relationship, and the analogues incorporated an additional substituent into the 3-aminophenyl group in order to enhance the selectivity for c-KIT<sup>D816V</sup>. In this series of analogues, it appeared that the presence of an additional substituent on the 3-aniline ring was generally tolerant to its function on c-KIT<sup>D816V</sup>. In contrast, the potency on the wild-type c-KIT was tunable by modification of the substitution patterns of the C5-aryl ring as seen in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. The relatively low potency for wild-type c-KIT of 7-azaindole inhibitors with a larger group substituted 5-aryl ring may be rationalized by the decreased volume of the ATP-binding pocket in wild-type c-KIT due to the approach of JMR residues to the gatekeeper site in the inactive conformation. The substitution patterns of C5 aryl ring also proved to be an important structural requirement for the design of c-KIT<sup>D816V</sup> selective inhibitors. Thus, introduction of an additional methoxy group at the <i>para</i>-position of the 3-aniline ring (<b>34</b>) resulted in highly amplified selectivity vs wild-type c-KIT (IC<sub>50</sub> >10000 nM for c-KIT, IC<sub>50</sub> = 25.6 nM for c-KIT<sup>D816V</sup>). In the D816V mutant, both substituents at the <i>meta</i>- and <i>para</i>-position of C5 aryl ring of compound <b>34</b> are expected to extend the P-loop and make favorable contacts with backbone groups of residues in the pocket (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>A). In addition, the methoxy group at the <i>para</i>-position appeared to establish an additional hydrogen bond with the side-chain amino group of Lys623. By contrast, this binding mode cannot be formed in the c-KITâ<b>34</b> complex because the P-loop is too distant from the ATP-binding site, and accessing to the extended P-loop is prevented by Phe811 in the wild-type c-KIT. Instead, it is observed that the C5 aryl ring points toward a small hydrophobic pocket formed by the side chains of Ile699, Thr670, Val622, Leu644, and Lys623-Glu640 salt bridge in the wild-type (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B). This hydrophobic region is too small to comfortably accommodate the two substituents coming off the C5 aryl ring, and unfavorable steric contacts would be present in the wild-type c-KIT. The structural comparison of c-KIT and c-KIT<sup>D816V</sup> in the P-loop revealed that the interaction of 7-azaindole with hydrophobic pocket in the P-loop could serve a key structural determinant of the specificity of the D816V mutant selective inhibitors.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Predicted binding mode of <b>34</b> with c-KIT<sup>D816V</sup> and (B) with wild-type c-KIT. Each navy dotted line indicates a hydrogen bond.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Because these structural differences provided a guideline toward favorable impact on selectivity improvement for the D816V mutant, several other groups were designed to extend the substituent at this region (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). The preference of <i>meta-</i> and <i>para</i>-substituents of C5-aryl ring for the enhancement of selectivity for c-KIT<sup>D816V</sup> is further illustrated by the potency of analogue <b>31</b> bearing in the form of a morpholinoacetyl group (IC<sub>50</sub> = 9140 nM for c-KIT, IC<sub>50</sub> = 8.5 nM for c-KIT<sup>D816V</sup>). The inhibitory activity was also increased over the D816V mutant when the methoxy group was replaced with a 2-morpholinoethoxy appendage (<b>40</b>, IC<sub>50</sub> = 13.9 nM) while retaining excellent selectivity over the wild-type c-KIT. The 3,4,5-trimethoxy aryl group was also tolerable to the D816V mutant, and <b>32</b> (IC<sub>50</sub> = 8.8 nM) was more potent than the corresponding 4-methoxy derivative <b>18</b> (IC<sub>50</sub> = 32.1 nM) and 3-methoxy derivative <b>41</b> (IC<sub>50</sub> = 28.7 nM). Methyl substitution (<b>33</b>) had no appreciable change on both the wild-type c-KIT and the D816V mutant when compared with the corresponding <b>34</b>. Intriguingly, replacement of the 3-NH<sub>2</sub> group of <b>34</b> with a 3-OMe group (<b>19</b>) resulted in about 10-fold increase in potency on the D816V mutant (IC<sub>50</sub> = 2.1 nM). Attempts to further increase potency by linking or repositioning substituents of C5-aryl ring (<b>35</b>, <b>36</b>, and <b>39</b>) were unremarkable, and no compound offered any advantage relative to the corresponding compound <b>19</b>. Cumulatively, these results indicate that disubstitution at the <i>meta</i>- and <i>para</i>-position of C5 aryl ring in this series was most effective for achieving high selectivity for the D816V mutant.</div><div class="NLM_p">Interestingly, moving the substituent from the <i>meta</i>- to the <i>para</i>-position of C5 aryl ring led to increase in the inhibitory activity against the wild-type c-KIT, thus reducing the selectivity for the D816V mutant (<b>18</b>, <b>37</b>, and <b>38</b>). For example, changing the substituent from 3-aminobenzene in <b>4</b> to 4-aminobenzene in <b>37</b> led to almost a 20-fold increase in the inhibitory activity against the wild-type c-KIT (IC<sub>50</sub> = 56.8 nM) but only a slight change in the IC<sub>50</sub> values with respect to the D816V mutant (IC<sub>50</sub> = 9.1 nM). Compound <b>18</b> bearing a 4-methoxy group at the <i>para</i>-position also showed a decrease in selectivity for the D816V mutant. When the <i>para</i>-amino group in compound <b>37</b> was replaced by the methyl group in compound <b>17</b>, it resulted in a substantial loss of activity on both the wild-type c-KIT (IC<sub>50</sub> >10\000 nM) and the D816V mutant (IC<sub>50</sub> = 571.3 nM). Because moving the substituent from the <i>meta</i>- to the <i>para</i>-position of C5 aryl ring resulted in an increased potency over the wild-type, the binding mode of <b>37</b> was further analyzed with MD simulations.</div><div class="NLM_p">The binding modes of <b>37</b> in the ATP-binding sites of the wild-type c-KIT and the D816V mutant, obtained from energy minimizations of the time-averaged structures of c-KITâ<b>37</b> and D816Vâ<b>37</b> complexes, are compared in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>. With regard to the structure, <b>37</b> is stabilized through bidentate hydrogen bonds between 7-azaindole ring and Cys673, hydrophobic interactions of aromatic rings with nonpolar residues, and a hydrogen bond between the NH<sub>2</sub> group and the backbone aminocarbonyl oxygen of Asp810. Despite the overall similarity in the binding modes of <b>4</b> and <b>37</b> toward the wild-type c-KIT, some differences in inhibitor positions with respect to the ATP-binding site and the P-loop are also observed in the wild-typeâ<b>37</b> complexes. For example, the inhibitor moves from the activation loop to the ATP-binding site (residues 670â677) in the c-KITâ<b>37</b> complex, establishing a hydrogen bond between the 4-aniline group of <b>37</b> and the backbone aminocarbonyl oxygen of Asp810 (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>B). This positional shift strengthens the bidentate hydrogen bonds between 7-azaindole ring and Cys673. The average NÂ·Â·Â·HâN and NâHÂ·Â·Â·O hydrogen bond distances are 1.82 and 1.78 Ã, respectively, in c-KITâ<b>37</b> complex. The approach of <b>37</b> to the ATP-binding may also have an effect in promoting van der Waals interactions between the 7-azaindole group and the side chains of Val654, Tyr672, and Leu799 (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>B). Therefore, the strengthening of the hydrogen bonds with the backbone groups of Asp810 and Cys673, as well as hydrophobic interactions with nonpolar residues around the ATP-binding site, may contribute to the potent inhibitory activity of <b>37</b> with respect to the wild-type c-KIT. The binding mode of <b>37</b> for the D816V mutant differs from that of the wild-type in that the role of the hydrogen bond acceptor with respect to the terminal aniline moiety is played by a side chain carboxylate ion of Glu640 instead of the backbone aminocarbonyl oxygen of Asp810 (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A). The above modeling analysis similarly applies to compound <b>18</b>, leading to an increased potency over the wild-type c-KIT. The loss of hydrogen bond interactions between derivative <b>17</b> bearing C5 <i>p</i>-tolyl group and the backbone aminocarbonyl oxygen of Asp810 may explain the substantial loss of activity on the wild-type c-KIT (IC<sub>50</sub> >10000 nM).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Representative MD trajectory snapshots of <b>37</b> in the ATP-binding sites of (A) c-KIT<sup>D816V</sup> and (B) wild-type. Carbon atoms of c-KIT and <b>37</b> are indicated in cyan and green, respectively. Each dotted line indicates a hydrogen bond.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Kinase Selectivity Profiling</h3><div class="NLM_p">To obtain the detailed picture of selectivity profile of this series, potent inhibitors were subjected to kinase selectivity profiling with a panel of 48 cancer related kinases, representing major branches (TK, TKL, STE, CMGC, CAMK, AGC, atypical, and other) on the kinome tree at 1 Î¼M concentrations in a high-throughput binding assay (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>, KINOMEscan, Ambit Biosciences).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Overall, this series of inhibitors showed moderate to good specificity profiles relative to current multitargeted c-KIT<sup>D816V</sup> inhibitors such as dasatinib and ponatinib; however, these inhibitors are less selective for the TK kinase family including FLT3, JAK2, TRKA, and TRKB. Other kinases inhibited by this series are DRAK1 (CAMK family), Aurora A, Aurora B, IKKa, and IKKb as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a> (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information Table S1">Supporting Information Table S1</a> for more details). Among this series of inhibitors, trimethoxy derivatve <b>32</b> exhibited an improved selectivity profile, and two kinases against which <b>32</b> demonstrated tight off-target binding affinity (IC<sub>50</sub> < 1 Î¼M) were FLT3, and DRAK1. On the other hand, compound <b>31</b> showed only modest specificity profiles against other kinases and displayed significant off-target activity over 10 kinases (ABL<sup>T315I</sup>, Aurora A, DRAK1, FLT3, IKKa, IKKb, JAK2, ROCK1, TRKA, and TRKB).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Selectivity profiles of compounds <b>19</b>, <b>21</b>, <b>31</b>, <b>32</b>, and <b>34</b>. A panel of 48 kinases was tested at 1 Î¼M concentrations in a high-throughput binding assay (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for details).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Antiproliferation Activity</h3><div class="NLM_p">This series of potent inhibitors were further tested for cellular growth inhibition against human mast cells (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). We carried out an evaluation of their antiproliferative activity on HMC-1.2 cell lines (V560G, D816V), which are imatinib-resistant. To measure the inhibitory effect of these compounds on cell growth, cell viability was tested by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in HMC-1.2 at various concentrations for 48 h. Notably, compounds <b>19</b>, <b>21</b>, <b>32</b>, and <b>34</b> showed potent antiproliferative effects at submicromolar concentration as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. This series of compounds displayed significant off-target activity (IC<sub>50</sub> < 10 Î¼M) over several kinases (DRAK1, FLT3, and IKK) which are believed to be involved in cell proliferation. On the basis of the selectivity data, off-target activity might be partially responsible for potent antiproliferative effects. For example, DRAK1 and FLT3 displayed tight binding to this series of compounds (DRAK1 by <b>19</b>, <b>31</b>, <b>32</b>, <b>34</b>; FLT3 by <b>19</b>, <b>31</b>, and <b>32</b>). Compound <b>31</b> also exhibited significant actvities over IKKa and IKKb.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Effect of C-KIT Inhibitors on Growth of HMC-1.2</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">HMC-1.2 (V560G, D816V) IC<sub>50</sub> (Î¼M)</th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">HMC-1.2 (V560G, D816V) IC<sub>50</sub> (Î¼M)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">imatinib</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="char" char=".">0.81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dasatinib</td><td class="colsep0 rowsep0" align="char" char=".">0.82</td><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char=".">2.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ponaitinib</td><td class="colsep0 rowsep0" align="char" char=".">0.35</td><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="char" char=".">0.91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">1.68</td><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="char" char=".">1.43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="char" char=".">0.76</td><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char=".">0.87</td></tr></tbody></table></div></div><div class="NLM_p last">A couple of cases of discordances were observed between IC<sub>50</sub> values over c-KIT<sup>D816V</sup> and cellular potencies, which may be attributed to the inability of the enzymatic assay data to accurately reflect the cell potencies. Because intracellular activity is influenced by the physicochemical properties of compounds, we further measured basic profiles of these compounds (see <a class="ref internalNav" href="#notes-1" aria-label="Table S5 in Supporting Information">Table S5 in Supporting Information</a>). The good ability of <b>21</b> and <b>34</b> to suppress the growth of HMC-1.2 cells might be attributable to their more desirable range of properties, whereas more potent compound <b>31</b> in the biochemical assay exhibited a lower AlogP value and higher topological polar surface area (tPSA). Likewise, compounds <b>19</b> and <b>32</b> showed a higher AlogP value and lower tPSA than <b>21</b> or <b>34</b>.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Cell-Signaling Effects</h3><div class="NLM_p">c-KIT signaling is transmitted through several pathways, including signal transducer and activator of transcription, and activation of the c-KIT pathway leads to the phosphorylation of STAT3, Akt, and Erk, a downstream effector of phosphatidylinositol 3-kinase. To ensure that the new series of compounds was inhibiting c-KIT-dependent downstream signaling pathways in HMC-1.2 cells, several potent inhibitors were further profiled for their ability to suppress cellular biomarkers, using Western immunoblotting. Consistent with the expectations for a potent c-KIT inhibitor, <b>19</b>, <b>21</b>, <b>32</b>, and <b>34</b> strongly suppressed the phosphorylation of STAT3, Akt, and Erk. We also compared the suppression of c-KIT signaling by these inhibitors with imatinib, dasatinib, and ponatinib as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Inhibition of cellular c-KIT pathway including STAT3, Akt, and Erk in HMC-1.2 (imatinib-resistant human mast cell). HMC-1.2 cells were starved with serum-free IMEM for 2 h and treated with imatinib, dasatinib, ponatinib, <b>19</b>, <b>21</b>, <b>32</b>, and <b>34</b> for 1 h at 5 Î¼M.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Cell-Cycle Distribution and Apoptotic Cell Death</h3><div class="NLM_p">In general, cell apoptosis and growth correlate with the cell cycle progression. Blocking the kinase pathway can change the cell cycle distribution and promote apoptosis. Because compound <b>19</b> successfully demonstrated the ability to inhibit p-STAT3, p-Akt, and pErk in HMC-1.2 cells, we further determined whether the inhibition of c-KIT in HMC-1.2 cells by compound <b>19</b> induces a cell cycle arrest. The cell cycle distribution was evaluated by a flow cytometric analysis. The treatment of <b>19</b> inhibited the cell cycle progression in HMC-1.2 cells, resulting in a significant increase in the percentage of cells in the SubG1/G1 phase in a dose dependent manner (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>).</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Effect of <b>19</b> on the cell cycle distribution. HMC-1.2 cells were exposed to increasing concentration of <b>19</b> and 5 Î¼M imatinib for 24 h. Compound <b>19</b> arrested the cell cycle at G1 phase in a dose-dependent manner.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We next analyzed the ability of <b>19</b> to induce apoptosis in HMC-1.2 cells. When HMC-1.2 cells were exposed to various doses of <b>19</b>, the DNA fragmentation, one of the hallmarks of apoptosis, was increased in a dose-dependent manner (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>). A flow cytometric analysis of HMC-1.2 cells, which were subjected to terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) staining, revealed that the percentage of TUNEL-positive cells increased after treatment with <b>19</b>, further supporting the conclusion that <b>19</b> induced apoptosis.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Effect of <b>19</b> on apoptosis in HMC-1.2 cells. HMC-1.2 cells were treated with various concentrations of <b>19</b> for 48 h, and apoptosis was determined by flow cytometry using TUNEL staining.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Chemical Synthesis</h3><div class="NLM_p">The general synthesis of representative 3,5-disubstituted 7-azaindole derivatives <b>48</b> is shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. A two-step reaction sequence, starting from a known-compound <b>45</b>, was utilized to afford the desired derivative <b>48</b>. An initial Pd-catalyzed cross-coupling with C3 (hetero)aryl partners was carried out to afford a C3 aryl intermediate, which were then subjected to benzenesulfonyl group deprotection under basic conditions, resulting in compound <b>46</b>. An assortment of the C5 groups of 7-azaindole was then explored through another Suzuki coupling reaction with the appropriate arylboronic acids or esters, yielding focused set of target compounds. For focused C5-aryl group array, the key intermediate <b>47</b> was prepared via direct borylation of 5-bromoazaindole <b>46</b>. The corresponding desired compounds <b>48</b> were then obtained by Pd-catalyzed cross-coupling with the appropriate aryl boronic acids or esters.</div><figure id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 7-Azaindole Derivatives</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35123" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35123" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The 7-azaindole-based hit <b>4</b> was modified by applying a structure-based de novo design to obtain new potent and selective inhibitors for the gain-of-function D816V mutant. The 7-azaindole derivatives with a 3,4-dimethoxybenzene moiety at the 3-postion and a polar aromatic group at the 5-position were found to have a nanomolar inhibitory activity for the D816V mutant, with more than 100-fold greater potency compared to the wild-type c-KIT. A decomposition analysis of the binding free energies indicates that the potency of an inhibitor can be optimized by reducing desolvation cost for enzymeâinhibitor complexation as well as by strengthening the interactions between the inhibitor and c-KIT in the ATP-binding site. Four of the compounds suppress cell growth and proliferation against imatinib-resistant HMC-1.2 cell lines in a submicromolar concentration range. Compound <b>19</b> also induced apoptosis through regulation of the c-KIT signaling pathway, which leads to strong anticancer activity in HMC-1.2 cells. Future studies may be necessary to fully identify the potential of this series as a modality for cancer treatment.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02606" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02606" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">I General Methods and Materials</h3><div class="NLM_p last">Unless stated otherwise, reactions were performed in a flame-dried glassware under positive pressure of nitrogen using freshly distilled solvents. Analytical thin layer chromatography (TLC) was performed on precoated silica gel 60 F<sub>254</sub> plates, and visualization on TLC was achieved via UV light (254 and 354 nm). Flash column chromatography was utilized on silica gel (400â630 mesh). <sup>1</sup>H NMR was recorded on 600 or 400 or 300 MHz, and chemical shifts were quoted in parts per million (ppm) referenced to the appropriate solvent peak or 0.0 ppm for tetramethylsilane. The following abbreviations were used to describe the peak splitting patterns when appropriate: br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublet. Coupling constants, <i>J</i>, were reported in hertz unit (Hz). <sup>13</sup>C NMR was recorded on 100 or 150 MHz and was fully decoupled by broad band proton decoupling. Chemical shifts were reported in ppm referenced to the center line of a triplet at 77.0 ppm of chloroform-<i>d</i>. Mass spectral data were obtained from the KAIST Basic Science Institute by Bruker Daltonik HR-MS using the EI method or Agilent LR-MS. High-performance liquid chromatography analyses for checking mass spectral data (using EI method) and the purity (>95% area) and of synthesized compounds were performed on a Agilent HPLC equipped with an Agilent Poroshell 120 EC-C18 reverse phase column (4.6 mm Ã 50 mm, 2.7 Î¼m) and by quadrupole LC/MS. The mobile phase was a mixture of MeOH (0.1% TFA) and H<sub>2</sub>O (0.1% TFA). Compound purity was determined by integrating the peak areas of liquid chromatogram, monitored at 254 nm. Flow rate (0.5 mL/min): Gradient system, from MeOH (0.1% TFA) 10% and H<sub>2</sub>O (0.1% TFA) 90% (0 min) to MeOH (0.1% TFA) 90% and H<sub>2</sub>O (0.1% TFA) 10% (18 min), the solvent ratio was maintained for 23 min; the solvent ratio was changed to MeOH (0.1% TFA) 10% and H<sub>2</sub>O (0.1% TFA) 90% (25 min). All final compounds were found to have >95% purity. Commercial grade reagents and solvents were used without further purification except as indicated below. Dichloromethane was distilled from calcium hydride. THF was distilled from sodium.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19">II Preparation of Compounds</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> General Procedure (GP I) for Suzuki Coupling</h4><div id="sec4_2_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i21" class="anchor-spacer"></div><h5 class="article-section__title" id="_i21"> 5-Bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>46</b>)</h5><div class="NLM_p last">A solution of 5-bromo-3-iodo-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (600 mg, 1.3 mmol), 3,4-dimethoxyphenylboronic acid (284 mg, 1.56 mmol), Cs<sub>2</sub>CO<sub>3</sub> (1060 mg, 3.25 mmol), and PdCl<sub>2</sub>(dppf)Â·CH<sub>2</sub>Cl<sub>2</sub> (212 mg, 0.26 mmol) in 1,4-dioxane:H<sub>2</sub>O = 3:1 (7 mL) was heated to 80 Â°C for 2 h in sealed tube. The resulting solution was cooled to rt, and 4N KOH solution (4 mL) and MeOH was added. The reaction mixture was then heated to 60 Â°C and stirred for 1 h (<i>N</i>-deprotection of benzenesulfonyl group). The mixture was diluted with water and neutralized with 6 N HCl solution in ice bath. The two-phase mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layer was dried (MgSO<sub>4</sub>) and concentrated in vacuo. The residue was purified with flash column chromatography (EtOAc/hexanes, gradient 1:2 to 1:1) to give the product as yellow solid (369 mg, 85%). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 9.41 (s, 1H), 8.38 (d, <i>J</i> = 2.0 Hz, 1H), 8.28 (d, <i>J</i> = 2.0 Hz, 1H), 7.44 (s, 1H), 7.13 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.05 (d, <i>J</i> = 2.0 Hz, 1H), 6.97 (d, <i>J</i> = 8.2 Hz, 1H). 3.95 (s, 3H), 3.92 (s, 3H).</div></div><div id="sec4_2_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i22" class="anchor-spacer"></div><h5 class="article-section__title" id="_i22"> 3-(3,4-Dimethoxyphenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>47</b>)</h5><div class="NLM_p last">A solution of 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (75 mg, 0.23 mmol), bis(pinacolato)diboron (74.6 mg, 0.29 mmol), KOAc (44.4 mg, 0.452 mmol), and PdCl<sub>2</sub>(dppf)Â·CH<sub>2</sub>Cl<sub>2</sub> (37 mg, 0.045 mmol) in anhydrous 1,4-dioxane was heated to 90 Â°C for 12 h under an atmosphere of N<sub>2</sub>. The reaction mixture was cooled to rt and concentrated in vacuo. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub> and MeOH and then filtered through a short pad of silica (SiO<sub>2</sub>) and Celite eluting with CH<sub>2</sub>Cl<sub>2</sub> and MeOH (15:1). The filtrate was concentrated in vacuo then purified by flash column chromatography (EtOAc/hexanes, gradient 1:3 to 1:1) to give <b>47</b> as brown solid (63.9 mg, 74%). <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) Î´ 12.14 (s, 1H), 8.82 (d, <i>J</i> = 1.4 Hz, 1H), 8.68 (d, <i>J</i> = 1.4 Hz, 1H), 7.54 (s, 1H), 7.28 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.17 (d, <i>J</i> = 2.0 Hz, 1H), 7.02 (d, <i>J</i> = 8.3 Hz, 1H), 3.99 (s, 3H), 3.96 (s, 3H), 1.41(s, 12H).</div></div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> General Procedure (GP II) for Suzuki Coupling</h4><div id="sec4_2_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> 3-(3-(3,4-Dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)aniline (<b>4</b>)</h5><div class="NLM_p last">A solution of 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (40 mg, 0.12 mmol), 3-aminophenylboronic acid (23 mg, 0.15 mmol), Cs<sub>2</sub>CO<sub>3</sub> (78 mg, 0.24 mmol), and PdCl<sub>2</sub>(dppf)Â·CH<sub>2</sub>Cl<sub>2</sub> (20 mg, 0.024 mmol) in 1,4-dioxane/H<sub>2</sub>O = 3:1 (1 mL) was charged in capped tube and was heated to 100 Â°C for 3 h. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub>, and organic phase was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layer was dried with MgSO<sub>4</sub> and concentrated in vacuo. The mixture was purified with flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, gradient 30:1 to 15:1) to give the product as white solid (11 mg, 27%). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 10.57 (s, 1H), 8.56 (d, <i>J</i> = 2.0 Hz, 1H), 8.32 (d, <i>J</i> = 2.0 Hz, 1H), 7.48 (s, 1H), 7.25 (t, <i>J</i> = 7.8 Hz, 1H), 7.20 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.13 (d, <i>J</i> = 2.0 Hz, 1H), 7.01 (d, <i>J</i> = 7.8 Hz, 1H), 6.97 (d, <i>J</i> = 8.3 Hz, 1H), 6.92 (s, 1H), 6.69 (d, <i>J</i> = 7.8 Hz, 1H), 3.93 (s, 3H), 3.92 (s, 3H), 3.00 (br, 2H). <sup>13</sup>C NMR (150 MHz, chloroform-<i>d</i>) Î´ 149.4, 148.6, 147.9, 146.9, 142.5, 140.8, 130.3, 129.9, 127.8, 126.6, 122.2, 119.6, 118. 6, 117.9, 116.7, 114.1, 113. 9, 111.9, 110.9, 56.1. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 346.1556; found, 346.1543.</div></div><div id="sec4_2_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> <i>N</i>-(5-(3-(3,4-Dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)pyridin-3-yl)benzenesulfonamide (<b>1</b>)</h5><div class="NLM_p last">Benzenesulfonyl chloride (10.7 Î¼L, 0.084 mmol), pyridine (11.3 Î¼L, 0.14 mmol), and dichloromethane (1 mL) was added to 5-(3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)pyridin-3-amine (24.3 mg, 0.07 mmol). The reaction mixture was stirred at rt for overnight and then diluted with DCM and brine. Organic phase was extracted with DCM, dried over MgSO<sub>4</sub>. The concentrated crude was purified with flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, gradient 30:1 to 20:1) to give <b>1</b> (11.1 mg, 33%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 12.05 (s, 1H), 10.83 (s, 1H), 8.67 (d, <i>J</i> = 2.0 Hz, 1H), 8.44 (d, <i>J</i> = 2.0 Hz, 1H), 8.30 (s, 2H), 7.88â7.77 (m, 4H), 7.64â7.54 (m, 3H), 7.29â7.26 (m, 2H), 7.03 (d, <i>J</i> = 8.9 Hz, 1H), 3.85 (s, 3H), 3.79 (s, 3H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>22</sub>N<sub>4</sub>O<sub>4</sub>S [M + H]<sup>+</sup>, 487.1; found, 487.2.</div></div><div id="sec4_2_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> 5-(3-(3,4-Dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)pyridin-3-amine (<b>3</b>)</h5><div class="NLM_p last">Compound <b>3</b> was prepared (42.6 mg, 40%) according to GP II (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, gradient 20:1 to 15:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (101 mg, 0.3 mmol) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine (81 mg, 0.368 mmol) as white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.96 (s, 1H), 8.49 (s, 1H), 8.33 (s, 1H), 8.12 (s, 1H), 7.94 (s, 1H), 7.86 (s, 1H), 7.29 (d, <i>J</i> = 8.2 Hz, 1H), 7.23â7.30 (m, 2H), 7.02 (d, <i>J</i> = 8.2 Hz, 1H), 5.42 (s, 2H), 3.84 (s, 3H), 3.78 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 149.2, 148.7, 147.3, 144.9, 141.5, 135.4, 135.1, 134.6, 127.7, 126.3, 125.3, 124.1, 118.7, 117.9, 117.4, 114.8, 112.4, 110.7, 55.6. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 347.1508; found, 347.1508.</div></div><div id="sec4_2_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> 3-(3-(3,4-Dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzonitrile (<b>5</b>)</h5><div class="NLM_p last">Compound <b>5</b> was prepared (31.5 mg, 59%) according to GP II (EtOAc/hexanes, gradient 1:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (50 mg, 0.15 mmol) and (3-cyanophenyl)boronic acid (26.4 mg, 0.18 mmol) as white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.98 (s, 1H), 8.61 (d, <i>J</i> = 2.1 Hz, 1H), 8.49 (d, <i>J</i> = 2.1 Hz, 1H), 8.30 (s, 1H), 8.12 (d, <i>J</i> = 7.8 Hz, 1H), 7.86 (s, 1H), 7.81 (d, <i>J</i> = 7.8 Hz, 1H), 7.67 (t, <i>J</i> = 7.8 Hz, 1H), 7.35 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.27 (d, <i>J</i> = 2.0 Hz, 1H), 7.03 (d, <i>J</i> = 8.3 Hz, 1H), 3.85 (s, 3H), 3.78 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 149.2, 148.8, 147.3, 141.9, 140.3, 131.8, 130.6, 130.4, 130.1, 127.6, 126.5, 125.9, 124.2, 118.9, 118.8, 117.4, 115.1, 112.4, 112.1, 110.7, 55.6. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub> [M + Na]<sup>+</sup>, 378.1218; found, 378.1217.</div></div><div id="sec4_2_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> 3-(3-(3,4-Dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-<i>N</i>,<i>N</i>-dimethylaniline (<b>6</b>)</h5><div class="NLM_p last">Compound <b>6</b> was prepared (13.7 mg, 30%) according to GP II (EtOAc/hexanes, gradient 1:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (40 mg, 0.122 mmol) and (3-(dimethylamino)phenyl) boronic acid (24.2 mg, 0.146 mmol) as white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.85 (s, 1H), 8.51 (d, <i>J</i> = 2.1 Hz, 1H), 8.33 (d, <i>J</i> = 2.1 Hz, 1H), 7.81 (s, 1H), 7.29â7.21 (m, 3H), 7.03 (d, <i>J</i> = 7.5 Hz, 1H), 6.99â6.94 (m, 2H), 6.72 (d, <i>J</i> = 7.5 Hz, 1H), 3.84 (s, 3H), 3.77 (s, 3H) 2.95 (s, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 150.9, 149.1, 148.5, 147.2, 142.0, 139.9, 129.6, 129.4, 127.9, 125.3, 123.8, 118.5, 117.3, 115.2, 114.7, 112.5, 111.1, 111.1, 110.6, 55.6, 55.5, 40.2. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>23</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 374.1869; found, 374.1845.</div></div><div id="sec4_2_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 3-(3,4-Dimethoxyphenyl)-5-(<i>m</i>-tolyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pfyridine (<b>7</b>)</h5><div class="NLM_p last">Compound <b>7</b> was prepared (9.9 mg, 60%) according to GP II (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, gradient 60:1 to 30:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (16 mg, 0.048 mmol) and <i>m</i>-tolylboronic acid (7.8 mg, 0.58 mmol) as white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.87 (s, 1H), 8.52 (d, <i>J</i> = 2.1 Hz, 1H), 8.34 (d, <i>J</i> = 2.1 Hz, 1H), 7.81 (s, 1H), 7.54 (s, 1H), 7.51 (d, <i>J</i> = 7.6 Hz, 1H), 7.36 (t, <i>J</i> = 7.6 Hz, 1H), 7.29 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 7.25 (d, <i>J</i> = 2.1 Hz, 1H), 7.17 (d, <i>J</i> = 7.6 Hz, 1H), 7.03 (d, <i>J</i> = 8.2 Hz, 1H), 3.84 (s, 3H), 3.77 (s, 3H), 2.38 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 149.2, 148.5, 147.3, 141.8, 139.0, 138.1, 128.8, 128.7, 127.8, 127.7, 127.5, 125.2, 124.1, 123.9, 118.7, 117.4, 114.8, 112.5, 110.7, 55.6, 55.6, 21.1. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup>, 367.1422; found, 367.1423.</div></div><div id="sec4_2_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 3-(3,4-Dimethoxyphenyl)-5-(3-fluorophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>8</b>)</h5><div class="NLM_p last">Compound <b>8</b> was prepared (18.2 mg, 65%) according to GP II (EA/HX, gradient 1:3 to 1:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (26.5 mg, 0.08 mmol) and 3-fluorophenylboronic acid (15.7 mg, 0.1 mmol). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 10.80 (s, 1H), 8.59 (s, 1H), 8.34 (s, 1H), 7.53 (s, 1H), 7.45â7.39 (m, 2H), 7.31â7.33 (m, 1H), 7.21 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.13 (d, <i>J</i> = 2.0 Hz, 1H), 7.04â7.08 (m, 1H), 6.99 (d, <i>J</i> = 8.2 Hz, 1H), 3.94 (s, 3H), 3.93 (s, 3H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>17</sub>FN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 349.1; found, 349.2.</div></div><div id="sec4_2_2_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> 3-(3,4-Dimethoxyphenyl)-5-phenyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>9</b>)</h5><div class="NLM_p last">Compound <b>9</b> was prepared (42.4 mg, 43%) according to GP II (EtOAc/CH<sub>2</sub>Cl<sub>2</sub>, gradient 1:5 to 1:3) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (99 mg, 0.3 mmol) and phenylboronic acid (43.9 mg, 0.36 mmol) as white solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 11.19 (s, 1H), 8.62 (d, <i>J</i> = 2.1 Hz, 1H), 8.37 (d, <i>J</i> = 2.1 Hz, 1H), 7.67â7.61 (m, 2H), 7.53 (s, 1H), 7.48 (t, <i>J</i> = 7.5 Hz, 2H), 7.37 (t, <i>J</i> = 7.5 Hz, 1H), 7.22 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.15 (d, <i>J</i> = 2.0 Hz, 1H), 6.98 (d, <i>J</i> = 8.2 Hz, 1H), 3.94 (s, 3H), 3.93 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 149.27, 148.6, 147.3, 141.8, 139.1, 129.0, 128.6, 127.8, 127.1, 126.9, 125.3, 124.0, 118.7, 117.4, 114.9, 112.5, 110.6, 55.6. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub> [M + Na]<sup>+</sup>, 353.1266; found, 353.1253.</div></div><div id="sec4_2_2_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 3-(3,4-Dimethoxyphenyl)-5-(pyridin-4-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>10</b>)</h5><div class="NLM_p last">Compound <b>10</b> was prepared (19.9 mg, 72%) according to GP II (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, gradient 30:1 to 10:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (28 mg, 0.084 mmol) and 4-pyridinylboronic acid (12.4 mg, 0.101 mmol) as white solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 10.01 (s, 1H), 8.72â8.65 (m, 3H), 8.40 (d, <i>J</i> = 2.0 Hz, 1H), 7.56â7.58 (m, 2H), 7.52 (s, 1H), 7.20 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.12 (d, <i>J</i> = 2.0 Hz, 1H), 7.00 (d, <i>J</i> = 8.3 Hz, 1H), 3.95 (s, 3H), 3.94 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 150.1, 149.3, 149.2, 147.4, 146.1, 141.8, 127.5, 125.7, 125.4, 124.4, 121.4, 118.8, 117.4, 115.2, 112.5, 110.7, 55.6. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 332.1399; found, 332.1372.</div></div><div id="sec4_2_2_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 3-(3,4-Dimethoxyphenyl)-5-(pyridin-3-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>11</b>)</h5><div class="NLM_p last">Compound <b>11</b> was prepared (31 mg, 62%) according to GP II (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, gradient 30:1 to 15:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (50 mg, 0.15 mmol) and 3-pyridinylboronic acid (22.1 mg, 0.18 mmol) as white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 12.00 (s, 1H), 8.99 (s, 1H), 8.60 (d, <i>J</i> = 2.2 Hz, 1H), 8.56â8.57 (m, 1H), 8.47 (d, <i>J</i> = 2.2 Hz, 1H), 8.17 (d, <i>J</i> = 8.0 Hz, 1H), 7.87 (s, 1H), 7.48 (dd, <i>J</i> = 8.0, 4.8 Hz, 1H), 7.33 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 7.29 (d, <i>J</i> = 2.1 Hz, 1H), 7.02 (d, <i>J</i> = 8.2 Hz, 1H), 3.85 (s, 3H), 3.78 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 149.2, 148.8, 147.9, 147.3, 141.8, 134.7, 134.5, 127.6, 125.8, 125.5, 124.2, 123.9, 118.8, 117.5, 115.0, 112.4, 110.7, 55.6, 55.6. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 332.1399; found, 332.1385.</div></div><div id="sec4_2_2_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 3-(3,4-Dimethoxyphenyl)-5-<i>o</i>-tolyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>12</b>)</h5><div class="NLM_p last">Compound <b>12</b> was prepared (13.3 mg, 68%) according to GP II (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, gradient 30:1 to 10:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (18.9 mg, 0.057 mmol) and <i>o</i>-tolylboronic acid (9.3 mg, 0.068 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.90 (s, 1H), 8.22 (d, <i>J</i> = 2.1 Hz, 1H), 8.12 (d, <i>J</i> = 2.1 Hz, 1H), 7.84 (s, 1H), 7.27â7.32 (m, 4H), 7.25â7.22 (m, 2H), 6.99 (d, <i>J</i> = 8.7 Hz, 1H), 3.82 (s, 3H), 3.76 (s, 3H), 2.28 (s, 3H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 345.2; found, 345.2.</div></div><div id="sec4_2_2_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 2-(3-(3,4-Dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)aniline (<b>13</b>)</h5><div class="NLM_p last">Compound <b>13</b> was prepared (14.7 mg, 67%) according to GP II (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, gradient 30:1 to 1:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (21.4 mg, 0.064 mmol) and 2-aminophenylboronic acid (10.5 mg, 0.0768 mmol). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 10.21 (s, 1H), 8.44 (d, <i>J</i> = 2.0 Hz, 1H), 8.30 (d, <i>J</i> = 2.0 Hz, 1H), 7.52 (s, 1H), 7.21â7.17 (m, 3H), 7.13 (d, <i>J</i> = 2.0 Hz, 1H), 6.94 (d, <i>J</i> = 8.2 Hz, 1H), 6.86 (d, <i>J</i> = 7.7 Hz, 1H), 6.80 (d, <i>J</i> = 7.7 Hz, 1H), 3.93 (s, 3H), 3.91 (s, 3H), 3.75 (s, 2H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 346.2; found, 346.2.</div></div><div id="sec4_2_2_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 4-(3-(3,4-Dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzonitrile (<b>14</b>)</h5><div class="NLM_p last">Compound <b>14</b> was prepared (15.1 mg, 48%) according to GP III (EtOAc/hexanes, gradient 1:1 to 2:1) from 3-(3,4-dimethoxyphenyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (34 mg, 0.0894 mmol) and 4-bromobenzonitrile (19.5 mg, 0.107 mmol). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 10.61 (s, 1H), 8.60 (d, <i>J</i> = 2.0 Hz, 1H), 8.35 (d, <i>J</i> = 2.0 Hz, 1H), 7.76â7.71 (m, 4H), 7.54 (s, 1H), 7.20 (dd, <i>J</i> = 8.2, 1.9 Hz, 1H), 7.12 (d, <i>J</i> = 1.9 Hz, 1H), 6.99 (d, <i>J</i> = 8.2 Hz, 1H), 3.94 (s, 3H), 3.93 (s, 3H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 356.2; found, 356.2.</div></div><div id="sec4_2_2_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 3-(3,4-Dimethoxyphenyl)-5-(4-fluorophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>15</b>)</h5><div class="NLM_p last">Compound <b>15</b> was prepared (8.4 mg, 31%) according to GP II (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, gradient 30:1 to 10:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (26 mg, 0.078 mmol) and 4-fluorophenylboronic acid (13.2 mg, 0.094 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.90 (s, 1H), 8.52 (d, <i>J</i> = 2.1 Hz, 1H), 8.35 (d, <i>J</i> = 2.1 Hz, 1H), 7.83 (s, 1H), 7.77â7.83 (m, 2H), 7.32â7.28 (m, 3H), 7.26 (d, <i>J</i> = 2.0 Hz, 1H), 7.03 (d, <i>J</i> = 8.2 Hz, 1H), 3.84 (s, 3H), 3.78 (s, 3H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>17</sub>FN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup> ,349.1; found, 349.1.</div></div><div id="sec4_2_2_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 5-(4-Chlorophenyl)-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>16</b>)</h5><div class="NLM_p last">Compound <b>16</b> was prepared (20.3 mg, 76%) according to GP II (EtOAc/hexanes, gradient 1:3 to 1:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (24.3 mg, 0.0735 mmol) and 4-chlorophenylboronic acid (13.8 mg, 0.088 mmol). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 9.39 (s, 1H), 8.54 (d, <i>J</i> = 2.1 Hz, 1H), 8.29 (d, <i>J</i> = 2.1 Hz, 1H), 7.55 (d, <i>J</i> = 8.5 Hz, 2H), 7.47 (s, 1H), 7.43 (d, <i>J</i> = 8.5 Hz, 2H), 7.20 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.12 (d, <i>J</i> = 2.0 Hz, 1H), 6.98 (d, <i>J</i> = 8.2 Hz, 1H), 3.94 (s, 3H), 3.93 (s, 3H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>17</sub>ClN<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 365.1; found, 365.1.</div></div><div id="sec4_2_2_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 3-(3,4-Dimethoxyphenyl)-5-<i>p</i>-tolyl-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>17</b>)</h5><div class="NLM_p last">Compound <b>17</b> was prepared (34.4 mg, 57%) according to GP II (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, gradient 30:1 to 15:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (58 mg, 0.174 mmol) and <i>p</i>-tolylboronic acid (28.5 mg, 0.209 mmol). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 11.34 (s, 1H), 8.60 (d, <i>J</i> = 2.1 Hz, 1H), 8.35 (d, <i>J</i> = 2.1 Hz, 1H), 7.51â7.54 (m, 3H), 7.28 (d, <i>J</i> = 7.7 Hz, 2H), 7.21 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.15 (d, <i>J</i> = 2.0 Hz, 1H), 6.97 (d, <i>J</i> = 8.2 Hz, 1H), 3.93(s, 6H), 2.41 (s, 3H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 345.2; found, 345.2.</div></div><div id="sec4_2_2_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 3-(3,4-Dimethoxyphenyl)-5-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>18</b>)</h5><div class="NLM_p last">Compound <b>18</b> was prepared (22.2 mg, 68%) according to GP II (EtOAc/hexanes, gradient 1:3 to 1:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (29.9 mg, 0.09 mmol) and 4-methoxyphenylboronic acid (16.4 mg, 0.108 mmol). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 9.94 (s, 1H), 8.55 (d, <i>J</i> = 2.1 Hz, 1H), 8.30 (d, <i>J</i> = 2.1 Hz, 1H), 7.55 (d, <i>J</i> = 8.7 Hz, 2H), 7.48 (s, 1H), 7.21 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.15 (d, <i>J</i> = 2.0 Hz, 1H), 7.01 (d, <i>J</i> = 8.7 Hz, 2H), 6.98 (d, <i>J</i> = 8.2 Hz, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 3.85 (s, 3H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 361.2 ; found, 361.2.</div></div><div id="sec4_2_2_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 3,5-Bis(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>19</b>)</h5><div class="NLM_p last">Compound <b>19</b> was prepared (27 mg, 58%) according to GP II (EtOAc/hexanes, 2:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (40 mg, 0.12 mmol) and 3,4-dimethoxyphenylboronic acid (26.2 mg, 0.14 mmol) as white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.86 (s, 1H), 8.54 (d, <i>J</i> = 2.1 Hz, 1H), 8.35 (d, <i>J</i> = 2.1 Hz, 1H), 7.81 (s, 1H), 7.31â7.28 (m, 3H), 7.24 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.01â7.05 (m, 2H), 3.86 (s, 3H), 3.86 (s, 3H), 3.79 (s, 3H), 3.78 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 149.2, 149.2, 148.3, 148.2, 147.2, 141.8, 131.9, 128.7, 127.9, 125.0, 123.8, 119.1, 118.6, 117.3, 114.7, 112.5, 112.4, 111.0, 110.6, 55.6, 55.5. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub> [M + Na]<sup>+</sup>, 413.1477; found, 413.1482</div></div><div id="sec4_2_2_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 5-(3,5-Difluorophenyl)-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>20</b>)</h5><div class="NLM_p last">Compound <b>20</b> was prepared (24.1 mg, 82%) according to GP II (EtOAc/hexanes, gradient 1:3 to 1:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (26.8 mg, 0.0804 mmol) and 3,5-difluorophenylboronic acid (15.2 mg, 0.0965 mmol). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 10.23 (s, 1H), 8.48 (d, <i>J</i> = 2.0 Hz, 1H), 8.30 (d, <i>J</i> = 2.0 Hz, 1H), 7.51 (s, 1H), 7.45 (td, <i>J</i> = 8.6, 6.4 Hz, 1H), 7.19 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 7.14 (d, <i>J</i> = 2.0 Hz, 1H), 7.01â6.92 (m, 3H), 3.94 (s, 3H), 3.92 (s, 3H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>16</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 367.1; found, 367.1.</div></div><div id="sec4_2_2_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 3-(3-(3,4,5-Trimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)aniline (<b>21</b>)</h5><div class="NLM_p last">5-Bromo-3-(3,4,5-trimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine was prepared (91 mg, 77%) according to GP I from 5-bromo-3-iodo-1-(phenyl- sulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (150 mg, 0.325 mmol) and (3,4,5-trimethoxyphenyl)boronic acid (82.6 mg, 0.390 mmol). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 9.62 (s, 1H), 8.39 (s, 1H), 8.27 (s, 1H), 7.46 (s, 1H), 6.75 (s, 2H), 3.93 (s, 6H), 3.89 (s, 3H). Compound <b>21</b> was prepared (42.3 mg, 47%) according to GP II (EA/HX 2:1) 5-bromo-3-(3,4,5-trimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (87 mg, 0.24 mmol) and 3-aminophenylboronic acid (44.5 mg, 0.29 mmol) as white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.92 (s, 1H), 8.47 (d, <i>J</i> = 2.0 Hz, 1H), 8.29 (d, <i>J</i> = 2.0 Hz, 1H), 7.86 (s, 1H), 7.12 (t, <i>J</i> = 7.8 Hz, 1H), 6.95 (s, 2H), 6.91 (s, 1H), 6.87 (d, <i>J</i> = 7.8 Hz, 1H), 6.56 (d, <i>J</i> = 7.8 Hz, 1H), 5.18 (s, 2H), 3.87 (s, 6H), 3.69 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 153.3, 149.2, 148.4, 141.7, 139.6, 135.9, 130.7, 129.5, 129.4, 124.7, 124.4, 117.3, 114.9, 114.5, 112.7, 112.4, 104.1, 60.15, 56.0. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H21N<sub>3</sub>O<sub>3</sub> [M + Na]<sup>+</sup>, 398.1481; found, 398.1471.</div></div><div id="sec4_2_2_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 3-(3-(3-Fluoro-4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)aniline (<b>22</b>)</h5><div class="NLM_p last">5-Bromo-3-(3-fluoro-4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine was prepared (85.1 mg, 61%) according to GP I from 5-bromo-3-iodo-1-(phenyl- sulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (200 mg, 0.432 mmol) and 3-fluoro-4-methoxyphenylboronic acid (88.1 mg, 0.518 mmol). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 9.79 (s, 1H), 8.38 (d, <i>J</i> = 2.1 Hz, 1H), 8.28 (d, <i>J</i> = 2.1 Hz, 1H), 7.44 (s, 1H), 7.32â7.28 (m, 1H), 7.28â7.26 (m, 1H), 7.04 (t, <i>J</i> = 8.8 Hz, 1H), 3.93 (s, 3H). Compound <b>22</b> was prepared (37 mg, 46.1%) according to GP II (EA/HX, gradient 2:1) from 5-bromo-3-(3-fluoro-4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (77.3 mg, 0.24 mmol) and 3-aminophenylboronic acid (44.8 mg, 0.29 mmol) as white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.93 (s, 1H), 8.47 (d, <i>J</i> = 2.1 Hz, 1H), 8.28 (d, <i>J</i> = 2.1 Hz, 1H), 7.86 (s, 1H), 7.52â7.60 (m, 2H), 7.23 (t, <i>J</i> = 8.9 Hz, 1H), 7.12 (t, <i>J</i> = 7.8 Hz, 1H), 6.91 (s, 1H), 6.87 (d, <i>J</i> = 7.8 Hz, 1H), 6.57 (d, J = 7.8 Hz, 1H), 5.15 (s, 2H), 3.86 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 151.9 (d, <i>J</i> = 243.2 Hz), 149.2, 148.4, 145.2 (d, <i>J</i> = 10.7 Hz), 141.8, 139.6, 129.6, 129.5, 128.3 (d, <i>J</i> = 7.0 Hz), 124.8, 124.3, 122.4 (d, <i>J</i> = 3.3 Hz), 117.1, 114.8, 114.4 (d, <i>J</i> = 2.3 Hz), 113.8 (d, <i>J</i> = 18.4 Hz), 113.3 (d, <i>J</i> = 1.9 Hz), 112.8, 112.5, 56.1. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>16</sub>FN<sub>3</sub>O [M + H]<sup>+</sup>, 334.1356; found, 334.1326.</div></div><div id="sec4_2_2_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 2,3â²-(1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridine-3,5-diyl)dianiline (<b>23</b>)</h5><div class="NLM_p last">2-(5-Bromo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)aniline was prepared (32.5 mg, 50%) according to GP I (EtOAc/hexanes, gradient 1:3 to 1:1) from 5-bromo-3-iodo-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (105.2 mg, 0.2278 mmol) and 2-aminophenylboronic acid (37.4 mg, 0.2734 mmol). <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) 11.42 (s, 1H), 8.64 (d, <i>J</i> = 2.0 Hz, 1H), 8.45 (d, <i>J</i> = 2.0 Hz, 1H), 7.80 (s, 1H), 7.56â7.47 (m, 2H), 7.18â7.13 (m, 2H). Compound <b>23</b> was prepared (8.9 mg, 26.3%) according to GP II (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, gradient 30:1 to 15:1) from 2-(5-bromo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)aniline (32.5 mg, 0.1128 mmol) and 3-aminophenylboronic acid (18.5 mg, 0.135 mmol). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 9.52 (s, 1H), 8.58 (d, <i>J</i> = 2.1 Hz, 1H), 8.11 (d, <i>J</i> = 2.1 Hz, 1H), 7.47 (s, 1H), 7.29 (d, <i>J</i> = 7.5 Hz, 1H), 7.23â7.14 (m, 2H), 7.00 (d, <i>J</i> = 7.5 Hz, 1H), 6.91 (s, 1H), 6.87â6.77 (m, 2H), 6.66 (d, <i>J</i> = 7.5 Hz, 1H), 3.83 (s, 2H), 3.74 (s, 2H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>16</sub>N<sub>4</sub> [M + H]<sup>+</sup>, 301.1; found, 301.2.</div></div><div id="sec4_2_2_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 5-Bromo-3-(<i>p</i>-tolyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>24</b>)</h5><div class="NLM_p last">5-Bromo-3-(<i>p</i>-tolyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine was prepared (22.4 mg, 36%) according to GP I (EtOAc/hexanes, gradient 1:4 to 1:1) from 5-bromo-3-iodo-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (100 mg, 0.2168 mmol) and <i>p</i>-tolylboronic acid (37.4 mg, 0.2734 mmol). <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) 9.34 (s, 1H), 8.33 (s, 1H), 8.27 (s, 1H), 7.44â7.41 (m, 3H), 7.26â7.23 (m, 2H). Compound <b>24</b> was prepared (10.2 mg, 45.2%) according to GP II (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, gradient 20:1 to 15:1) from 5-bromo-3-(<i>p</i>-tolyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (22.4 mg, 0.078 mmol) and 3-aminophenylboronic acid (14.6 mg, 0.094 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.88 (s, 1H), 8.45 (d, <i>J</i> = 2.1 Hz, 1H), 8.27 (d, <i>J</i> = 2.1 Hz, 1H), 7.82 (s, 1H), 7.63 (d, <i>J</i> = 7.9 Hz, 2H), 7.26 (d, <i>J</i> = 7.9 Hz, 2H), 7.11 (t, <i>J</i> = 7.7 Hz, 1H), 6.89 (s, 1H), 6.85 (d, <i>J</i> = 7.7 Hz, 1H), 6.57â6.54 (m, 1H), 5.15 (s, 2H), 2.33 (s, 3H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>17</sub>N<sub>3</sub> [M + H]<sup>+</sup>, 300.2; found, 300.2.</div></div><div id="sec4_2_2_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 3-(3-(4-Methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)aniline (<b>25</b>)</h5><div class="NLM_p last">5-Bromo-3-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine was prepared (118 mg, 60%) according to GP I from 5-bromo-3-iodo-1-(phenyl-sulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (300 mg, 0.649 mmol) and 4-methoxyphenylboronic acid (118.4 mg, 0.78 mmol). <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) Î´ 9.29 (s, 1H), 8.36 (dd, <i>J</i> = 2.1, 0.4 Hz, 1H), 8.28 (d, <i>J</i> = 2.1, 1H), 7.49 (d, <i>J</i> = 8.8 Hz, 2H), 7.41 (s, 1H), 7.00 (d, <i>J</i> = 8.8 Hz, 2H), 3.85 (s, 3H). Compound <b>25</b> was prepared (83.7 mg, 69%) according to GP II (EtOAc/hexanes, 2:1) from 5-bromo-3-(4-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (117 mg, 0.39 mmol) and 3-aminophenylboronic acid (71.8 mg, 0.46 mmol) as white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.84 (s, 1H), 8.45 (d, <i>J</i> = 2.0 Hz, 1H), 8.26 (d, <i>J</i> = 2.0 Hz, 1H), 7.76 (s, 1H), 7.66 (d, <i>J</i> = 8.7 Hz, 2H), 7.12 (t, <i>J</i> = 7.7 Hz, 1H), 7.02 (d, <i>J</i> = 8.7 Hz, 2H), 6.90 (s, 1H), 6.85 (d, <i>J</i> = 7.7 Hz, 1H), 6.57 (d, <i>J</i> = 7.7 Hz, 1H), 5.15 (s, 2H), 3.78 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 157.5, 149.1, 148.4, 141.6, 139.6, 129.4, 129.4 127.6 127.4, 124.8 123.5 117.3 114.7 114.4 112.7 112.4, 55.1 HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>17</sub>N<sub>3</sub>O [M + H]<sup>+</sup>, 316.1450; found, 316.1424.</div></div><div id="sec4_2_2_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> 3-(3-(3-Methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)aniline (<b>26</b>)</h5><div class="NLM_p last">5-Bromo-3-(3-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine was prepared (34.1 mg, 52%) according to GP I (EtOAc/hexanes, gradient 1:5 to 1:1) from 5-bromo-3-iodo-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (99.7 mg, 0.216 mmol) and 3-methoxypheylboronic acid (39.4 mg, 0.259 mmol). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 12.18 (s, 1H), 8.39 (d, <i>J</i> = 2.1 Hz, 1H), 8.32 (d, <i>J</i> = 2.1 Hz, 1H), 7.97 (s, 1H), 7.35 (t, <i>J</i> = 7.9 Hz, 1H), 7.28 (d, <i>J</i> = 7.9 Hz, 1H), 7.20 (s, 1H), 6.84 (d, <i>J</i> = 7.9 Hz, 1H). Compound <b>26</b> was prepared (6.5 mg, 36.8%) according to GP II (EtOAc/hexanes, gradient 1:1 to 2:1) from 5-bromo-3-(3-methoxyphenyl)-1H-pyrrolo[2,3-<i>b</i>]pyridine (17 mg, 0.056 mmol) and 3-aminophenylboronic acid (9.2 mg, 0.0672 mmol). <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) Î´ 10.63 (s, 1H), 8.58 (s, 1H), 8.37 (s, 1H), 7.56 (s, 1H), 7.38 (s, 1H), 7.27â7.20 (m, 3H), 7.03 (d, <i>J</i> = 8.1 Hz, 1H), 6.93 (s, 1H), 6.86 (d, <i>J</i> = 8.4 Hz, 1H), 6.70 (d, <i>J</i> = 8.4 Hz, 1H), 3.86 (s, 3H), 3.79 (s, 2H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>17</sub>N<sub>3</sub>O [M + H]<sup>+</sup>, 316.1; found, 316.2.</div></div><div id="sec4_2_2_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> 3-(3-(3,5-Dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)aniline (<b>27</b>)</h5><div class="NLM_p last">5-Bromo-3-(3,5-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine was prepared (12.7 mg, 18%) according to GP I (EtOAc/hexanes, gradient 1:4 to 1:1) from 5-bromo-3-iodo-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (100 mg, 0.216 mmol) and 3,5-dimethoxyphenylboronic acid (47.2 mg, 0.259 mmol). <sup>1</sup>H NMR (300 MHz, methanol-<i>d</i><sub>4</sub>) Î´ 8.31 (d, <i>J</i> = 2.1 Hz, 1H), 8.25 (d, <i>J</i> = 2.1 Hz, 1H), 7.61 (s, 1H), 7.16â7.14 (m, 2H), 7.02 (d, <i>J</i> = 8.9 Hz, 1H). Compound <b>27</b> was prepared (4.5 mg, 34%) according to GP II (EtOAc/hexanes, gradient 1:1 to 2:1) from 5-bromo-3-(3,5-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (12.7 mg, 0.038 mmol) and 3-aminophenylboronic acid (6.2 mg, 0.0456 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.97 (s, 1H), 8.46 (d, <i>J</i> = 2.1 Hz, 1H), 8.25 (d, <i>J</i> = 2.1 Hz, 1H), 7.91 (s, 1H), 7.12 (t, <i>J</i> = 7.9 Hz, 1H), 6.89 (s,, 1H), 6.85â6.83 (m, 3H), 6.56 (d, <i>J</i> = 7.9 Hz, 1H), 6.42 (s, 1H), 5.17 (s, 2H), 3.81 (s, 6H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 346.2; found, 346.2.</div></div><div id="sec4_2_2_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> 3,3â²-(1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridine-3,5-diyl)dianiline (<b>28</b>)</h5><div class="NLM_p last">3-(5-Bromo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)aniline was prepared (27.8 mg, 45%) according to GP I (EtOAc/hexanes, gradient 1:2 to 1:1) from 5-bromo-3-iodo-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (100 mg, 0.216 mmol) and 3-aminophenylboronic acid (35.6 mg, 0.26 mmol). <sup>1</sup>H NMR (300 MHz, methanol-<i>d</i><sub>4</sub>) Î´ 8.35 (d, <i>J</i> = 2.1 Hz, 1H), 8.24 (d, <i>J</i> = 2.1 Hz 1H), 7.57 (s, 1H), 7.16 (t, <i>J</i> = 7.9 Hz, 1H), 7.00 (s, 1H), 6.94â6.92 (m, 1H), 6.66 (dd, <i>J</i> = 7.9, 2.1 Hz, 1H). Compound <b>28</b> was prepared (6.8 mg, 23.5%) according to GP II (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, gradient 30:1 to 15:1) from 3-(5-bromo-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-3-yl)aniline (27.8 mg, 0.0965 mmol) and 3-aminophenylboronic acid (15.9 mg, 0.1158 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.83 (s, 1H), 8.43 (d, <i>J</i> = 2.1 Hz, 1H), 8.29 (d, <i>J</i> = 2.1 Hz, 1H), 7.71 (s, 1H), 7.12 (t, <i>J</i> = 7.8 Hz, 1H), 7.07 (t, <i>J</i> = 7.6 Hz, 1H), 6.97 (s, 1H), 6.88 (s, 1H), 6.86â6.83 (m, 2H), 6.56 (d, <i>J</i> = 7.8 Hz, 1H), 6.46 (d, <i>J</i> = 7.6 Hz, 1H), 5.15 (s, 2H), 5.10 (s, 2H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>16</sub>N<sub>4</sub> [M + H]<sup>+</sup>, 301.1; found, 301.2.</div></div><div id="sec4_2_2_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> 3-(3-(4-Chlorophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)aniline (<b>29</b>)</h5><div class="NLM_p last">5-Bromo-3-(4-chlorophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine was prepared (19.2 mg, 28%) according to GP I (EtOAc/hexanes, gradient 1:3 to 1:1) from 5-bromo-3-iodo-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (101.4 mg, 0.2195 mmol) and 4-chlorophenylboronic acid (41.2 mg, 0.2634 mmol). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.65 (s, 1H), 8.45 (d, <i>J</i> = 2.1 Hz, 1H), 8.33 (d, <i>J</i> = 2.1 Hz, 1H), 8.01 (s, 1H), 7.75 (d, <i>J</i> = 8.5 Hz, 2H), 7.46 (d, <i>J</i> = 8.5 Hz, 2H). Compound <b>29</b> was prepared (2.4 mg, 12%) according to GP II (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, 30:1) from 5-bromo-3-(4-chlorophenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (19.2 mg, 0.0624 mmol) and 3-aminophenylboronic acid (10.3 mg, 0.0749 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 12.02 (s, 1H), 8.46 (d, <i>J</i> = 2.1 Hz, 1H), 8.30 (d, <i>J</i> = 2.1 Hz, 1H), 7.94 (s, 1H), 7.79 (d, <i>J</i> = 8.5 Hz, 2H), 7.48 (d, <i>J</i> = 8.5 Hz, 2H), 7.12 (t, <i>J</i> = 7.8 Hz, 1H), 6.89 (s, 1H), 6.86 (d, <i>J</i> = 7.8 Hz, 1H), 6.57 (d, <i>J</i> = 7.8 Hz, 1H), 5.15 (s, 2H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>14</sub>ClN<sub>3</sub> [M + H]<sup>+</sup>, 320.1; found, 320.1.</div></div><div id="sec4_2_2_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> <i>N</i>-(3-(3-(3,4-Dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)phenyl)acetamide (<b>30</b>)</h5><div class="NLM_p last">Compound <b>30</b> was prepared (41.9 mg, 31%) according to GP II (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, gradient 30:1 to 15:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (117 mg, 0.351 mmol) and <i>N</i>-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide (110 mg, 0.421 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.91 (s, 1H), 10.02 (s, 1H), 8.50 (d, <i>J</i> = 2.0 Hz, 1H), 8.32 (d, <i>J</i> = 2.0 Hz, 1H), 7.91 (s, 1H), 7.84 (s, 1H), 7.59 (d, <i>J</i> = 7.1 Hz, 1H), 7.43â7.37 (m, 2H), 7.28â7.26 (m, 2H), 7.04 (d, <i>J</i> = 8.2 Hz, 1H), 3.85 (s, 3H), 3.78 (s, 3H), 2.06 (s, 3H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 388.2; found, 388.2.</div></div><div id="sec4_2_2_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> (2-Amino-4-(3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)phenyl)(morpholino)-methanone (<b>31</b>)</h5><div class="NLM_p last">Compound <b>31</b> was prepared (52.4 mg, 43%) according to GP II (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, gradient 20:1 to 15:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (90 mg, 0.267 mmol) and (2-amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)(morpholino)methanone (107 mg, 0.321 mmol) as as pale-yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.90 (s, 1H), 8.51 (s, 1H), 8.33 (s, 1H), 7.82 (s, 1H), 7.28â7.25 (m, 2H), 7.12 (d, <i>J</i> = 7.8 Hz, 1H), 7.09 (s, 1H), 7.03 (d, <i>J</i> = 8.1 Hz, 1H), 6.96 (d, <i>J</i> = 7.8 Hz, 1H), 5.34 (s, 2H), 3.84 (s, 3H), 3.77 (s, 3H) 3.61â3.60 (m, 4H), 4H. <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 168.6, 149.2, 148.6, 147.3, 146.6, 141.6, 140.8, 128.8, 128.4, 127.8, 125.0, 124.0, 118.7, 117.6, 117.4, 114.9, 114.4, 113.8, 112.5, 110.7, 66.2, 55.6, 55.6. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub> [M + Na]<sup>+</sup>, 481.1852; found, 481.1866.</div></div><div id="sec4_2_2_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 3-(3,4-Dimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>32</b>)</h5><div class="NLM_p last">Compound <b>32</b> was prepared (37 mg, 59%) according to GP II (EtOAc/hexanes, 2:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (50 mg, 0.15 mmol) and (3,4,5-trimethoxyphenyl) boronic acid (38.2 mg, 0.18 mmol) as white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.89 (s, 1H), 8.57 (d, <i>J</i> = 2.1 Hz, 1H), 8.40 (d, <i>J</i> = 2.1 Hz, 1H), 7.82 (s, 1H), 7.32â7.29 (m, 2H), 7.02 (d, <i>J</i> = 8.1 Hz, 1H), 6.99 (s, 2H), 3.87 (s, 6H), 3.86 (s, 3H), 3.78 (s, 3H), 3.70 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 153.3, 149.2, 148.5, 147.2, 142.0, 136.8, 135.0, 128.9, 127.9, 125.5, 123.9, 118.6, 117.2, 114.8, 112.5, 110.6, 104.7, 60.0, 56.0, 55.6, 55.5. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub> [M + Na]<sup>+</sup>, 443.1583; found, 443.1566.</div></div><div id="sec4_2_2_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> 5-(3-(3,4-Dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-2-methylaniline (<b>33</b>)</h5><div class="NLM_p last">Compound <b>33</b> was prepared (31.8 mg, 57%) according to GP II (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, gradient 60:1 to 30:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (50 mg, 0.15 mmol) and 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (42 mg, 0.18 mmol) as white solid. <sup>1</sup>H NMR(400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.82 (s, 1H), 8.44 (d, <i>J</i> = 2.1 Hz, 1H), 8.24 (d, <i>J</i> = 2.1 Hz, 1H), 7.79 (s, 1H), 7.26â7.23 (m, 2H), 7.04 (d, <i>J</i> = 8.0 Hz, 1H), 7.01 (d, <i>J</i> = 7.6 Hz, 1H), 6.95 (d, <i>J</i> = 1.9 Hz, 1H), 6.82 (dd, <i>J</i> = 7.6, 1.9 Hz, 1H), 4.91 (s, 2H), 3.84 (s, 3H), 3.78 (s, 3H), 2.08 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 149.2, 148.3, 147.2, 147.0, 141.6, 137.2, 130.5, 129.3, 127.9, 124.6, 123.7, 120.0, 118.5, 117.4, 114.7, 114.6, 112.5, 112.4, 110.6, 55.6, 55.6, 17.1. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 360.1712; found, 360.1691.</div></div><div id="sec4_2_2_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> 5-(3-(3,4-Dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-2-methoxyaniline (<b>34</b>)</h5><div class="NLM_p last">Compound <b>34</b> was prepared (44.2 mg, 39%) according to GP II (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, gradient 30:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (100 mg, 0.3 mmol) and 2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (89.7 mg, 0.36 mmol) as white solid. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 10.98 (s, 1H), 8.52 (d, <i>J</i> = 2.0 Hz, 1H), 8.27 (d, <i>J</i> = 2.0 Hz, 1H), 7.46 (s, 1H), 7.19 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.13 (d, <i>J</i> = 2.0 Hz, 1H), 6.97â6.95 (m, 3H), 6.87 (d, <i>J</i> = 8.7 Hz, 1H), 3.92 (s, 3H), 3.92 (s, 3H), 3.89 (s, 3H). <sup>13</sup>C NMR (100 MHz, chloroform-<i>d</i>) Î´ 149.3, 148.3, 147.8, 146.8, 142.0, 136.6, 132.6, 130.1, 127.9, 126.3, 122.3, 119.6, 118.6, 117.4, 116.4, 114.0, 111.8, 110.8, 110.8, 56.0, 56.0, 55.6. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 376.1661; found, 376.1635.</div></div><div id="sec4_2_2_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> 5-(Benzo[<i>d</i>][1,3]dioxol-5-yl)-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>35</b>)</h5><div class="NLM_p last">Compound <b>35</b> was prepared (21.6 mg, 66%) according to GP II (EtOAc/hexanes, gradient 1:3 to 1:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (29 mg, 0.087 mmol) and 3,4-(methylenedioxy)-phenyl boronic acid (17.3 mg, 0.1044 mmol). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 10.49 (s, 1H), 8.53 (d, <i>J</i> = 2.0 Hz, 1H), 8.27 (d, <i>J</i> = 2.0 Hz, 1H), 7.50 (s, 1H), 7.20 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.14 (d, <i>J</i> = 2.0 Hz, 1H), 7.10 (d, <i>J</i> = 1.8 Hz, 1H), 7.07 (dd, <i>J</i> = 7.9, 1.8 Hz, 1H), 6.98 (d, <i>J</i> = 8.2 Hz, 1H), 6.91 (d, <i>J</i> = 7.9 Hz, 1H), 6.00 (s, 2H), 3.94 (s, 3H), 3.93 (s, 3H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>18</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 375.1; found, 375.2.</div></div><div id="sec4_2_2_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> 5-(2,4-Dimethoxyphenyl)-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>36</b>)</h5><div class="NLM_p last">Compound <b>36</b> was prepared (86.2 mg, 74%) according to GP II (EtOAc/hexanes, gradient 1:3 to 1:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (100 mg, 0.3 mmol) and 2,4-dimethoxyphenyl boronic acid (65.5 mg, 0.36 mmol). <sup>1</sup>H NMR (300 MHz, chloroform-<i>d</i>) Î´ 9.94 (s, 1H), 8.48 (s, 1H), 8.28 (s, 1H), 7.46 (s, 1H), 7.28 (d, <i>J</i> = 8.8 Hz, 1H), 7.19 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.16 (d, <i>J</i> = 2.0 Hz, 1H), 6.95 (d, <i>J</i> = 8.2 Hz, 1H), 6.61â6.59 (m, 2H), 3.93 (s, 3H), 3.91 (s, 3H), 3.86 (s, 3H), 3.80 (s, 3H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>22</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 391.2; found, 391.2.</div></div><div id="sec4_2_2_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> 4-(3-(3,4-Dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)aniline (<b>37</b>)</h5><div class="NLM_p last">Compound <b>37</b> was prepared (29.3 mg, 57%) according to GP II (EtOAc/hexanes, gradient 1:1 to 3:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (50 mg, 0.15 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (39.5 mg, 0.18 mmol) as yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.76 (s, 1H), 8.44 (d, <i>J</i> = 2.1 Hz, 1H), 8.23 (d, <i>J</i> = 2.1 Hz, 1H), 7.77 (s, 1H), 7.41 (d, <i>J</i> = 8.5 Hz, 2H), 7.28 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.25 (d, <i>J</i> = 2.0 Hz, 1H), 7.02 (d, <i>J</i> = 8.2 Hz, 1H), 6.68 (d, <i>J</i> = 8.5 Hz, 2H), 5.16 (s, 2H), 3.85 (s, 3H), 3.78 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 149.2, 147.9, 147.9, 147.2, 141.3, 129.4, 128.0, 127.5, 126.4, 123.8, 123.5, 118.6, 117.4, 114.5, 114.4, 112.5, 110.6, 55.6, 55.6. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 346.1556; found, 346.1534.</div></div><div id="sec4_2_2_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> 5-(3-(3,4-Dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)pyrimidin-2-amine (<b>38</b>)</h5><div class="NLM_p last">Compound <b>38</b> was prepared (30.2 mg, 29%) according to GP II (EtOAc/hexanes, gradient 1:3 to 1:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (101.6 mg, 0.305 mmol) and (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine (74.2 mg, 0.335 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.90 (s, 1H), 8.63 (s, 2H), 8.46 (d, <i>J</i> = 2.0 Hz, 1H), 8.33 (d, <i>J</i> = 2.0 Hz, 1H), 7.82 (s, 1H), 7.31 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 7.26 (d, <i>J</i> = 2.1 Hz, 1H), 7.01 (d, <i>J</i> = 8.2 Hz, 1H), 6.71 (s, 2H), 3.84 (s, 3H), 3.77 (s, 3H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>17</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 348.1; found, 348.2.</div></div><div id="sec4_2_2_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> 3-(3-(3,4-Dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-5-methoxyaniline (<b>39</b>)</h5><div class="NLM_p last">Compound <b>39</b> was prepared (40.8 mg, 36%) according to GP II (EtOAc/hexanes, 3:1) from 5-bromo-3-(3,4-dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (100 mg, 0.3 mmol) and 3-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (89.7 mg, 0.36 mmol) as white solid. <sup>1</sup>H NMR(400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 11.86 (s, 1H), 8.47 (d, <i>J</i> = 2.1 Hz, 1H), 8.27 (d, <i>J</i> = 2.1 Hz, 1H), 7.81 (s, 1H), 7.28â7.26 (m, 2H), 7.04 (d, <i>J</i> = 8.8 Hz, 1H), 6.51 (s, 1H), 6.44 (s, 1H), 6.16 (s, 1H), 5.19 (s, 2H), 3.85 (s, 3H), 3.78 (s, 3H), 3.73 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 160.8, 150.3, 149.2, 148.5, 147.3, 141.7, 140.6, 129.4, 127.8, 124.9, 123.8, 118.6, 117.3, 114.7, 112.5, 110.7, 105.6, 100.7, 98.2, 55.6, 55.6, 54.7. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 376.1661; found, 376.1643.</div></div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> General Procedure (GP III) for Suzuki Coupling</h4><div id="sec4_2_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> 5-(3-(3,4-Dimethoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)-2-(2-morpholinoethoxy)aniline (<b>40</b>)</h5><div class="NLM_p last">A solution of <b>47</b> (35 mg, 0.092 mmol), 5-bromo-2-(2-morpholinoethoxy)aniline (33 mg, 0.11 mmol), Cs<sub>2</sub>CO<sub>3</sub> (60 mg, 0.184 mmol), and PdCl<sub>2</sub>(dppf)Â·CH<sub>2</sub>Cl<sub>2</sub> (18.8 mg, 0.023 mmol) in 1,4-dioxane/H<sub>2</sub>O = 3:1 (1.5 mL) was charged in capped tube and was heated to 100 Â°C for 3 h. The reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was diluted with CH<sub>2</sub>Cl<sub>2</sub> and organic phase was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layer was dried with MgSO<sub><span class="strike">4</span></sub> and concentrated in vacuo. The mixture was purified with flash column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH, gradient 30:1 to 15:1) to give the product, compound <b>40</b> as white solid (12.9 mg, 30%). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 9.48 (s, 1H), 8.52 (s, 1H), 8.27 (s, 1H), 7.44 (s, 1H), 7.20 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 7.12 (d, <i>J</i> = 2.0 Hz, 1H), 6.98â6.88 (m, 4H), 4.17 (t, <i>J</i> = 5.6 Hz, 2H), 3.94 (s, 3H), 3.92(s, 3H), 3.73 (t, <i>J</i> = 4.6 Hz, 4H), 2.82 (t, <i>J</i> = 5.6 Hz, 2H), 2.59 (t, <i>J</i> = 4.6 Hz, 4H). <sup>13</sup>C NMR (150 MHz, chloroform-<i>d</i>) Î´ 149.4, 148.2, 148.0, 145.9, 142.8, 137.4, 133.4, 130.4, 127.7, 126.2, 121.8, 119.7, 118.4, 117.4, 116.9, 114.3, 113.3, 111.9, 110.9, 67.0, 66.8, 57.8, 56.1, 56.1, 54.0. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>27</sub>H<sub>30</sub>N<sub>4</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 475.2345; found, 475.2350.</div></div><div id="sec4_2_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> 3-(3,4-Dimethoxyphenyl)-5-(3-methoxyphenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>41</b>)</h5><div class="NLM_p last">Compound <b>41</b> was prepared (5.4 mg, 23%) according to GP I (EtOAc/hexanes, 1:1) from 5-bromo-3-iodo-1-(phenyl- sulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (77.5 mg, 0.233 mmol) and 3-methoxyphenyl boronic acid (42.5 mg, 0.28 mmol). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) Î´ 9.61 (s, 1H), 8.38 (s, 1H), 7.48 (s, 1H), 7.39 (t, <i>J</i> = 7.9 Hz, 1H), 7.24 (s, 1H), 7.23â7.16 (m, 2H), 7.14â7.09 (m, 2H), 6.98 (d, <i>J</i> = 8.3 Hz, 1H), 6.92 (dd, <i>J</i> = 8.3, 2.5 Hz, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 3.87 (s, 3H). MS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>20</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 361.2; found, 361.2.</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i65"><a href="/doi/suppl/10.1021/jm500413g">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48223" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48223" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Spectra, rescoring of the generated 7-azaindole derivatives, kinase selectivity profiling, and physicochemical properties predicted by Accelrys DB.  This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm500413g/suppl_file/jm500413g_si_001.pdf">jm500413g_si_001.pdf (6.27 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm500413g" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68310" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68310" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Soon-Sun Hong</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedical Sciences, College of Medicine,
Inha University, Incheon, 400-712, Korea</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#dab2b5b4bda99ab3b4b2bbf4bbb9f4b1a8"><span class="__cf_email__" data-cfemail="036b6c6d6470436a6d6b622d62602d6871">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sungwoo Hong</span> - <span class="hlFld-Affiliation affiliation">Center
for Catalytic Hydrocarbon Functionalizations, Institute for Basic Science (IBS), Daejeon 305-701, Korea</span>;Â 
    <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Korea Advanced Institute of
Science and Technology (KAIST), Yuseong-gu, E6-4, Daejeon 305-701, Korea</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#83ebecede4ecf1e4c3e8e2eaf0f7ade2e0ade8f1"><span class="__cf_email__" data-cfemail="a7cfc8c9c0c8d5c0e7ccc6ced4d389c6c489ccd5">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Soyoung Lee</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Korea Advanced Institute of
Science and Technology (KAIST), Yuseong-gu, E6-4, Daejeon 305-701, Korea</span>;Â 
    <span class="hlFld-Affiliation affiliation">Center
for Catalytic Hydrocarbon Functionalizations, Institute for Basic Science (IBS), Daejeon 305-701, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hyunseung Lee</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedical Sciences, College of Medicine,
Inha University, Incheon, 400-712, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinhee Kim</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Korea Advanced Institute of
Science and Technology (KAIST), Yuseong-gu, E6-4, Daejeon 305-701, Korea</span>;Â 
    <span class="hlFld-Affiliation affiliation">Center
for Catalytic Hydrocarbon Functionalizations, Institute for Basic Science (IBS), Daejeon 305-701, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suhyun Lee</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Korea Advanced Institute of
Science and Technology (KAIST), Yuseong-gu, E6-4, Daejeon 305-701, Korea</span>;Â 
    <span class="hlFld-Affiliation affiliation">Center
for Catalytic Hydrocarbon Functionalizations, Institute for Basic Science (IBS), Daejeon 305-701, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Soo Jung Kim</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedical Sciences, College of Medicine,
Inha University, Incheon, 400-712, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Byong-Seok Choi</span> - <span class="hlFld-Affiliation affiliation">Department
of Chemistry, Korea Advanced Institute of
Science and Technology (KAIST), Yuseong-gu, E6-4, Daejeon 305-701, Korea</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d2938e5030-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i66">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30743" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30743" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This research was supported by National Research Foundation of Korea (NRF) through general research grants (NRF-2011-0020322, Medical Research Center (2014009392)) and the Institute for Basic Science (IBS-R010-G1).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i67" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i67"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i68" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i68"> Abbreviations Used</h2><tr><td class="NLM_term">SCF</td><td class="NLM_def"><p class="first last">stem cell factor</p></td></tr><tr><td class="NLM_term">c-Kit</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase for the stem cell factor</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phophatidylinositol-3-kinase</p></td></tr><tr><td class="NLM_term">Akt</td><td class="NLM_def"><p class="first last">known as protein kinase B (PKB)</p></td></tr><tr><td class="NLM_term">MAP kinase</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus-activated kinase</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">Src</td><td class="NLM_def"><p class="first last">a nonreceptor protein tyrosine kinase protein that in humans is encoded by the SRC gene</p></td></tr><tr><td class="NLM_term">SFK</td><td class="NLM_def"><p class="first last">Src family kinase</p></td></tr><tr><td class="NLM_term">GISTs</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumors</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">SM</td><td class="NLM_def"><p class="first last">systemic mastocytosis</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild-type</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine-5â²-triphosphate</p></td></tr><tr><td class="NLM_term">A-loop</td><td class="NLM_def"><p class="first last">activation loop</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structureâactivity relationship</p></td></tr><tr><td class="NLM_term">DFG</td><td class="NLM_def"><p class="first last">Asp-Phe-Gly</p></td></tr><tr><td class="NLM_term">ADP</td><td class="NLM_def"><p class="first last">adenosine diphosphate</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">POC</td><td class="NLM_def"><p class="first last">percent of control</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term">Erk</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">TUNEL</td><td class="NLM_def"><p class="first last">terminal deoxynucleotidyl transferase-mediated nick end labeling</p></td></tr><tr><td class="NLM_term">tPSA</td><td class="NLM_def"><p class="first last">topological polar suface area</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i69">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60776" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60776" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 26 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Kitamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirotab, S.</span><span> </span><span class="NLM_article-title">Kit as a human oncogenic tyrosine kinase</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">2924</span><span class="NLM_x">â</span> <span class="NLM_lpage">2931</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1007%2Fs00018-004-4273-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=15583854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXot1agsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2004&pages=2924-2931&author=Y.+Kitamuraauthor=S.+Hirotab&title=Kit+as+a+human+oncogenic+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Kit as a human oncogenic tyrosine kinase</span></div><div class="casAuthors">Kitamura, Y.; Hirota, S.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2924-2931</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  Signals through Kit receptor tyrosine kinase are essential for development of erythrocytes, melanocytes, germ cells, mast cells and interstitial cells of Cajal (ICCs).  Mice and rats with a double gene dose of loss-of-function mutations of Kit show depletion of these cells.  Although human homozygotes with loss-of-function mutations of Kit have not been reported, gain-of-function mutations of Kit result in development of tumors from mast cells, germ cells and ICCs in humans.  The ICC tumors are called gastrointestinal stromal tumors (GISTs), and GISTs are a good target for the Kit inhibitor imatinib mesylate.  The interrelationship between the type of Kit gain-of-function mutations and the therapeutic effect of imatinib mesylate has been well characterized in GISTs.  Kit is interesting from both a biol. and clin. viewpoint.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz-wPI3gyLIrVg90H21EOLACvtfcHk0lg2bBzpOqurFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXot1agsQ%253D%253D&md5=db442791f78485725ac8811ecec512b8</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2Fs00018-004-4273-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-004-4273-y%26sid%3Dliteratum%253Aachs%26aulast%3DKitamura%26aufirst%3DY.%26aulast%3DHirotab%26aufirst%3DS.%26atitle%3DKit%2520as%2520a%2520human%2520oncogenic%2520tyrosine%2520kinase%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2004%26volume%3D61%26spage%3D2924%26epage%3D2931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Blume Jensen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claesson Welsh, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegbahn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zsebo, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westermark, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heldin, C. H.</span><span> </span><span class="NLM_article-title">Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">4121</span><span class="NLM_x">â</span> <span class="NLM_lpage">4128</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1991&pages=4121-4128&author=P.+Blume+Jensenauthor=L.+Claesson+Welshauthor=A.+Siegbahnauthor=K.+M.+Zseboauthor=B.+Westermarkauthor=C.+H.+Heldin&title=Activation+of+the+human+c-kit+product+by+ligand-induced+dimerization+mediates+circular+actin+reorganization+and+chemotaxis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlume%2BJensen%26aufirst%3DP.%26aulast%3DClaesson%2BWelsh%26aufirst%3DL.%26aulast%3DSiegbahn%26aufirst%3DA.%26aulast%3DZsebo%26aufirst%3DK.%2BM.%26aulast%3DWestermark%26aufirst%3DB.%26aulast%3DHeldin%26aufirst%3DC.%2BH.%26atitle%3DActivation%2520of%2520the%2520human%2520c-kit%2520product%2520by%2520ligand-induced%2520dimerization%2520mediates%2520circular%2520actin%2520reorganization%2520and%2520chemotaxis%26jtitle%3DEMBO%2520J.%26date%3D1991%26volume%3D10%26spage%3D4121%26epage%3D4128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ronnstrand, L.</span><span> </span><span class="NLM_article-title">Signal transduction via the stem cell factor receptor/c-kit</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_fpage">2535</span><span class="NLM_x">â</span> <span class="NLM_lpage">2548</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1007%2Fs00018-004-4189-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=15526160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A280%3ADC%252BD2crltlaitg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=2535-2548&author=L.+Ronnstrand&title=Signal+transduction+via+the+stem+cell+factor+receptor%2Fc-kit"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction via the stem cell factor receptor/c-Kit</span></div><div class="casAuthors">Ronnstrand L</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and molecular life sciences : CMLS</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19-20</span>),
    <span class="NLM_cas:pages">2535-48</span>
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    </div><div class="casAbstract">Together with its ligand, stem cell factor, the receptor tyrosine kinase c-Kit is a key controlling receptor for a number of cell types, including hematopoietic stem cells, mast cells, melanocytes and germ cells.  Gain-of-function mutations in c-Kit have been described in a number of human cancers, including testicular germinomas, acute myeloid leukemia and gastrointestinal stromal tumors.  Stimulation of c-Kit by its ligand leads to dimerization of receptors, activation of its intrinsic tyrosine kinase activity and phosphorylation of key tyrosine residues within the receptor.  These phosphorylated tyrosine residues serve as docking sites for a number of signal transduction molecules containing Src homology 2 domains, which will thereby be recruited to the receptor and activated many times through phosphorylation by the receptor.  This review discusses our current knowledge of signal transduction molecules and signal transduction pathways activated by c-Kit and how their activation can be connected to the physiological outcome of c-Kit signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAUF5kuUZ4BP_I8Jvzw4xCfW6udTcc2eap2qGowO6r_bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crltlaitg%253D%253D&md5=984cf4afb43a2772b217425b7fc93c00</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1007%2Fs00018-004-4189-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-004-4189-6%26sid%3Dliteratum%253Aachs%26aulast%3DRonnstrand%26aufirst%3DL.%26atitle%3DSignal%2520transduction%2520via%2520the%2520stem%2520cell%2520factor%2520receptor%252Fc-kit%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2004%26spage%3D2535%26epage%3D2548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Blume Jensen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janknecht, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span> </span><span class="NLM_article-title">The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136</span> <span class="citation_source-journal">Curr. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">779</span><span class="NLM_x">â</span> <span class="NLM_lpage">782</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1016%2FS0960-9822%2898%2970302-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=9651683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADyaK1cXktVKqtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=779-782&author=P.+Blume+Jensenauthor=R.+Janknechtauthor=T.+Hunter&title=The+kit+receptor+promotes+cell+survival+via+activation+of+PI+3-kinase+and+subsequent+Akt-mediated+phosphorylation+of+Bad+on+Ser136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">The Kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136</span></div><div class="casAuthors">Blume-Jensen, Peter; Janknecht, Ralf; Hunter, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">779-782</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Ltd.</span>)
        </div><div class="casAbstract">The c-kit-encoded receptor protein tyrosine kinase for stem cell factor (kit/SCF-R) is essential for the development of cells within the hematopoietic, melanogenic and gametogenic lineages.  SCF stimulation induces activation of phosphatidylinositol (PI) 3-kinase, which is required for SCF-induced mitogenesis and cell survival, and for activation of the serine/threonine protein kinase Akt.  Using Kit/SCF-R mutants, the authors found that, in response to SCF, Akt became activated and mediated phosphorylation of Bad, a pro-apoptotic mol., in a PI-3-kinase-dependent manner.  Phosphorylation of Bad was restricted to Ser 112 and Ser 136 in vivo, but only the Akt phosphorylation site Ser 136 was essential for SCF-promoted cell survival.  Furthermore, Bad and Akt interacted and colocalized in intact cells.  A Kit/SCF-R gain-of-function mutant that has increased mitogenic and PI 3-kinase activation potential, due to the absence of the two protein kinase C neg. feedback phosphorylation sites, enhanced both Akt activation and Bad phosphorylation and also resulted in increased cell survival.  Such a mechanism may account for how deregulated PI 3-kinase activity and naturally occurring gain-of-function point mutants of Kit/SCF-R lead to cellular transformation and fatal malignancies in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBKQgC5ys1SLVg90H21EOLACvtfcHk0liVGsp7Pu-i3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXktVKqtb0%253D&md5=fa1e1aacccdcfe75f53045c16ed1dc4d</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1016%2FS0960-9822%2898%2970302-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9822%252898%252970302-1%26sid%3Dliteratum%253Aachs%26aulast%3DBlume%2BJensen%26aufirst%3DP.%26aulast%3DJanknecht%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26atitle%3DThe%2520kit%2520receptor%2520promotes%2520cell%2520survival%2520via%2520activation%2520of%2520PI%25203-kinase%2520and%2520subsequent%2520Akt-mediated%2520phosphorylation%2520of%2520Bad%2520on%2520Ser136%26jtitle%3DCurr.%2520Biol.%26date%3D1998%26volume%3D8%26spage%3D779%26epage%3D782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Masson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronnstrand, L.</span><span> </span><span class="NLM_article-title">Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3</span> <span class="citation_source-journal">Cell Signal.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1717</span><span class="NLM_x">â</span> <span class="NLM_lpage">1726</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1016%2Fj.cellsig.2009.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=19540337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GgtrrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=1717-1726&author=K.+Massonauthor=L.+Ronnstrand&title=Oncogenic+signaling+from+the+hematopoietic+growth+factor+receptors+c-Kit+and+Flt3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3</span></div><div class="casAuthors">Masson, Kristina; Roennstrand, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1717-1726</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Signal transduction in response to growth factors is a strictly controlled process with networks of feedback systems, highly selective interactions and finely tuned on-and-off switches.  In the context of cancer, detailed signaling studies have resulted in the development of some of the most frequently used means of therapy, with several well established examples such as the small mol. inhibitors imatinib and dasatinib in the treatment of chronic myeloid leukemia.  Impaired function of receptor tyrosine kinases is implicated in various types of tumors, and much effort is put into mapping the many interactions and downstream pathways.  Here we discuss the hematopoietic growth factor receptors c-Kit and Flt3 and their downstream signaling in normal as well as malignant cells.  Both receptors are members of the same family of tyrosine kinases and crucial mediators of stem-and progenitor-cell proliferation and survival in response to ligand stimuli from the surrounding microenvironment.  Gain-of-function mutations/alterations render the receptors constitutively and ligand-independently activated, resulting in aberrant signaling which is a crucial driving force in tumorigenesis.  Frequently found mutations in c-Kit and Flt3 are point mutations of aspartic acid 816 and 835 resp., in the activation loop of the kinase domains.  Several other point mutations have been identified, but in the case of Flt3, the most common alterations are internal tandem duplications (ITDs) in the juxtamembrane region, reported in approx. 30% of patients with acute myeloid leukemia (AML).  During the last couple of years, the increasing understanding of c-Kit and Flt3 signaling has also revealed the complexity of these receptor systems.  The impact of gain-of-function mutations of c-Kit and Flt3 in different malignancies is well established and shown to be of clin. relevance in both prognosis and therapy.  Many inhibitors of both c-Kit or Flt3 or of their downstream substrates are in clin. trials with encouraging results, and targeted therapy using a combination of such inhibitors is considered a promising approach for future treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBlFdmKXZP3bVg90H21EOLACvtfcHk0liVGsp7Pu-i3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GgtrrJ&md5=24e0dfaf3edbe72f82012424c391b422</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2009.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2009.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DMasson%26aufirst%3DK.%26aulast%3DRonnstrand%26aufirst%3DL.%26atitle%3DOncogenic%2520signaling%2520from%2520the%2520hematopoietic%2520growth%2520factor%2520receptors%2520c-Kit%2520and%2520Flt3%26jtitle%3DCell%2520Signal.%26date%3D2009%26volume%3D21%26spage%3D1717%26epage%3D1726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kemmer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreevey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wait, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span> </span><span class="NLM_article-title">KIT mutations are common in testicular seminomas</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">â</span> <span class="NLM_lpage">313</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1016%2FS0002-9440%2810%2963120-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=14695343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsVCmsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2004&pages=305-313&author=K.+Kemmerauthor=C.+L.+Corlessauthor=J.+A.+Fletcherauthor=L.+McGreeveyauthor=A.+Haleyauthor=D.+Griffithauthor=O.+W.+Cummingsauthor=C.+Waitauthor=A.+Townauthor=M.+C.+Heinrich&title=KIT+mutations+are+common+in+testicular+seminomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">KIT mutations are common in testicular seminomas</span></div><div class="casAuthors">Kemmer, Kathleen; Corless, Christopher L.; Fletcher, Jonathan A.; McGreevey, Laura; Haley, Andrea; Griffith, Diana; Cummings, Oscar W.; Wait, Cecily; Town, Ajia; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">305-313</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Expression of KIT tyrosine kinase is crit. for normal germ cell development and is obsd. in the majority of seminomas.  Activating mutations in KIT are common in gastrointestinal stromal tumors and mastocytosis.  In this study we examd. the frequency and spectrum of KIT mutations in 54 testicular seminomas, 1 ovarian dysgerminoma and 37 nonseminomatous germ cell tumors (NSGCT).  Fourteen seminomas (25.9%) contained exon 17 point mutations including D816V (6 cases), D816H (3 cases), Y823D (2 cases), and single examples of Y823C, N822K, and T801I.  No KIT mutations were found in the ovarian dysgerminoma or the NSGCTs.  In transient transfection assays, mutant isoforms D816V, D816H, Y823D, and N822K were constitutively phosphorylated in the absence of the natural ligand for KIT, stem cell factor (SCF).  In contrast, activation of T801I and wild-type KIT required SCF.  Mutants N822K and Y823D were inhibited by imatinib mesylate (Gleevec, previously STI571) whereas D816V and D816H were both resistant to imatinib mesylate.  Biochem. evidence of KIT activation, as assessed by KIT phosphorylation and KIT assocn. with phosphatidylinositol (PI) 3-kinase in tumor cell lysates, was largely confined to seminomas with a genomic KIT mutation.  These findings suggest that activating KIT mutations may contribute to tumorigenesis in a subset of seminomas, but are not involved in NSGCT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgGTPo5NB007Vg90H21EOLACvtfcHk0liVGsp7Pu-i3A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsVCmsg%253D%253D&md5=d273c18384b9896578b8f21f7d19bcb6</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2963120-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252963120-3%26sid%3Dliteratum%253Aachs%26aulast%3DKemmer%26aufirst%3DK.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DMcGreevey%26aufirst%3DL.%26aulast%3DHaley%26aufirst%3DA.%26aulast%3DGriffith%26aufirst%3DD.%26aulast%3DCummings%26aufirst%3DO.%2BW.%26aulast%3DWait%26aufirst%3DC.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DKIT%2520mutations%2520are%2520common%2520in%2520testicular%2520seminomas%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2004%26volume%3D164%26spage%3D305%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span> </span><span class="NLM_article-title">Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1692</span><span class="NLM_x">â</span> <span class="NLM_lpage">1703</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1200%2FJCO.20.6.1692" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=11896121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD38XivFeit7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=1692-1703&author=M.+C.+Heinrichauthor=C.+D.+Blankeauthor=B.+J.+Drukerauthor=C.+L.+Corless&title=Inhibition+of+KIT+tyrosine+kinase+activity%3A+a+novel+molecular+approach+to+the+treatment+of+KIT-positive+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies</span></div><div class="casAuthors">Heinrich, Michael C.; Blanke, Charles D.; Druker, Brian J.; Corless, Christopher L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1692-1703</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Activation of the KIT tyrosine kinase by somatic mutation has been documented in a no. of human malignancies, including gastrointestinal stromal tumor (GIST), seminoma, acute myelogenous leukemia (AML), and mastocytosis.  In addn., paracrine or auto-crine activation of this kinase has been postulated in numerous other malignancies, including small-cell lung cancer and ovarian cancer.  In this review, we discuss the rationale for and development of KIT tyrosine kinase inhibitors for the treatment of human malignancies.  Studies were identified through a MEDLINE search, review of bibliogs. of relevant articles, and review of abstrs. from national meetings.  Four tyrosine kinase inhibitors that have activity against KIT are currently being used in clin. trials, and one, STI571, has recently been approved by the United States Food and Drug Administration for treating patients with chronic myelogenous leukemia.  The role of KIT inhibitors in treating KIT-pos. malignancies is reviewed.  Targeted therapy to inhibit the kinase activity of KIT is a rationale approach to the treatment of KIT-pos. malignancies.  Two key factors are the potency of a given inhibitor and the relative contribution of KIT activation to the growth of the tumor.  Given our current understanding of KIT activity in human malignancy, the best candidate diseases for treatment with KIT inhibitors are GIST, mastocytosis, seminoma and possibly some cases of AML.  Addnl., KIT inhibitors may play an adjunctive role in diseases such as small-cell lung cancer, in which KIT activation is secondary to ligand binding rather than an acquired mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeOID4WLppJLVg90H21EOLACvtfcHk0lhrMLHSv0MExw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivFeit7o%253D&md5=0618c2d38d736b6b33e978f3bce93fd1</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1200%2FJCO.20.6.1692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.20.6.1692%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26atitle%3DInhibition%2520of%2520KIT%2520tyrosine%2520kinase%2520activity%253A%2520a%2520novel%2520molecular%2520approach%2520to%2520the%2520treatment%2520of%2520KIT-positive%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D1692%26epage%3D1703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Nagata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worobec, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chowdhury, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tannenbaum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalfe, D. D.</span><span> </span><span class="NLM_article-title">Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">10560</span><span class="NLM_x">â</span> <span class="NLM_lpage">10564</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1995&pages=10560-10564&author=H.+Nagataauthor=A.+S.+Worobecauthor=C.+K.+Ohauthor=B.+A.+Chowdhuryauthor=S.+Tannenbaumauthor=Y.+Suzukiauthor=D.+D.+Metcalfe&title=Identification+of+a+point+mutation+in+the+catalytic+domain+of+the+protooncogene+c-kit+in+peripheral+blood+mononuclear+cells+of+patients+who+have+mastocytosis+with+an+associated+hematologic+disorder"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagata%26aufirst%3DH.%26aulast%3DWorobec%26aufirst%3DA.%2BS.%26aulast%3DOh%26aufirst%3DC.%2BK.%26aulast%3DChowdhury%26aufirst%3DB.%2BA.%26aulast%3DTannenbaum%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DMetcalfe%26aufirst%3DD.%2BD.%26atitle%3DIdentification%2520of%2520a%2520point%2520mutation%2520in%2520the%2520catalytic%2520domain%2520of%2520the%2520protooncogene%2520c-kit%2520in%2520peripheral%2520blood%2520mononuclear%2520cells%2520of%2520patients%2520who%2520have%2520mastocytosis%2520with%2520an%2520associated%2520hematologic%2520disorder%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1995%26volume%3D92%26spage%3D10560%26epage%3D10564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Heinrich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wait, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zigler, A.</span><span> </span><span class="NLM_article-title">Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">925</span><span class="NLM_x">â</span> <span class="NLM_lpage">932</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2000&pages=925-932&author=M.+Heinrichauthor=D.+Griffithauthor=B.+Drukerauthor=C.+Waitauthor=K.+Ottauthor=A.+Zigler&title=Inhibition+of+c-kit+receptor+tyrosine+kinase+activity+by+STI+571%2C+a+selective+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%26aulast%3DGriffith%26aufirst%3DD.%26aulast%3DDruker%26aufirst%3DB.%26aulast%3DWait%26aufirst%3DC.%26aulast%3DOtt%26aufirst%3DK.%26aulast%3DZigler%26aufirst%3DA.%26atitle%3DInhibition%2520of%2520c-kit%2520receptor%2520tyrosine%2520kinase%2520activity%2520by%2520STI%2520571%252C%2520a%2520selective%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DBlood%26date%3D2000%26volume%3D96%26spage%3D925%26epage%3D932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Abbeele, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiese, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span> </span><span class="NLM_article-title">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x">, </span> <span class="NLM_fpage">472</span><span class="NLM_x">â</span> <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1056%2FNEJMoa020461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=12181401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2002&pages=472-480&author=G.+D.+Demetriauthor=M.+von+Mehrenauthor=C.+D.+Blankeauthor=A.+D.+van+den+Abbeeleauthor=B.+Eisenbergauthor=P.+J.+Robertsauthor=M.+C.+Heinrichauthor=D.+A.+Tuvesonauthor=S.+Singerauthor=M.+Janicekauthor=J.+A.+Fletcherauthor=S.+G.+Silvermanauthor=S.+L.+Silbermanauthor=R.+Capdevilleauthor=B.+Kieseauthor=B.+Pengauthor=S.+Dimitrijevicauthor=B.+J.+Drukerauthor=C.+Corlessauthor=C.+D.+Fletcherauthor=H.+Joensuu&title=Efficacy+and+safety+of+imatinib+mesylate+in+advanced+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span></div><div class="casAuthors">Demetri, George D.; von Mehren, Margaret; Blanke, Charles D.; Van den Abbeele, Annick D.; Eisenberg, Burton; Roberts, Peter J.; Heinrich, Michael C.; Tuveson, David A.; Singer, Samuel; Janicek, Milos; Fletcher, Jonathan A.; Silverman, Stuart G.; Silberman, Sandra L.; Capdeville, Renaud; Kiese, Beate; Peng, Bin; Dimitrijevic, Sasa; Druker, Brian J.; Corless, Christopher; Fletcher, Christopher D. M.; Joensuu, Heikki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">472-480</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Constitutive activation of KIT receptor tyrosine kinase is crit. in the pathogenesis of gastrointestinal stromal tumors.  Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclin. models and preliminary clin. studies to have activity against such tumors.  We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor.  We assessed antitumor response and the safety and tolerability of the drug.  Pharmacokinetics were assessed in a subgroup of patients.  A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily.  Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for tech. reasons, response could not be evaluated in 7 patients (4.8 percent).  No patient had a complete response to the treatment.  The median duration of response had not been reached after a median follow-up of 24 wk after the onset of response.  Early resistance to imatinib was noted in 20 patients (13.6 percent).  Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common.  Gastrointestinal or intraabdominal hemorrhage occurred in approx. 5 percent of patients.  There were no significant differences in toxic effects or response between the two doses.  Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia.  Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor.  Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVE0HpuuKXXrVg90H21EOLACvtfcHk0lhrMLHSv0MExw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D&md5=95c9ea076dd2b0e053ae2061cb3f5d24</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa020461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa020461%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3Dvan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DJanicek%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DSilverman%26aufirst%3DS.%2BG.%26aulast%3DSilberman%26aufirst%3DS.%2BL.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DKiese%26aufirst%3DB.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DCorless%26aufirst%3DC.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DJoensuu%26aufirst%3DH.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520imatinib%2520mesylate%2520in%2520advanced%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D347%26spage%3D472%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mol, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowakowski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McRee, D. E.</span><span> </span><span class="NLM_article-title">Structure of a KIT product complex reveals the basis for kinase transactivation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">31461</span><span class="NLM_x">â</span> <span class="NLM_lpage">31464</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=31461-31464&author=C.+D.+Molauthor=K.+B.+Limauthor=V.+Sridharauthor=H.+Zouauthor=E.+Y.+Chienauthor=B.+C.+Sangauthor=J.+Nowakowskiauthor=D.+B.+Kasselauthor=C.+N.+Croninauthor=D.+E.+McRee&title=Structure+of+a+KIT+product+complex+reveals+the+basis+for+kinase+transactivation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMol%26aufirst%3DC.%2BD.%26aulast%3DLim%26aufirst%3DK.%2BB.%26aulast%3DSridhar%26aufirst%3DV.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChien%26aufirst%3DE.%2BY.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DNowakowski%26aufirst%3DJ.%26aulast%3DKassel%26aufirst%3DD.%2BB.%26aulast%3DCronin%26aufirst%3DC.%2BN.%26aulast%3DMcRee%26aufirst%3DD.%2BE.%26atitle%3DStructure%2520of%2520a%2520KIT%2520product%2520complex%2520reveals%2520the%2520basis%2520for%2520kinase%2520transactivation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D31461%26epage%3D31464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mol, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougan, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheibe, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. P.</span><span> </span><span class="NLM_article-title">Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">31655</span><span class="NLM_x">â</span> <span class="NLM_lpage">31663</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1074%2Fjbc.M403319200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=15123710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlslOrtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=31655-31663&author=C.+D.+Molauthor=D.+R.+Douganauthor=T.+R.+Schneiderauthor=R.+J.+Skeneauthor=M.+L.+Krausauthor=D.+N.+Scheibeauthor=G.+P.+Snellauthor=H.+Zouauthor=B.+C.+Sangauthor=K.+P.+Wilson&title=Structural+basis+for+the+autoinhibition+and+STI-571+inhibition+of+c-Kit+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase</span></div><div class="casAuthors">Mol, Clifford D.; Dougan, Douglas R.; Schneider, Thomas R.; Skene, Robert J.; Kraus, Michelle L.; Scheibe, Daniel N.; Snell, Gyorgy P.; Zou, Hua; Sang, Bi-Ching; Wilson, Keith P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">31655-31663</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The activity of the c-Kit receptor protein-tyrosine kinase is tightly regulated in normal cells, whereas deregulated c-Kit kinase activity is implicated in the pathogenesis of human cancers.  The c-Kit juxtamembrane region is known to have an autoinhibitory function; however the precise mechanism by which c-Kit is maintained in an autoinhibited state is not known.  We report the 1.9-Ã resoln. crystal structure of native c-Kit kinase in an autoinhibited conformation and compare it with active c-Kit kinase.  Autoinhibited c-Kit is stabilized by the juxtamembrane domain, which inserts into the kinase-active site and disrupts formation of the activated structure.  A 1.6-Ã crystal structure of c-Kit in complex with STI-571 (Imatinib or Gleevec) demonstrates that inhibitor binding disrupts this natural mechanism for maintaining c-Kit in an autoinhibited state.  Together, these results provide a structural basis for understanding c-Kit kinase autoinhibition and will facilitate the structure-guided design of specific inhibitors that target the activated and autoinhibited conformations of c-Kit kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWJsKx1IzXQbVg90H21EOLACvtfcHk0lgK7XzgOLqi0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlslOrtrc%253D&md5=df6065a62b44e4c2e6b020da0f797ab4</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M403319200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M403319200%26sid%3Dliteratum%253Aachs%26aulast%3DMol%26aufirst%3DC.%2BD.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DSchneider%26aufirst%3DT.%2BR.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DKraus%26aufirst%3DM.%2BL.%26aulast%3DScheibe%26aufirst%3DD.%2BN.%26aulast%3DSnell%26aufirst%3DG.%2BP.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DWilson%26aufirst%3DK.%2BP.%26atitle%3DStructural%2520basis%2520for%2520the%2520autoinhibition%2520and%2520STI-571%2520inhibition%2520of%2520c-Kit%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D31655%26epage%3D31663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDougall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Molecular correlates of imatinib resistance in gastrointestinal stromal tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">764</span><span class="NLM_x">â</span> <span class="NLM_lpage">774</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=764-774&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=C.+D.+Blankeauthor=G.+D.+Demetriauthor=H.+Joensuuauthor=P.+J.+Robertsauthor=B.+L.+Eisenbergauthor=M.+von+Mehrenauthor=C.+D.+Fletcherauthor=K.+Sandauauthor=K.+McDougallauthor=W.+B.+Ouauthor=C.+J.+Chenauthor=J.+A.+Fletcher&title=Molecular+correlates+of+imatinib+resistance+in+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DEisenberg%26aufirst%3DB.%2BL.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DSandau%26aufirst%3DK.%26aulast%3DMcDougall%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DW.%2BB.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DMolecular%2520correlates%2520of%2520imatinib%2520resistance%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D764%26epage%3D774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lasota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debiec Rychter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciot, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardelmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merkelbach Bruse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schildhaus, H. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steigen, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stachura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wozniak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonescu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daum, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Muro, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miettinen, M.</span><span> </span><span class="NLM_article-title">Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases</span> <span class="citation_source-journal">Mod. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">476</span><span class="NLM_x">â</span> <span class="NLM_lpage">484</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1038%2Fmodpathol.2008.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=18246046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjs1aku7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=476-484&author=J.+Lasotaauthor=C.+L.+Corlessauthor=M.+C.+Heinrichauthor=M.+Debiec+Rychterauthor=R.+Sciotauthor=E.+Wardelmannauthor=S.+Merkelbach+Bruseauthor=H.+U.+Schildhausauthor=S.+E.+Steigenauthor=J.+Stachuraauthor=A.+Wozniakauthor=C.+Antonescuauthor=O.+Daumauthor=J.+Martinauthor=J.+G.+Del+Muroauthor=M.+Miettinen&title=Clinicopathologic+profile+of+gastrointestinal+stromal+tumors+%28GISTs%29+with+primary+KIT+exon+13+or+exon+17+mutations%3A+a+multicenter+study+on+54+cases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases</span></div><div class="casAuthors">Lasota, Jerzy; Corless, Christopher L.; Heinrich, Michael C.; Debiec-Rychter, Maria; Sciot, Raf; Wardelmann, Eva; Merkelbach-Bruse, Sabine; Schildhaus, Hans-Ulrich; Steigen, Sonja E.; Stachura, Jerzy; Wozniak, Agnieszka; Antonescu, Cristina; Daum, Ondrej; Martin, Javier; del Muro, Javier Garcia; Miettinen, Markku</div><div class="citationInfo"><span class="NLM_cas:title">Modern Pathology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">476-484</span>CODEN:
                <span class="NLM_cas:coden">MODPEO</span>;
        ISSN:<span class="NLM_cas:issn">0893-3952</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms driven by oncogenic, mutational activation of KIT or platelet-derived growth factor receptor Î± (PDGFRA).  GIST-specific KIT or PDGFRA mutations have been linked to tumor location, tumor cell morphol. and clin. behavior.  The purpose of this study was to evaluate the clinicopathol. profile of GISTs that have KIT exon 13 or exon 17 mutations.  Through the collaboration of several GIST research groups, the authors gathered 54 cases from the pre-imatinib era that had such primary mutations.  From the observations and those in the literature, the authors est. that the frequency of these mutations is no higher than 1-2%.  Almost all (32 of 33, 97%) of the KIT exon 13 mutations were the 1945A>G substitution leading to Lys642Glu.  A majority (15 of 21, 71.4%) of the KIT exon 17 mutations were the 2487T>A substitution leading to Asn822Lys.  Demog. and clinicopathol. data were available for 26 and 14 KIT exon 13 and exon 17 mutant GISTs, resp.  Median age and male to female ratio were similar to ones reported in other GIST studies.  Small intestinal tumors were two times more frequent than gastric ones among KIT exon 17 mutants.  Also, intestinal tumors were slightly overrepresented among KIT exon 13 mutants when compared with population-based studies.  The majority of KIT exon 13 or exon 17 mutants had a spindle-cell morphol. and only a few had epithelioid features.  Tumor size varied from 1.2 to 25 cm and av. mitotic rates were 9.5 and 4.2 for KIT exon 13 and exon 17 mutants, resp.  Gastric KIT exon 13 mutant GISTs tend to be slightly larger and more aggressive than gastric GISTs in av., whereas the behavior of small intestinal GISTs with KIT exon 13 mutations does not differ from other small intestinal GISTs.  The latter is also true for all KIT exon 17 mutant GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL32NFTz6mtrVg90H21EOLACvtfcHk0lgK7XzgOLqi0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjs1aku7c%253D&md5=5cc996a149e1f7decb59b9cd4330961d</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1038%2Fmodpathol.2008.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmodpathol.2008.2%26sid%3Dliteratum%253Aachs%26aulast%3DLasota%26aufirst%3DJ.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DDebiec%2BRychter%26aufirst%3DM.%26aulast%3DSciot%26aufirst%3DR.%26aulast%3DWardelmann%26aufirst%3DE.%26aulast%3DMerkelbach%2BBruse%26aufirst%3DS.%26aulast%3DSchildhaus%26aufirst%3DH.%2BU.%26aulast%3DSteigen%26aufirst%3DS.%2BE.%26aulast%3DStachura%26aufirst%3DJ.%26aulast%3DWozniak%26aufirst%3DA.%26aulast%3DAntonescu%26aufirst%3DC.%26aulast%3DDaum%26aufirst%3DO.%26aulast%3DMartin%26aufirst%3DJ.%26aulast%3DDel%2BMuro%26aufirst%3DJ.%2BG.%26aulast%3DMiettinen%26aufirst%3DM.%26atitle%3DClinicopathologic%2520profile%2520of%2520gastrointestinal%2520stromal%2520tumors%2520%2528GISTs%2529%2520with%2520primary%2520KIT%2520exon%252013%2520or%2520exon%252017%2520mutations%253A%2520a%2520multicenter%2520study%2520on%252054%2520cases%26jtitle%3DMod.%2520Pathol.%26date%3D2008%26volume%3D21%26spage%3D476%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Longley, B. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalfe, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tharp, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyrrell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heitjan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span> </span><span class="NLM_article-title">Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">1609</span><span class="NLM_x">â</span> <span class="NLM_lpage">1614</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1073%2Fpnas.96.4.1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=9990072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADyaK1MXhsFSqs7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=1609-1614&author=B.+J.+Longleyauthor=D.+D.+Metcalfeauthor=M.+Tharpauthor=X.+Wangauthor=L.+Tyrrellauthor=S.+Z.+Luauthor=D.+Heitjanauthor=Y.+Ma&title=Activating+and+dominant+inactivating+c-KIT+catalytic+domain+mutations+in+distinct+clinical+forms+of+human+mastocytosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis</span></div><div class="casAuthors">Longley, B. Jack Jr.; Metcalfe, Dean D.; Tharp, Michael; Wang, Xiaomei; Tyrrell, Lynda; Lu, Shu-zhuang; Heitjan, David; Ma, Yongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1609-1614</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Human mastocytosis is characterized by increased mast cells.  It usually occurs as a sporadic disease that is often transient and limited in children and persistent or progressive in adults.  The c-KIT protooncogene encodes KIT, a tyrosine kinase that is the receptor for mast cell growth factor.  Because mutated KIT can transform cells, the authors examd. c-KIT in skin lesions of 22 patients with sporadic mastocytosis and 3 patients with familial mastocytosis.  All patients with adult sporadic mastocytosis had somatic c-KIT mutations in codon 816 causing substitution of valine for aspartate and spontaneous activation of mast cell growth factor receptor.  A subset of four pediatric onset cases with clin. unusual disease also had codon 816 activating mutations substituting valine, tyrosine, or phenylalanine for aspartate.  Typical pediatric patients lacked 816 mutations, but limited sequencing showed three of six had a novel dominant inactivating mutation substituting lysine for glutamic acid in position 839, the site of a potential salt bridge that is highly conserved in receptor tyrosine kinases.  No c-KIT mutations were found in the entire coding region of three patients with familial mastocytosis.  The authors conclude that c-KIT somatic mutations substituting valine in position 816 of KIT are characteristic of sporadic adult mastocytosis and may cause this disease.  Similar mutations causing activation of the mast cell growth factor receptor are found in children apparently at risk for extensive or persistent disease.  In contrast, typical pediatric mastocytosis patients lack these mutations and may express inactivating c-KIT mutations.  Familial mastocytosis, however, may occur in the absence of c-KIT coding mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6m1TDiADq27Vg90H21EOLACvtfcHk0lgK7XzgOLqi0Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsFSqs7k%253D&md5=242e0b352a75df6db1178830f26c085f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.4.1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.4.1609%26sid%3Dliteratum%253Aachs%26aulast%3DLongley%26aufirst%3DB.%2BJ.%26aulast%3DMetcalfe%26aufirst%3DD.%2BD.%26aulast%3DTharp%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTyrrell%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DS.%2BZ.%26aulast%3DHeitjan%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DY.%26atitle%3DActivating%2520and%2520dominant%2520inactivating%2520c-KIT%2520catalytic%2520domain%2520mutations%2520in%2520distinct%2520clinical%2520forms%2520of%2520human%2520mastocytosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D1609%26epage%3D1614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Pardanani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentm, P.</span><span> </span><span class="NLM_article-title">Pathogenesis, clinical features, and treatment advances in mastocytosis</span> <span class="citation_source-journal">Best Pract. Res. Clin. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">595</span><span class="NLM_x">â</span> <span class="NLM_lpage">615</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1016%2Fj.beha.2005.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=16781490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD28Xls1aqurY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=595-615&author=A.+Pardananiauthor=C.+Akinauthor=P.+Valentm&title=Pathogenesis%2C+clinical+features%2C+and+treatment+advances+in+mastocytosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Pathogenesis, clinical features, and treatment advances in mastocytosis</span></div><div class="casAuthors">Pardanani, A.; Akin, C.; Valent, P.</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Haematology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">595-615</span>CODEN:
                <span class="NLM_cas:coden">BPRCA5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Systemic mastocytosis (SM) is characterized by the abnormal growth and accumulation of mast cells (MC) in one or more organs.  The interaction between the cytokine stem cell factor (SCF) and its cognate receptor, the c-kit receptor tyrosine kinase (KIT), plays a central role in regulating MC growth and differentiation.  Whereas germline and somatically acquired activating mutations of KIT have been identified in SM, the issue as to whether individual KIT mutation(s) are necessary and sufficient to cause MC transformation remains unclear based on currently available data.  Activating mutations of platelet-derived growth factor receptor-alpha (FIP1 L1-PDGFRA) are identified in a significant no. of SM cases that have assocd. eosinophilia.  To date, as with gastrointestinal stromal tumors, activating mutations of KIT and PDGFRA appear to be alternative and mutually exclusive genetic events in SM.  The World Health Organization has specified criteria for classification of SM into six major subtypes: cutaneous mastocytosis, indolent systemic mastocytosis (ISM), systemic mastocytosis with an assocd. clonal hematol. non-mast-cell disorder (SM-AHNMD), aggressive systemic mastocytosis (ASM), mast cell leukemia, and mast cell sarcoma.  The ability to molecularly classify individual SM cases based on the presence or absence of specific mutations allows for molecularly targeted therapy in a growing no. of cases.  Imatinib mesylate therapy might result in complete remission of SM cases with wild-type KIT, certain KIT mutations, such as F522C, or the FIP1L1-PDGFRA fusion gene, but not of D816V-KIT-bearing SM.  For the latter, interferon-Î± and 2-CdA are potential first- and second-line therapeutic options.  Other drugs under investigation include novel tyrosine kinase inhibitors, as well as NF-ÎºB inhibitors, which might display greater selectivity towards D816V-KIT as compared to wild type KIT.  The pathogenesis of mastocytosis, its major clin. subtypes, and recent treatment advances are discussed in this chapter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5AZRS75zpTrVg90H21EOLACvtfcHk0lhLZkv9FuCrLA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xls1aqurY%253D&md5=41da65817b71bbe957e7f12331352791</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.beha.2005.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.beha.2005.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DAkin%26aufirst%3DC.%26aulast%3DValentm%26aufirst%3DP.%26atitle%3DPathogenesis%252C%2520clinical%2520features%252C%2520and%2520treatment%2520advances%2520in%2520mastocytosis%26jtitle%3DBest%2520Pract.%2520Res.%2520Clin.%2520Haematol.%26date%3D2006%26volume%3D19%26spage%3D595%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Longley, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyrrell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modlin, I.</span><span> </span><span class="NLM_article-title">Somatic c-KIT activating mutation in urticarial pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm</span> <span class="citation_source-journal">Nature Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">312</span><span class="NLM_x">â</span> <span class="NLM_lpage">314</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1038%2Fng0396-312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=8589724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADyaK28XhvVSgtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1996&pages=312-314&author=B.+J.+Longleyauthor=L.+Tyrrellauthor=S.+Z.+Luauthor=Y.+S.+Maauthor=K.+Langleyauthor=T.+G.+Dingauthor=T.+Duffyauthor=P.+Jacobsauthor=L.+H.+Tangauthor=I.+Modlin&title=Somatic+c-KIT+activating+mutation+in+urticarial+pigmentosa+and+aggressive+mastocytosis%3A+establishment+of+clonality+in+a+human+mast+cell+neoplasm"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm</span></div><div class="casAuthors">Longley, B. Jack; Tyrrell, Lynda; Lu, Shu-Zhuang; Ma, Yong-Sheng; Langley, Keith; Ding, Tie-gang; Duffy, Thomas; Jacobs, Peter; Tang, Laura H.; Modlin, Irvin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">312-14</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Mastocytosis is characterized by accumulations of mast cells in various organs.  Most cases are indolent and confined to the skin, where discrete mast cell infiltrates are assocd. with increased epidermal melanin, a clin. picture known as urticaria pigmentosa (UP).  Other forms of mastocytosis combine UP with aggressive involvement of other organs or with hematol. abnormalities.  It is not known whether all forms of mastocytosis are true neoplasms or whether some might represent reactive hyperplasias.  The c-KIT proto-oncogene encodes a type III receptor tyrosine kinase (KIT) that is crit. to the development and survival of mast cells and melanocytes.  The ligand for KIT (KL) can stimulate mast cell development, proliferation, and mediator release, as well as melanocyte proliferation and pigment prodn.  To det. the role of c-KIT in the pathogenesis of mastocytosis, the authors examd. tissue and cells isolated from a patient with UP and aggressive systemic mastocytosis with massive splenic involvement.  The authors found a mutation that results in constitutive activation and expression of c-KIT in mast cells of both skin and spleen.  This is the first in situ demonstration of an activating c-KIT mutation in neoplastic cells.  It also demonstrates the clonal and neoplastic nature of this form of mastocytosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA_1Vru4XZjbVg90H21EOLACvtfcHk0lhLZkv9FuCrLA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhvVSgtb8%253D&md5=c777d63dec18db918a90ccb34ac07c0b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fng0396-312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng0396-312%26sid%3Dliteratum%253Aachs%26aulast%3DLongley%26aufirst%3DB.%2BJ.%26aulast%3DTyrrell%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DS.%2BZ.%26aulast%3DMa%26aufirst%3DY.%2BS.%26aulast%3DLangley%26aufirst%3DK.%26aulast%3DDing%26aufirst%3DT.%2BG.%26aulast%3DDuffy%26aufirst%3DT.%26aulast%3DJacobs%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DL.%2BH.%26aulast%3DModlin%26aufirst%3DI.%26atitle%3DSomatic%2520c-KIT%2520activating%2520mutation%2520in%2520urticarial%2520pigmentosa%2520and%2520aggressive%2520mastocytosis%253A%2520establishment%2520of%2520clonality%2520in%2520a%2520human%2520mast%2520cell%2520neoplasm%26jtitle%3DNature%2520Genet.%26date%3D1996%26volume%3D12%26spage%3D312%26epage%3D314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Bodemer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermine, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">PalmÃ©rini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandpeix Guyodo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leventhal, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadj Rabia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georgin Lavialle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen Akenine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Launay, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barete, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arock, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catteau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sans, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stalder, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skowron, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorette, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plantin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordigoni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lortholary, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Prost, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moussy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sobol, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubreuil, P.</span><span> </span><span class="NLM_article-title">Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">804</span><span class="NLM_x">â</span> <span class="NLM_lpage">815</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2010&pages=804-815&author=C.+Bodemerauthor=O.+Hermineauthor=F.+Palm%C3%A9riniauthor=Y.+Yangauthor=C.+Grandpeix+Guyodoauthor=P.+S.+Leventhalauthor=S.+Hadj+Rabiaauthor=L.+Nascaauthor=S.+Georgin+Lavialleauthor=A.+Cohen+Akenineauthor=J.+M.+Launayauthor=S.+Bareteauthor=F.+Fegerauthor=M.+Arockauthor=B.+Catteauauthor=B.+Sansauthor=J.+F.+Stalderauthor=F.+Skowronauthor=L.+Thomasauthor=G.+Loretteauthor=P.+Plantinauthor=P.+Bordigoniauthor=O.+Lortholaryauthor=Y.+de+Prostauthor=A.+Moussyauthor=H.+Sobolauthor=P.+Dubreuil&title=Pediatric+mastocytosis+is+a+clonal+disease+associated+with+D816V+and+other+activating+c-KIT+mutations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBodemer%26aufirst%3DC.%26aulast%3DHermine%26aufirst%3DO.%26aulast%3DPalm%25C3%25A9rini%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGrandpeix%2BGuyodo%26aufirst%3DC.%26aulast%3DLeventhal%26aufirst%3DP.%2BS.%26aulast%3DHadj%2BRabia%26aufirst%3DS.%26aulast%3DNasca%26aufirst%3DL.%26aulast%3DGeorgin%2BLavialle%26aufirst%3DS.%26aulast%3DCohen%2BAkenine%26aufirst%3DA.%26aulast%3DLaunay%26aufirst%3DJ.%2BM.%26aulast%3DBarete%26aufirst%3DS.%26aulast%3DFeger%26aufirst%3DF.%26aulast%3DArock%26aufirst%3DM.%26aulast%3DCatteau%26aufirst%3DB.%26aulast%3DSans%26aufirst%3DB.%26aulast%3DStalder%26aufirst%3DJ.%2BF.%26aulast%3DSkowron%26aufirst%3DF.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3DLorette%26aufirst%3DG.%26aulast%3DPlantin%26aufirst%3DP.%26aulast%3DBordigoni%26aufirst%3DP.%26aulast%3DLortholary%26aufirst%3DO.%26aulast%3Dde%2BProst%26aufirst%3DY.%26aulast%3DMoussy%26aufirst%3DA.%26aulast%3DSobol%26aufirst%3DH.%26aulast%3DDubreuil%26aufirst%3DP.%26atitle%3DPediatric%2520mastocytosis%2520is%2520a%2520clonal%2520disease%2520associated%2520with%2520D816V%2520and%2520other%2520activating%2520c-KIT%2520mutations%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2010%26volume%3D130%26spage%3D804%26epage%3D815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNitto, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">English, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greig, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacques, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunney, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quenzer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmett, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">1542</span><span class="NLM_x">â</span> <span class="NLM_lpage">1547</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1073%2Fpnas.0812413106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=19164557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=1542-1547&author=K.+S.+Gajiwalaauthor=J.+C.+Wuauthor=J.+Christensenauthor=G.+D.+Deshmukhauthor=W.+Diehlauthor=J.+P.+DiNittoauthor=J.+M.+Englishauthor=M.+J.+Greigauthor=Y.+A.+Heauthor=S.+L.+Jacquesauthor=E.+A.+Lunneyauthor=M.+McTigueauthor=D.+Molinaauthor=T.+Quenzerauthor=P.+A.+Wellsauthor=X.+Yuauthor=Y.+Zhangauthor=A.+Zouauthor=M.+R.+Emmettauthor=A.+G.+Marshallauthor=H.+M.+Zhangauthor=G.+D.+Demetri&title=KIT+kinase+mutants+show+unique+mechanisms+of+drug+resistance+to+imatinib+and+sunitinib+in+gastrointestinal+stromal+tumor+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span></div><div class="casAuthors">Gajiwala, Ketan S.; Wu, Joe C.; Christensen, James; Deshmukh, Gayatri D.; Diehl, Wade; DiNitto, Jonathan P.; English, Jessie M.; Greig, Michael J.; He, You-Ai; Jacques, Suzanne L.; Lunney, Elizabeth A.; McTigue, Michele; Molina, Dave; Quenzer, Terri; Wells, Peter A.; Yu, Xiu; Zhang, Yan; Zou, Aihua; Emmett, Mark R.; Marshall, Alan G.; Zhang, Hui-Min; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1542-1547</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GISTs) exhibit aberrant activation of the receptor tyrosine kinase (RTK) KIT.  The efficacy of the inhibitors imatinib mesylate and sunitinib malate in GIST patients has been linked to their inhibition of these mutant KIT proteins.  However, patients on imatinib can acquire secondary KIT mutations that render the protein insensitive to the inhibitor.  Sunitinib has shown efficacy against certain imatinib-resistant mutants, although a subset that resides in the activation loop, including D816H/V, remains resistant.  Biochem. and structural studies were undertaken to det. the mol. basis of sunitinib resistance.  Our results show that sunitinib targets the autoinhibited conformation of WT KIT and that the D816H mutant undergoes a shift in conformational equil. toward the active state.  These findings provide a structural and enzymol. explanation for the resistance profile obsd. with the KIT inhibitors.  Prospectively, they have implications for understanding oncogenic kinase mutants and for circumventing drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkwFxa-p-iWbVg90H21EOLACvtfcHk0lj7GjeuHhe3pw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D&md5=dd226c914c6f9a258426c0f4984a5258</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0812413106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0812413106%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DDeshmukh%26aufirst%3DG.%2BD.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DEnglish%26aufirst%3DJ.%2BM.%26aulast%3DGreig%26aufirst%3DM.%2BJ.%26aulast%3DHe%26aufirst%3DY.%2BA.%26aulast%3DJacques%26aufirst%3DS.%2BL.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMolina%26aufirst%3DD.%26aulast%3DQuenzer%26aufirst%3DT.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DA.%26aulast%3DEmmett%26aufirst%3DM.%2BR.%26aulast%3DMarshall%26aufirst%3DA.%2BG.%26aulast%3DZhang%26aufirst%3DH.%2BM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DKIT%2520kinase%2520mutants%2520show%2520unique%2520mechanisms%2520of%2520drug%2520resistance%2520to%2520imatinib%2520and%2520sunitinib%2520in%2520gastrointestinal%2520stromal%2520tumor%2520patients%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D1542%26epage%3D1547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Frost, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrao, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashman, L. K.</span><span> </span><span class="NLM_article-title">Juxtamembrane mutant V560G Kit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816V Kit is resistant</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1115</span><span class="NLM_x">â</span> <span class="NLM_lpage">1124</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=12481435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmtFamsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=1115-1124&author=M.+J.+Frostauthor=P.+T.+Ferraoauthor=T.+P.+Hughesauthor=L.+K.+Ashman&title=Juxtamembrane+mutant+V560G+Kit+is+more+sensitive+to+Imatinib+%28STI571%29+compared+with+wild-type+c-kit+whereas+the+kinase+domain+mutant+D816V+Kit+is+resistant"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-Kit whereas the kinase domain mutant D816VKit is resistant</span></div><div class="casAuthors">Frost, Michelle J.; Ferrao, Petranel T.; Hughes, Timothy P.; Ashman, Leonie K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1115-1124</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Imatinib (Glivec; STI571) is an ATP-competitive kinase inhibitor of c-Abl, BCR/ABL, c-Kit, and platelet-derived growth factor receptor.  Overexpression or constitutive activation of Kit by mutations have been assocd. with various malignancies.  Mutations in the intracellular juxtamembrane region of Kit (e.g., V560G) are common in gastrointestinal stromal tumors and have been linked to poor prognosis.  Mutations in the kinase domain of Kit (e.g., D816V) have been detected in mastocytosis, acute myeloid leukemia, and germ-cell tumors.  To det. the sensitivity of Kit mutants to Imatinib in the same cellular background, wild-type Kit (WTKit), V560GKit and D816VKit were expressed in FDC-P1 cells.  Growth of FDC(WTKit) was inhibited by Imatinib with GI50 (a concn. of drug at which 50% inhibition of growth occurs) of 0.1-0.2 Î¼M but FDC(V560GKit) were more sensitive to Imatinib with a GI50 of 0.01-0.025 Î¼M and FDC(D816VKit) were resistant to Imatinib with a GI50 greater than 5 Î¼M.  The naturally occurring isoforms of c-Kit did not differ in their sensitivity to Imatinib.  Immunopptn. and Western blot anal. indicated that 1 Î¼M Imatinib reduced phosphorylation of WTKit and completely blocked phosphorylation of V560GKit but did not affect D816VKit phosphorylation.  In signaling studies, addn. of stem cell factor (SCF) induced phosphorylation of ERK and Akt by WTKit, and ERK, Akt and STAT3 by V560GKit, which were all blocked by Imatinib.  Imatinib also blocked the constitutive activation of Akt and STAT3 by V560GKit but had no affect on the constitutive activation of ERK, Akt, and STAT3 by D816VKit.  Overall, these findings demonstrate the increased susceptibility of the Kit juxtamembrane mutant, V560G, and the resistance of the kinase domain mutant, D816V, to Imatinib compared with WTKit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ1dLhDZXIMLVg90H21EOLACvtfcHk0lj7GjeuHhe3pw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmtFamsQ%253D%253D&md5=21eb56cdb9bc2c99e921ec9bfdb7f9ca</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFrost%26aufirst%3DM.%2BJ.%26aulast%3DFerrao%26aufirst%3DP.%2BT.%26aulast%3DHughes%26aufirst%3DT.%2BP.%26aulast%3DAshman%26aufirst%3DL.%2BK.%26atitle%3DJuxtamembrane%2520mutant%2520V560G%2520Kit%2520is%2520more%2520sensitive%2520to%2520Imatinib%2520%2528STI571%2529%2520compared%2520with%2520wild-type%2520c-kit%2520whereas%2520the%2520kinase%2520domain%2520mutant%2520D816V%2520Kit%2520is%2520resistant%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2002%26volume%3D1%26spage%3D1115%26epage%3D1124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akin, C.</span><span> </span><span class="NLM_article-title">Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">286</span><span class="NLM_x">â</span> <span class="NLM_lpage">291</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=286-291&author=N.+P.+Shahauthor=F.+Y.+Leeauthor=R.+Luoauthor=Y.+Jiangauthor=M.+Donkerauthor=C.+Akin&title=Dasatinib+%28BMS-354825%29+inhibits+KITD816V%2C+an+imatinib-resistant+activating+mutation+that+triggers+neoplastic+growth+in+most+patients+with+systemic+mastocytosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DLuo%26aufirst%3DR.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DDonker%26aufirst%3DM.%26aulast%3DAkin%26aufirst%3DC.%26atitle%3DDasatinib%2520%2528BMS-354825%2529%2520inhibits%2520KITD816V%252C%2520an%2520imatinib-resistant%2520activating%2520mutation%2520that%2520triggers%2520neoplastic%2520growth%2520in%2520most%2520patients%2520with%2520systemic%2520mastocytosis%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D286%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Lierman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smits, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewaele, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debiec Rychter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandenberghe, P.</span><span> </span><span class="NLM_article-title">Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1693</span><span class="NLM_x">â</span> <span class="NLM_lpage">1695</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=1693-1695&author=E.+Liermanauthor=S.+Smitsauthor=J.+Coolsauthor=B.+Dewaeleauthor=M.+Debiec+Rychterauthor=P.+Vandenberghe&title=Ponatinib+is+active+against+imatinib-resistant+mutants+of+FIP1L1-PDGFRA+and+KIT%2C+and+against+FGFR1-derived+fusion+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLierman%26aufirst%3DE.%26aulast%3DSmits%26aufirst%3DS.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DDewaele%26aufirst%3DB.%26aulast%3DDebiec%2BRychter%26aufirst%3DM.%26aulast%3DVandenberghe%26aufirst%3DP.%26atitle%3DPonatinib%2520is%2520active%2520against%2520imatinib-resistant%2520mutants%2520of%2520FIP1L1-PDGFRA%2520and%2520KIT%252C%2520and%2520against%2520FGFR1-derived%2520fusion%2520kinases%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D1693%26epage%3D1695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Features of selective kinase inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">621</span><span class="NLM_x">â</span> <span class="NLM_lpage">637</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1016%2Fj.chembiol.2005.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=15975507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=621-637&author=Z.+A.+Knightauthor=K.+M.+Shokat&title=Features+of+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Features of Selective Kinase Inhibitors</span></div><div class="casAuthors">Knight, Zachary A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">621-637</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Summary: Small-mol. inhibitors of protein and lipid kinases have emerged as indispensable tools for studying signal transduction.  Despite the widespread use of these reagents, there is little consensus about the biochem. criteria that define their potency and selectivity in cells.  We discuss some of the features that det. the cellular activity of kinase inhibitors and propose a framework for interpreting inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAJWhVxtSrCLVg90H21EOLACvtfcHk0lhdWJSr4LLLMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D&md5=ce5b3505a0326b04479172ec05573152</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2005.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2005.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DFeatures%2520of%2520selective%2520kinase%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2005%26volume%3D12%26spage%3D621%26epage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Smyth, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Measuring and interpreting the selectivity of protein kinase inhibitors</span> <span class="citation_source-journal">J. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">â</span> <span class="NLM_lpage">151</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1007%2Fs12154-009-0023-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=19568781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A280%3ADC%252BD1MrkslGqtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=131-151&author=L.+A.+Smythauthor=I.+Collins&title=Measuring+and+interpreting+the+selectivity+of+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Measuring and interpreting the selectivity of protein kinase inhibitors</span></div><div class="casAuthors">Smyth Lynette A; Collins Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of chemical biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">131-51</span>
        ISSN:<span class="NLM_cas:issn">1864-6158</span>.
    </div><div class="casAbstract">Protein kinase inhibitors are a well-established class of clinically useful drugs, particularly for the treatment of cancer.  Achieving inhibitor selectivity for particular protein kinases often remains a significant challenge in the development of new small molecules as drugs or as tools for chemical biology research.  This review summarises the methodologies available for measuring kinase inhibitor selectivity, both in vitro and in cells.  The interpretation of kinase inhibitor selectivity data is discussed, particularly with reference to the structural biology of the protein targets.  Measurement and prediction of kinase inhibitor selectivity will be important for the development of new multi-targeted kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzU9rA5WZcz9FxYDaSSP8XfW6udTcc2eYPvueRX0RBhrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrkslGqtA%253D%253D&md5=f78ff1202a949a71ffd65e804298c37f</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1007%2Fs12154-009-0023-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12154-009-0023-9%26sid%3Dliteratum%253Aachs%26aulast%3DSmyth%26aufirst%3DL.%2BA.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DMeasuring%2520and%2520interpreting%2520the%2520selectivity%2520of%2520protein%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D2%26spage%3D131%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hasinoff, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâHara, K. A.</span><span> </span><span class="NLM_article-title">Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1722</span><span class="NLM_x">â</span> <span class="NLM_lpage">1728</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2008&pages=1722-1728&author=B.+B.+Hasinoffauthor=D.+Patelauthor=K.+A.+O%E2%80%99Hara&title=Mechanisms+of+myocyte+cytotoxicity+induced+by+the+multiple+receptor+tyrosine+kinase+inhibitor+sunitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHasinoff%26aufirst%3DB.%2BB.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Hara%26aufirst%3DK.%2BA.%26atitle%3DMechanisms%2520of%2520myocyte%2520cytotoxicity%2520induced%2520by%2520the%2520multiple%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520sunitinib%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D74%26spage%3D1722%26epage%3D1728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crespo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">FernÃ¡ndez, A.</span><span> </span><span class="NLM_article-title">Turning promiscuous kinase inhibitors into safer drugs</span> <span class="citation_source-journal">Trends Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">â</span> <span class="NLM_lpage">301</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=295-301&author=X.+Zhangauthor=A.+Crespoauthor=A.+Fern%C3%A1ndez&title=Turning+promiscuous+kinase+inhibitors+into+safer+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DCrespo%26aufirst%3DA.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DA.%26atitle%3DTurning%2520promiscuous%2520kinase%2520inhibitors%2520into%2520safer%2520drugs%26jtitle%3DTrends%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D295%26epage%3D301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Verheul, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinedo, H. M.</span><span> </span><span class="NLM_article-title">Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">475</span><span class="NLM_x">â</span> <span class="NLM_lpage">485</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16e&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1038%2Fnrc2152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16e&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=17522716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16e&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD2sXls1Kjsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=475-485&author=H.+M.+Verheulauthor=H.+M.+Pinedo&title=Possible+molecular+mechanisms+involved+in+the+toxicity+of+angiogenesis+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16eR"><div class="casContent"><span class="casTitleNuber">16e</span><div class="casTitle"><span class="NLM_cas:atitle">Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition</span></div><div class="casAuthors">Verheul, Henk. M. W.; Pinedo, Herbert M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">475-485</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Contrary to initial expectations, angiogenesis inhibitors can cause toxicities in patients with cancer.  The toxicity profiles of these inhibitors reflect the disturbance of growth factor signaling pathways that are important for maintaining homeostasis.  Experiences with angiogenesis inhibitors in clin. trials indicate that short-term toxicities are mostly manageable.  However, these agents will also be given in prolonged treatment strategies, so we need to anticipate possible long-term toxicities.  In addn., understanding the mol. mechanisms involved in the toxicity of angiogenesis inhibition should allow more specific and more potent inhibitors to be developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZf_zBF-HferVg90H21EOLACvtfcHk0lhdWJSr4LLLMA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1Kjsb4%253D&md5=3754e28af3f27b0c68c08bc9ee129ffd</span></div><a href="/servlet/linkout?suffix=cit16e&amp;dbid=16384&amp;doi=10.1038%2Fnrc2152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2152%26sid%3Dliteratum%253Aachs%26aulast%3DVerheul%26aufirst%3DH.%2BM.%26aulast%3DPinedo%26aufirst%3DH.%2BM.%26atitle%3DPossible%2520molecular%2520mechanisms%2520involved%2520in%2520the%2520toxicity%2520of%2520angiogenesis%2520inhibition%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D475%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small moleculeâkinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">â</span> <span class="NLM_lpage">336</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Bendettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule%E2%80%93kinase+interaction+map+for+clinical+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0ljs070QWQN8tg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBendetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule%25E2%2580%2593kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNature%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span> </span><span class="NLM_article-title">Discovery of new azaindole-based PI3KÎ± inhibitors: apoptotic and antiangiogenic effect on cancer cells</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">7212</span><span class="NLM_x">â</span> <span class="NLM_lpage">7215</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7212-7215&author=S.+Hongauthor=S.+Leeauthor=B.+Kimauthor=H.+Leeauthor=S.-S.+Hongauthor=S.+Hong&title=Discovery+of+new+azaindole-based+PI3K%CE%B1+inhibitors%3A+apoptotic+and+antiangiogenic+effect+on+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DHong%26aufirst%3DS.-S.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520new%2520azaindole-based%2520PI3K%25CE%25B1%2520inhibitors%253A%2520apoptotic%2520and%2520antiangiogenic%2520effect%2520on%2520cancer%2520cells%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7212%26epage%3D7215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span> </span><span class="NLM_article-title">Design, synthesis and evaluation of 3,5-disubstituted 7-azaindoles as Trk inhibitors with anticancer and anti-angiogenic activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5337</span><span class="NLM_x">â</span> <span class="NLM_lpage">5349</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3002982" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5337-5349&author=S.+Hongauthor=J.+Kimauthor=J.+Seoauthor=K.+Jungauthor=S.-S.+Hongauthor=S.+Hong&title=Design%2C+synthesis+and+evaluation+of+3%2C5-disubstituted+7-azaindoles+as+Trk+inhibitors+with+anticancer+and+anti-angiogenic+activities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1021%2Fjm3002982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3002982%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSeo%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DK.%26aulast%3DHong%26aufirst%3DS.-S.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520evaluation%2520of%25203%252C5-disubstituted%25207-azaindoles%2520as%2520Trk%2520inhibitors%2520with%2520anticancer%2520and%2520anti-angiogenic%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5337%26epage%3D5349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Knight, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhari, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darcy, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donatelli, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luengo, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newlander, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parrish, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ridgers, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarpong, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Aller, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamond, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkins, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garver, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gontarek, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kershner, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raha, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherk, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tummino, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wegrzyn, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auger, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhanak, D.</span><span> </span><span class="NLM_article-title">Discovery of GSK2126458, a Highly potent inhibitor of PI3K and the mammalian target of rapamycin</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">â</span> <span class="NLM_lpage">43</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml900028r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmvF2qtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=39-43&author=S.+D.+Knightauthor=N.+D.+Adamsauthor=J.+L.+Burgessauthor=A.+M.+Chaudhariauthor=M.+G.+Darcyauthor=C.+A.+Donatelliauthor=J.+I.+Luengoauthor=K.+A.+Newlanderauthor=C.+A.+Parrishauthor=L.+H.+Ridgersauthor=M.+A.+Sarpongauthor=S.+J.+Schmidtauthor=G.+S.+Van+Allerauthor=J.+D.+Carsonauthor=M.+A.+Diamondauthor=P.+A.+Elkinsauthor=C.+M.+Gardinerauthor=E.+Garverauthor=S.+A.+Gilbertauthor=R.+R.+Gontarekauthor=J.+R.+Jacksonauthor=K.+L.+Kershnerauthor=L.+Luoauthor=K.+Rahaauthor=C.+S.+Sherkauthor=C.+M.+Sungauthor=D.+Suttonauthor=P.+J.+Tumminoauthor=R.+J.+Wegrzynauthor=K.+R.+Augerauthor=D.+Dhanak&title=Discovery+of+GSK2126458%2C+a+Highly+potent+inhibitor+of+PI3K+and+the+mammalian+target+of+rapamycin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin</span></div><div class="casAuthors">Knight, Steven D.; Adams, Nicholas D.; Burgess, Joelle L.; Chaudhari, Amita M.; Darcy, Michael G.; Donatelli, Carla A.; Luengo, Juan I.; Newlander, Ken A.; Parrish, Cynthia A.; Ridgers, Lance H.; Sarpong, Martha A.; Schmidt, Stanley J.; Van Aller, Glenn S.; Carson, Jeffrey D.; Diamond, Melody A.; Elkins, Patricia A.; Gardiner, Christine M.; Garver, Eric; Gilbert, Seth A.; Gontarek, Richard R.; Jackson, Jeffrey R.; Kershner, Kevin L.; Luo, Lusong; Raha, Kaushik; Sherk, Christian S.; Sung, Chiu-Mei; Sutton, David; Tummino, Peter J.; Wegrzyn, Ronald J.; Auger, Kurt R.; Dhanak, Dashyant</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-43</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase Î± (PI3KÎ±) is a crit. regulator of cell growth and transformation, and its signaling pathway is the most commonly mutated pathway in human cancers.  The mammalian target of rapamycin (mTOR), a class IV PI3K protein kinase, is also a central regulator of cell growth, and mTOR inhibitors are believed to augment the antiproliferative efficacy of PI3K/AKT pathway inhibition. 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide (GSK2126458, 1 (I)) has been identified as a highly potent, orally bioavailable inhibitor of PI3KÎ± and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models.  Compd. 1 is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBH6_ywCnjCrVg90H21EOLACvtfcHk0ljs070QWQN8tg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmvF2qtw%253D%253D&md5=72fcca85702dba95529ac03281e0bdbc</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fml900028r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml900028r%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DS.%2BD.%26aulast%3DAdams%26aufirst%3DN.%2BD.%26aulast%3DBurgess%26aufirst%3DJ.%2BL.%26aulast%3DChaudhari%26aufirst%3DA.%2BM.%26aulast%3DDarcy%26aufirst%3DM.%2BG.%26aulast%3DDonatelli%26aufirst%3DC.%2BA.%26aulast%3DLuengo%26aufirst%3DJ.%2BI.%26aulast%3DNewlander%26aufirst%3DK.%2BA.%26aulast%3DParrish%26aufirst%3DC.%2BA.%26aulast%3DRidgers%26aufirst%3DL.%2BH.%26aulast%3DSarpong%26aufirst%3DM.%2BA.%26aulast%3DSchmidt%26aufirst%3DS.%2BJ.%26aulast%3DVan%2BAller%26aufirst%3DG.%2BS.%26aulast%3DCarson%26aufirst%3DJ.%2BD.%26aulast%3DDiamond%26aufirst%3DM.%2BA.%26aulast%3DElkins%26aufirst%3DP.%2BA.%26aulast%3DGardiner%26aufirst%3DC.%2BM.%26aulast%3DGarver%26aufirst%3DE.%26aulast%3DGilbert%26aufirst%3DS.%2BA.%26aulast%3DGontarek%26aufirst%3DR.%2BR.%26aulast%3DJackson%26aufirst%3DJ.%2BR.%26aulast%3DKershner%26aufirst%3DK.%2BL.%26aulast%3DLuo%26aufirst%3DL.%26aulast%3DRaha%26aufirst%3DK.%26aulast%3DSherk%26aufirst%3DC.%2BS.%26aulast%3DSung%26aufirst%3DC.%2BM.%26aulast%3DSutton%26aufirst%3DD.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DWegrzyn%26aufirst%3DR.%2BJ.%26aulast%3DAuger%26aufirst%3DK.%2BR.%26aulast%3DDhanak%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520GSK2126458%252C%2520a%2520Highly%2520potent%2520inhibitor%2520of%2520PI3K%2520and%2520the%2520mammalian%2520target%2520of%2520rapamycin%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D39%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span> </span><span class="NLM_article-title">Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2455</span><span class="NLM_x">â</span> <span class="NLM_lpage">2466</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2455-2466&author=S.+Hongauthor=J.+Kimauthor=J.+H.+Seoauthor=K.+H.+Jungauthor=S.+S.+Hongauthor=S.+Hong&title=Design+and+synthesis+of+imidazopyridine+analogues+as+inhibitors+of+phosphoinositide+3-kinase+signaling+and+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26aulast%3DJung%26aufirst%3DK.%2BH.%26aulast%3DHong%26aufirst%3DS.%2BS.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520imidazopyridine%2520analogues%2520as%2520inhibitors%2520of%2520phosphoinositide%25203-kinase%2520signaling%2520and%2520angiogenesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2455%26epage%3D2466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span> </span><span class="NLM_article-title">Selectivity enhancement arising from interactions at the PI3K unique pocket</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1379</span><span class="NLM_x">â</span> <span class="NLM_lpage">1383</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1379-1383&author=S.+Hongauthor=J.+Kimauthor=J.+H.+Seoauthor=K.+H.+Jungauthor=S.+S.+Hongauthor=S.+Hong&title=Selectivity+enhancement+arising+from+interactions+at+the+PI3K+unique+pocket"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26aulast%3DJung%26aufirst%3DK.%2BH.%26aulast%3DHong%26aufirst%3DS.%2BS.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DSelectivity%2520enhancement%2520arising%2520from%2520interactions%2520at%2520the%2520PI3K%2520unique%2520pocket%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D1379%26epage%3D1383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Jeong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span> </span><span class="NLM_article-title">Selective and Potent Small-Molecule Inhibitors of Phosphatidylinositol 3-Kinases</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">737</span><span class="NLM_x">â</span> <span class="NLM_lpage">756</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.4155%2Ffmc.14.28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvFCrsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=737-756&author=Y.+Jeongauthor=D.+Kwonauthor=S.+Hong&title=Selective+and+Potent+Small-Molecule+Inhibitors+of+Phosphatidylinositol+3-Kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20cR"><div class="casContent"><span class="casTitleNuber">20c</span><div class="casTitle"><span class="NLM_cas:atitle">Selective and potent small-molecule inhibitors of PI3Ks</span></div><div class="casAuthors">Jeong, Yujeong; Kwon, Daeil; Hong, Sungwoo</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">737-756</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Class I PI3Ks are composed of four catalytic subunit variants (p110Î±, p110Î², p110Î´ and p110Î³).  The PI3K pathway is among the most frequently activated pathways in many diseases, and has emerged as an attractive target for drug development, in particular for the treatment of many human cancers including breast, prostate, ovarian, gastric, colon and hepatocellular cancers.  One of the challenges in the discovery of drugs that target kinases is designing small-mol. inhibitors that are sufficiently selective to minimize off-target activity and reduce the risk of potential toxicity.  This review explores the current landscape of PI3K-selective inhibitor development and highlights recent advances in achieving selectivity for PI3Ks over other protein kinases, with an emphasis on available structural information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9ZY08eojS4bVg90H21EOLACvtfcHk0lhexUr348EegA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvFCrsb0%253D&md5=f683c444e4bfb9e325a43819617b39d3</span></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.28%26sid%3Dliteratum%253Aachs%26aulast%3DJeong%26aufirst%3DY.%26aulast%3DKwon%26aufirst%3DD.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DSelective%2520and%2520Potent%2520Small-Molecule%2520Inhibitors%2520of%2520Phosphatidylinositol%25203-Kinases%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D737%26epage%3D756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">VendÃ´me, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svinarchuk, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubreuil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auclair, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Bret, M.</span><span> </span><span class="NLM_article-title">Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6194</span><span class="NLM_x">â</span> <span class="NLM_lpage">6201</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050231m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6194-6201&author=J.+Vend%C3%B4meauthor=S.+Letardauthor=F.+Martinauthor=F.+Svinarchukauthor=P.+Dubreuilauthor=C.+Auclairauthor=M.+Le+Bret&title=Molecular+modeling+of+wild-type+and+D816V+c-Kit+inhibition+based+on+ATP-competitive+binding+of+ellipticine+derivatives+to+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm050231m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050231m%26sid%3Dliteratum%253Aachs%26aulast%3DVend%25C3%25B4me%26aufirst%3DJ.%26aulast%3DLetard%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DF.%26aulast%3DSvinarchuk%26aufirst%3DF.%26aulast%3DDubreuil%26aufirst%3DP.%26aulast%3DAuclair%26aufirst%3DC.%26aulast%3DLe%2BBret%26aufirst%3DM.%26atitle%3DMolecular%2520modeling%2520of%2520wild-type%2520and%2520D816V%2520c-Kit%2520inhibition%2520based%2520on%2520ATP-competitive%2520binding%2520of%2520ellipticine%2520derivatives%2520to%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6194%26epage%3D6201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Mol, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowakowski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McRee, D. E.</span><span> </span><span class="NLM_article-title">Structure of a c-Kit product complex reveals the basis for kinase transactivation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">31461</span><span class="NLM_x">â</span> <span class="NLM_lpage">31464</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1074%2Fjbc.C300186200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=12824176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsVOnsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=31461-31464&author=C.+D.+Molauthor=K.+B.+Limauthor=V.+Sridharauthor=H.+Zouauthor=E.+Y.+Chienauthor=B.+C.+Sangauthor=J.+Nowakowskiauthor=D.+B.+Kasselauthor=C.+N.+Croninauthor=D.+E.+McRee&title=Structure+of+a+c-Kit+product+complex+reveals+the+basis+for+kinase+transactivation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of a c-Kit Product Complex Reveals the Basis for Kinase Transactivation</span></div><div class="casAuthors">Mol, Clifford D.; Lim, Kheng B.; Sridhar, Vandana; Zou, Hua; Chien, Ellen Y. T.; Sang, Bi-Ching; Nowakowski, Jacek; Kassel, Daniel B.; Cronin, Ciaran N.; McRee, Duncan E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">31461-31464</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The c-Kit proto-oncogene is a receptor protein-tyrosine kinase assocd. with several highly malignant human cancers.  Upon binding its ligand, stem cell factor (SCF), c-Kit forms an active dimer that autophosphorylates itself and activates a signaling cascade that induces cell growth.  Disease-causing human mutations that activate SCF-independent constitutive expression of c-Kit are found in acute myelogenous leukemia, human mast cell disease, and gastrointestinal stromal tumors.  We report on the phosphorylation state and crystal structure of a c-Kit product complex.  The c-Kit structure is in a fully active form, with ordered kinase activation and phosphate-binding loops.  These results provide key insights into the mol. basis for c-Kit kinase transactivation to assist in the design of new competitive inhibitors targeting activated mutant forms of c-Kit that are resistant to current chemotherapy regimes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv0eZJ9UHNILVg90H21EOLACvtfcHk0lhexUr348EegA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsVOnsb0%253D&md5=f537b5c9903adb6cc057406bd20f0f5a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C300186200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C300186200%26sid%3Dliteratum%253Aachs%26aulast%3DMol%26aufirst%3DC.%2BD.%26aulast%3DLim%26aufirst%3DK.%2BB.%26aulast%3DSridhar%26aufirst%3DV.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChien%26aufirst%3DE.%2BY.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DNowakowski%26aufirst%3DJ.%26aulast%3DKassel%26aufirst%3DD.%2BB.%26aulast%3DCronin%26aufirst%3DC.%2BN.%26aulast%3DMcRee%26aufirst%3DD.%2BE.%26atitle%3DStructure%2520of%2520a%2520c-Kit%2520product%2520complex%2520reveals%2520the%2520basis%2520for%2520kinase%2520transactivation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D31461%26epage%3D31464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Nolen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, G.</span><span> </span><span class="NLM_article-title">Regulation of protein kinases: controlling activity through activation segment conformation</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">661</span><span class="NLM_x">â</span> <span class="NLM_lpage">675</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1016%2Fj.molcel.2004.08.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=15350212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFyhsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=661-675&author=B.+Nolenauthor=S.+Taylorauthor=G.+Ghosh&title=Regulation+of+protein+kinases%3A+controlling+activity+through+activation+segment+conformation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of protein kinases: Controlling activity through activation segment conformation</span></div><div class="casAuthors">Nolen, Brad; Taylor, Susan; Ghosh, Gourisankar</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">661-675</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  There are currently at least 46 unique protein kinase crystal structures, 24 of which are available in an active state.  Here, the authors examine these structures using a structural bioinformatics approach to understand how the conformation of the activation segment controls kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAdRcy6kkUnbVg90H21EOLACvtfcHk0ljn5lFPWgx5Zw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFyhsro%253D&md5=e1fc9a323c271a856ccd944a77c83a7f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2004.08.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2004.08.024%26sid%3Dliteratum%253Aachs%26aulast%3DNolen%26aufirst%3DB.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DG.%26atitle%3DRegulation%2520of%2520protein%2520kinases%253A%2520controlling%2520activity%2520through%2520activation%2520segment%2520conformation%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D15%26spage%3D661%26epage%3D675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, L.</span><span> </span><span class="NLM_article-title">LigBuilder: a multi-purpose program for structure-based drug design</span> <span class="citation_source-journal">J. Mol. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">498</span><span class="NLM_x">â</span> <span class="NLM_lpage">516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1007%2Fs0089400060498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVemtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=498-516&author=R.+Wangauthor=Y.+Gaoauthor=L.+Lai&title=LigBuilder%3A+a+multi-purpose+program+for+structure-based+drug+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">LigBuilder: a multi-purpose program for structure-based drug design</span></div><div class="casAuthors">Wang, Renxiao; Gao, Ying; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling [online computer file]</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">498-516</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">The authors have developed a new multi-purpose program, LigBuilder, for structure-based drug design.  Within the structural constraints of the target protein, LigBuilder builds up ligands step by step using a library of org. fragments.  Various operations, such as growing, linking, and mutation, were implemented to manipulate mol. structures.  The user can choose either growing or linking strategies for ligand construction and a genetic algorithm is adopted to control the whole construction process.  Binding affinities of the ligands are estd. by an empirical scoring function and the bioavailabilities are evaluated by a set of chem. rules.  Using thrombin and dihydrofolate reductase as examples, the authors have demonstrated that LigBuilder is able to generate chem. structures similar to the known ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSJoH1AEzJDbVg90H21EOLACvtfcHk0ljn5lFPWgx5Zw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVemtLo%253D&md5=0edc2bb21366e6fad52fc6b0e1c52552</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs0089400060498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs0089400060498%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DLigBuilder%253A%2520a%2520multi-purpose%2520program%2520for%2520structure-based%2520drug%2520design%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2000%26volume%3D6%26spage%3D498%26epage%3D516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, L.</span><span> </span><span class="NLM_article-title">SCORE: A new empirical method for estimating the binding affinity of a proteinâligand complex</span> <span class="citation_source-journal">J. Mol. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">â</span> <span class="NLM_lpage">394</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1007%2Fs008940050096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADyaK1MXntFSiug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1998&pages=379-394&author=R.+Wangauthor=L.+Liuauthor=L.+Lai&title=SCORE%3A+A+new+empirical+method+for+estimating+the+binding+affinity+of+a+protein%E2%80%93ligand+complex"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">SCORE: A new empirical method for estimating the binding affinity of a protein-ligand complex</span></div><div class="casAuthors">Wang, Renxiao; Liu, Liang; Lai, Luhua; Tang, Youqi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling [Electronic Publication]</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">379-394</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A new method is presented to est. the binding affinity of a protein-ligand complex with known three-dimensional structure.  The method, SCORE, uses an empirical scoring function to describe the binding free energy, which includes terms to account for van der Waals contact, metal-ligand bonding, hydrogen bonding, desolvation effect, and deformation penalty upon the binding process.  The coeffs. of each term are obtained by multivariate regressional anal. of a diverse training set of 170 protein-ligand complexes.  The final scoring function reproduces the binding free energies of the whole training set with a cross-validated deviation of 6.3 kJ/mol.  The predictive ability of the function is further tested by a set of 11 endothiapepsin complexes and the internal consistency of the function is demonstrated in a stepwise procedure named Evolutionary Test.  A major innovation of this method is the introduction of an at. binding score which allows the researcher to inspect and optimize the lead compd. rationally in a structure-based drug design scheme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqImu0miXYf7Vg90H21EOLACvtfcHk0ljn5lFPWgx5Zw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFSiug%253D%253D&md5=057012f22eb084d0c754b7e4ae6cc87f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs008940050096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs008940050096%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DSCORE%253A%2520A%2520new%2520empirical%2520method%2520for%2520estimating%2520the%2520binding%2520affinity%2520of%2520a%2520protein%25E2%2580%2593ligand%2520complex%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D1998%26volume%3D4%26spage%3D379%26epage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="note"><p class="first last">The IC<sub>50</sub> determinations were performed at the Reaction Biology Corp. (Malvern, PA, USA). POC determinations were performed at the Ambit Bioscience Corp. (San Diego, CA, USA).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b'],'ref3':['cit3a','cit3b'],'ref4':['cit4a','cit4b','cit4c'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b'],'ref8':['cit8a','cit8b'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16a','cit16b','cit16c','cit16d','cit16e'],'ref17':['cit17'],'ref18':['cit18a','cit18b'],'ref19':['cit19'],'ref20':['cit20a','cit20b','cit20c'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':[]}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 15 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Alaâa S. Shraim, Abdelrahim Hunaiti, Abdalla Awidi, Walhan Alshaer, Nidaa A. Ababneh, Bashaer Abu-Irmaileh, Fadwa Odeh, <span class="NLM_string-name hlFld-ContribAuthor">Said Ismail</span>. </span><span class="cited-content_cbyCitation_article-title">Developing and Characterization of Chemically Modified RNA Aptamers for Targeting Wild Type and Mutated c-KIT Receptor Tyrosine Kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (5)
                                     , 2209-2228. <a href="https://doi.org/10.1021/acs.jmedchem.9b00868" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00868</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00868%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDeveloping%252Band%252BCharacterization%252Bof%252BChemically%252BModified%252BRNA%252BAptamers%252Bfor%252BTargeting%252BWild%252BType%252Band%252BMutated%252Bc-KIT%252BReceptor%252BTyrosine%252BKinases%26aulast%3DShraim%26aufirst%3DAla%25E2%2580%2599a%2BS.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D29052019%26date%3D15082019%26date%3D01082019%26volume%3D63%26issue%3D5%26spage%3D2209%26epage%3D2228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hwangseo  Park</span>, <span class="hlFld-ContribAuthor ">Yongje  Shin</span>, <span class="hlFld-ContribAuthor ">Jinhee  Kim</span>, and <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>  . </span><span class="cited-content_cbyCitation_article-title">Application of Fragment-Based de Novo Design to the Discovery of Selective Picomolar Inhibitors of Glycogen Synthase Kinase-3 Beta. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (19)
                                     , 9018-9034. <a href="https://doi.org/10.1021/acs.jmedchem.6b00944" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00944</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00944%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DApplication%252Bof%252BFragment-Based%252Bde%252BNovo%252BDesign%252Bto%252Bthe%252BDiscovery%252Bof%252BSelective%252BPicomolar%252BInhibitors%252Bof%252BGlycogen%252BSynthase%252BKinase-3%252BBeta%26aulast%3DPark%26aufirst%3DHwangseo%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D28062016%26date%3D30092016%26date%3D13102016%26date%3D27092016%26volume%3D59%26issue%3D19%26spage%3D9018%26epage%3D9034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hwangseo  Park</span>, <span class="hlFld-ContribAuthor ">Soyoung  Lee</span>, and <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Dual Inhibitors for Wild Type and D816V Mutant of c-KIT Kinase through Virtual and Biochemical Screening of Natural Products. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2016,</strong> <em>79 </em>
                                    (2)
                                     , 293-299. <a href="https://doi.org/10.1021/acs.jnatprod.5b00851" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.5b00851</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.5b00851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.5b00851%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DDiscovery%252Bof%252BDual%252BInhibitors%252Bfor%252BWild%252BType%252Band%252BD816V%252BMutant%252Bof%252Bc-KIT%252BKinase%252Bthrough%252BVirtual%252Band%252BBiochemical%252BScreening%252Bof%252BNatural%252BProducts%26aulast%3DPark%26aufirst%3DHwangseo%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D08102015%26date%3D25012016%26date%3D26022016%26volume%3D79%26issue%3D2%26spage%3D293%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huaqian  Chen</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Minglong  Qiao</span>, <span class="hlFld-ContribAuthor ">Jiawen  Hu</span>, <span class="hlFld-ContribAuthor ">Chunmei  Li</span>, <span class="hlFld-ContribAuthor ">Chenze  Qi</span>, <span class="hlFld-ContribAuthor ">Furen  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient domino strategy for synthesis of 3âsubstituted 1,5âdihydro
              
                â4
                H
              
              âpyrrolo[3,2â
              c
              ]pyridinâ4âone derivatives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2021,</strong> <em>24 </em><a href="https://doi.org/10.1002/jhet.4339" title="DOI URL">https://doi.org/10.1002/jhet.4339</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.4339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.4339%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DEfficient%252Bdomino%252Bstrategy%252Bfor%252Bsynthesis%252Bof%252B3%2525E2%252580%252590substituted%252B1%25252C5%2525E2%252580%252590dihydro%252B%2525E2%252580%2525904%252BH%252B%2525E2%252580%252590pyrrolo%25255B3%25252C2%2525E2%252580%252590%252Bc%252B%25255Dpyridin%2525E2%252580%2525904%2525E2%252580%252590one%252Bderivatives%26aulast%3DChen%26aufirst%3DHuaqian%26date%3D2021%26date%3D2021%26volume%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheolhee  Kim</span>, <span class="hlFld-ContribAuthor ">Eunae  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>26 </em>
                                    (42)
                                     , 7623-7640. <a href="https://doi.org/10.2174/0929867325666180622143548" title="DOI URL">https://doi.org/10.2174/0929867325666180622143548</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867325666180622143548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867325666180622143548%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DRational%252BDrug%252BDesign%252BApproach%252Bof%252BReceptor%252BTyrosine%252BKinase%252BType%252BIII%252BInhibitors%26aulast%3DKim%26aufirst%3DCheolhee%26date%3D2020%26volume%3D26%26issue%3D42%26spage%3D7623%26epage%3D7640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siham  Bibi</span>, <span class="hlFld-ContribAuthor ">Michel  Arock</span>. </span><span class="cited-content_cbyCitation_article-title">Tyrosine Kinase Inhibition in Mastocytosis. </span><span class="cited-content_cbyCitation_journal-name">Immunology and Allergy Clinics of North America</span><span> <strong>2018,</strong> <em>38 </em>
                                    (3)
                                     , 527-543. <a href="https://doi.org/10.1016/j.iac.2018.04.007" title="DOI URL">https://doi.org/10.1016/j.iac.2018.04.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.iac.2018.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.iac.2018.04.007%26sid%3Dliteratum%253Aachs%26jtitle%3DImmunology%2520and%2520Allergy%2520Clinics%2520of%2520North%2520America%26atitle%3DTyrosine%252BKinase%252BInhibition%252Bin%252BMastocytosis%26aulast%3DBibi%26aufirst%3DSiham%26date%3D2018%26volume%3D38%26issue%3D3%26spage%3D527%26epage%3D543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dong  Wang</span>, <span class="hlFld-ContribAuthor ">Jianyong  Hu</span>, <span class="hlFld-ContribAuthor ">Junjie  Zhao</span>, <span class="hlFld-ContribAuthor ">Meng  Shen</span>, <span class="hlFld-ContribAuthor ">Yuxi  Wang</span>, <span class="hlFld-ContribAuthor ">Peng  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Transition-metal-free access to 7-azaindoles. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2018,</strong> <em>74 </em>
                                    (30)
                                     , 4100-4110. <a href="https://doi.org/10.1016/j.tet.2018.06.025" title="DOI URL">https://doi.org/10.1016/j.tet.2018.06.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2018.06.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2018.06.025%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DTransition-metal-free%252Baccess%252Bto%252B7-azaindoles%26aulast%3DWang%26aufirst%3DDong%26date%3D2018%26volume%3D74%26issue%3D30%26spage%3D4100%26epage%3D4110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohammed I.  El-Gamal</span>, <span class="hlFld-ContribAuthor ">Hanan S.  Anbar</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances of pyrrolopyridines derivatives: a patent and literature review. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2017,</strong> <em>27 </em>
                                    (5)
                                     , 591-606. <a href="https://doi.org/10.1080/13543776.2017.1280465" title="DOI URL">https://doi.org/10.1080/13543776.2017.1280465</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2017.1280465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2017.1280465%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DRecent%252Badvances%252Bof%252Bpyrrolopyridines%252Bderivatives%25253A%252Ba%252Bpatent%252Band%252Bliterature%252Breview%26aulast%3DEl-Gamal%26aufirst%3DMohammed%2BI.%26date%3D2017%26date%3D2017%26volume%3D27%26issue%3D5%26spage%3D591%26epage%3D606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miroslava  Kissova</span>, <span class="hlFld-ContribAuthor ">Giovanni  Maga</span>, <span class="hlFld-ContribAuthor ">Emmanuele  Crespan</span>. </span><span class="cited-content_cbyCitation_article-title">The human tyrosine kinase Kit and its gatekeeper mutant T670I, show different kinetic properties: Implications for drug design. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (19)
                                     , 4555-4562. <a href="https://doi.org/10.1016/j.bmc.2016.07.059" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.07.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.07.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.07.059%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bhuman%252Btyrosine%252Bkinase%252BKit%252Band%252Bits%252Bgatekeeper%252Bmutant%252BT670I%25252C%252Bshow%252Bdifferent%252Bkinetic%252Bproperties%25253A%252BImplications%252Bfor%252Bdrug%252Bdesign%26aulast%3DKissova%26aufirst%3DMiroslava%26date%3D2016%26volume%3D24%26issue%3D19%26spage%3D4555%26epage%3D4562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suresh  Narva</span>, <span class="hlFld-ContribAuthor ">Surendar  Chitti</span>, <span class="hlFld-ContribAuthor ">Bhaskara Rao  Bala</span>, <span class="hlFld-ContribAuthor ">Mallika  Alvala</span>, <span class="hlFld-ContribAuthor ">Nishant  Jain</span>, <span class="hlFld-ContribAuthor ">Venkata Gowri Chandra Sekhar  Kondapalli</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of pyrrolo[2,3- b ]pyridine analogues as antiproliferative agents and their interaction with calf thymus DNA. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>114 </em>, 220-231. <a href="https://doi.org/10.1016/j.ejmech.2016.02.059" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.02.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.02.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.02.059%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bpyrrolo%25255B2%25252C3-%252Bb%252B%25255Dpyridine%252Banalogues%252Bas%252Bantiproliferative%252Bagents%252Band%252Btheir%252Binteraction%252Bwith%252Bcalf%252Bthymus%252BDNA%26aulast%3DNarva%26aufirst%3DSuresh%26date%3D2016%26volume%3D114%26spage%3D220%26epage%3D231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shilpa  Sharma</span>, <span class="hlFld-ContribAuthor ">Gurudutta  Gangenahalli</span>. </span><span class="cited-content_cbyCitation_article-title">Gene Expression Profiling of Human c-Kit Mutant D816V. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cancer Therapy</span><span> <strong>2016,</strong> <em>07 </em>
                                    (06)
                                     , 439-454. <a href="https://doi.org/10.4236/jct.2016.76046" title="DOI URL">https://doi.org/10.4236/jct.2016.76046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4236/jct.2016.76046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4236%2Fjct.2016.76046%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cancer%2520Therapy%26atitle%3DGene%252BExpression%252BProfiling%252Bof%252BHuman%252Bc-Kit%252BMutant%252BD816V%26aulast%3DSharma%26aufirst%3DShilpa%26date%3D2016%26volume%3D07%26issue%3D06%26spage%3D439%26epage%3D454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeonghwan  Youk</span>, <span class="hlFld-ContribAuthor ">Youngil  Koh</span>, <span class="hlFld-ContribAuthor ">Ji-Won  Kim</span>, <span class="hlFld-ContribAuthor ">Dae-Yoon  Kim</span>, <span class="hlFld-ContribAuthor ">Hyunkyung  Park</span>, <span class="hlFld-ContribAuthor ">Woo June  Jung</span>, <span class="hlFld-ContribAuthor ">Kwang-Sung  Ahn</span>, <span class="hlFld-ContribAuthor ">Hongseok  Yun</span>, <span class="hlFld-ContribAuthor ">Inho  Park</span>, <span class="hlFld-ContribAuthor ">Choong-Hyun  Sun</span>, <span class="hlFld-ContribAuthor ">Seungmook  Lee</span>, <span class="hlFld-ContribAuthor ">Sung-Soo  Yoon</span>. </span><span class="cited-content_cbyCitation_article-title">A scientific treatment approach for acute mast cell leukemia: using a strategy based on next-generation sequencing data. </span><span class="cited-content_cbyCitation_journal-name">Blood Research</span><span> <strong>2016,</strong> <em>51 </em>
                                    (1)
                                     , 17. <a href="https://doi.org/10.5045/br.2016.51.1.17" title="DOI URL">https://doi.org/10.5045/br.2016.51.1.17</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5045/br.2016.51.1.17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5045%2Fbr.2016.51.1.17%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%2520Research%26atitle%3DA%252Bscientific%252Btreatment%252Bapproach%252Bfor%252Bacute%252Bmast%252Bcell%252Bleukemia%25253A%252Busing%252Ba%252Bstrategy%252Bbased%252Bon%252Bnext-generation%252Bsequencing%252Bdata%26aulast%3DYouk%26aufirst%3DJeonghwan%26date%3D2016%26volume%3D51%26issue%3D1%26spage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinge  Zhao</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Yazhou  Wang</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Qiu  Jin</span>, <span class="hlFld-ContribAuthor ">Jianfeng  Cai</span>, <span class="hlFld-ContribAuthor ">Feng  Tang</span>, <span class="hlFld-ContribAuthor ">Yong  Zhao</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrrolo[2,3-b]pyridine derivatives as potent Brutonâs tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (15)
                                     , 4344-4353. <a href="https://doi.org/10.1016/j.bmc.2015.06.023" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.06.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.06.023%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DPyrrolo%25255B2%25252C3-b%25255Dpyridine%252Bderivatives%252Bas%252Bpotent%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DZhao%26aufirst%3DXinge%26date%3D2015%26volume%3D23%26issue%3D15%26spage%3D4344%26epage%3D4353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anindya  Chatterjee</span>, <span class="hlFld-ContribAuthor ">Joydeep  Ghosh</span>, <span class="hlFld-ContribAuthor ">Reuben  Kapur</span>. </span><span class="cited-content_cbyCitation_article-title">Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2015,</strong> <em>6 </em>
                                    (21)
                                     , 18250-18264. <a href="https://doi.org/10.18632/oncotarget.4213" title="DOI URL">https://doi.org/10.18632/oncotarget.4213</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.4213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.4213%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DMastocytosis%25253A%252Ba%252Bmutated%252BKIT%252Breceptor%252Binduced%252Bmyeloproliferative%252Bdisorder%26aulast%3DChatterjee%26aufirst%3DAnindya%26date%3D2015%26date%3D2015%26volume%3D6%26issue%3D21%26spage%3D18250%26epage%3D18264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yechan  Kim</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Rh(
              iii
              )-catalyzed 7-azaindole synthesis via CâH activation/annulative coupling of aminopyridines with alkynes. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2015,</strong> <em>51 </em>
                                    (56)
                                     , 11202-11205. <a href="https://doi.org/10.1039/C5CC03497C" title="DOI URL">https://doi.org/10.1039/C5CC03497C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C5CC03497C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC5CC03497C%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DRh%252528%252Biii%252B%252529-catalyzed%252B7-azaindole%252Bsynthesis%252Bvia%252BC%2525E2%252580%252593H%252Bactivation%25252Fannulative%252Bcoupling%252Bof%252Baminopyridines%252Bwith%252Balkynes%26aulast%3DKim%26aufirst%3DYechan%26date%3D2015%26date%3D2015%26volume%3D51%26issue%3D56%26spage%3D11202%26epage%3D11205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Initial hit for c-KIT<sup>D816V</sup> inhibitors. Compounds were tested against c-KIT<sup>D816V</sup> and PI3KÎ±.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design of new scaffolds as c-KIT<sup>D816V</sup> inhibitors and opportunities for modification in the schematic active site of c-KIT<sup>D816V</sup>. (A) Predicted binding mode of <b>1</b> in PI3KÎ±. (B) Predicted binding mode of <b>1</b> in c-KIT<sup>D816V</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Flowchart for the discovery process of potent and selective inhibitors of D816V mutant of c-KIT through the structure-based de novo design.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Representative MD trajectory snapshots of the hydrophobic pocket constructed by phosphate-binding loop and activation loop in the ATP-binding sites of (A) c-KIT<sup>D816V</sup> and (B) wild-type c-KIT. (C) Predicted binding mode of <b>4</b> with the D816V mutant of c-KIT. Carbon atoms of c-KIT and <b>4</b> are indicated in gray and green, respectively. Asp810 and Phe811 of DFG motif are indicated in magenta. Each navy dotted line indicates a hydrogen bond.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Predicted binding mode of <b>34</b> with c-KIT<sup>D816V</sup> and (B) with wild-type c-KIT. Each navy dotted line indicates a hydrogen bond.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Representative MD trajectory snapshots of <b>37</b> in the ATP-binding sites of (A) c-KIT<sup>D816V</sup> and (B) wild-type. Carbon atoms of c-KIT and <b>37</b> are indicated in cyan and green, respectively. Each dotted line indicates a hydrogen bond.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Selectivity profiles of compounds <b>19</b>, <b>21</b>, <b>31</b>, <b>32</b>, and <b>34</b>. A panel of 48 kinases was tested at 1 Î¼M concentrations in a high-throughput binding assay (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for details).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Inhibition of cellular c-KIT pathway including STAT3, Akt, and Erk in HMC-1.2 (imatinib-resistant human mast cell). HMC-1.2 cells were starved with serum-free IMEM for 2 h and treated with imatinib, dasatinib, ponatinib, <b>19</b>, <b>21</b>, <b>32</b>, and <b>34</b> for 1 h at 5 Î¼M.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Effect of <b>19</b> on the cell cycle distribution. HMC-1.2 cells were exposed to increasing concentration of <b>19</b> and 5 Î¼M imatinib for 24 h. Compound <b>19</b> arrested the cell cycle at G1 phase in a dose-dependent manner.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Effect of <b>19</b> on apoptosis in HMC-1.2 cells. HMC-1.2 cells were treated with various concentrations of <b>19</b> for 48 h, and apoptosis was determined by flow cytometry using TUNEL staining.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/medium/jm-2014-00413g_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 7-Azaindole Derivatives</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-15/jm500413g/production/images/large/jm-2014-00413g_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm500413g&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i69">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16067" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16067" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 26 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Kitamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirotab, S.</span><span> </span><span class="NLM_article-title">Kit as a human oncogenic tyrosine kinase</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">2924</span><span class="NLM_x">â</span> <span class="NLM_lpage">2931</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1007%2Fs00018-004-4273-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=15583854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXot1agsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2004&pages=2924-2931&author=Y.+Kitamuraauthor=S.+Hirotab&title=Kit+as+a+human+oncogenic+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Kit as a human oncogenic tyrosine kinase</span></div><div class="casAuthors">Kitamura, Y.; Hirota, S.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2924-2931</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  Signals through Kit receptor tyrosine kinase are essential for development of erythrocytes, melanocytes, germ cells, mast cells and interstitial cells of Cajal (ICCs).  Mice and rats with a double gene dose of loss-of-function mutations of Kit show depletion of these cells.  Although human homozygotes with loss-of-function mutations of Kit have not been reported, gain-of-function mutations of Kit result in development of tumors from mast cells, germ cells and ICCs in humans.  The ICC tumors are called gastrointestinal stromal tumors (GISTs), and GISTs are a good target for the Kit inhibitor imatinib mesylate.  The interrelationship between the type of Kit gain-of-function mutations and the therapeutic effect of imatinib mesylate has been well characterized in GISTs.  Kit is interesting from both a biol. and clin. viewpoint.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz-wPI3gyLIrVg90H21EOLACvtfcHk0liv0NMJUKWyvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXot1agsQ%253D%253D&md5=db442791f78485725ac8811ecec512b8</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2Fs00018-004-4273-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-004-4273-y%26sid%3Dliteratum%253Aachs%26aulast%3DKitamura%26aufirst%3DY.%26aulast%3DHirotab%26aufirst%3DS.%26atitle%3DKit%2520as%2520a%2520human%2520oncogenic%2520tyrosine%2520kinase%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2004%26volume%3D61%26spage%3D2924%26epage%3D2931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Blume Jensen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Claesson Welsh, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegbahn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zsebo, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westermark, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heldin, C. H.</span><span> </span><span class="NLM_article-title">Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">4121</span><span class="NLM_x">â</span> <span class="NLM_lpage">4128</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1991&pages=4121-4128&author=P.+Blume+Jensenauthor=L.+Claesson+Welshauthor=A.+Siegbahnauthor=K.+M.+Zseboauthor=B.+Westermarkauthor=C.+H.+Heldin&title=Activation+of+the+human+c-kit+product+by+ligand-induced+dimerization+mediates+circular+actin+reorganization+and+chemotaxis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlume%2BJensen%26aufirst%3DP.%26aulast%3DClaesson%2BWelsh%26aufirst%3DL.%26aulast%3DSiegbahn%26aufirst%3DA.%26aulast%3DZsebo%26aufirst%3DK.%2BM.%26aulast%3DWestermark%26aufirst%3DB.%26aulast%3DHeldin%26aufirst%3DC.%2BH.%26atitle%3DActivation%2520of%2520the%2520human%2520c-kit%2520product%2520by%2520ligand-induced%2520dimerization%2520mediates%2520circular%2520actin%2520reorganization%2520and%2520chemotaxis%26jtitle%3DEMBO%2520J.%26date%3D1991%26volume%3D10%26spage%3D4121%26epage%3D4128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ronnstrand, L.</span><span> </span><span class="NLM_article-title">Signal transduction via the stem cell factor receptor/c-kit</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_fpage">2535</span><span class="NLM_x">â</span> <span class="NLM_lpage">2548</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1007%2Fs00018-004-4189-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=15526160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A280%3ADC%252BD2crltlaitg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&pages=2535-2548&author=L.+Ronnstrand&title=Signal+transduction+via+the+stem+cell+factor+receptor%2Fc-kit"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction via the stem cell factor receptor/c-Kit</span></div><div class="casAuthors">Ronnstrand L</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and molecular life sciences : CMLS</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19-20</span>),
    <span class="NLM_cas:pages">2535-48</span>
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    </div><div class="casAbstract">Together with its ligand, stem cell factor, the receptor tyrosine kinase c-Kit is a key controlling receptor for a number of cell types, including hematopoietic stem cells, mast cells, melanocytes and germ cells.  Gain-of-function mutations in c-Kit have been described in a number of human cancers, including testicular germinomas, acute myeloid leukemia and gastrointestinal stromal tumors.  Stimulation of c-Kit by its ligand leads to dimerization of receptors, activation of its intrinsic tyrosine kinase activity and phosphorylation of key tyrosine residues within the receptor.  These phosphorylated tyrosine residues serve as docking sites for a number of signal transduction molecules containing Src homology 2 domains, which will thereby be recruited to the receptor and activated many times through phosphorylation by the receptor.  This review discusses our current knowledge of signal transduction molecules and signal transduction pathways activated by c-Kit and how their activation can be connected to the physiological outcome of c-Kit signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAUF5kuUZ4BP_I8Jvzw4xCfW6udTcc2eYlu7WPN15sSrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crltlaitg%253D%253D&md5=984cf4afb43a2772b217425b7fc93c00</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1007%2Fs00018-004-4189-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-004-4189-6%26sid%3Dliteratum%253Aachs%26aulast%3DRonnstrand%26aufirst%3DL.%26atitle%3DSignal%2520transduction%2520via%2520the%2520stem%2520cell%2520factor%2520receptor%252Fc-kit%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2004%26spage%3D2535%26epage%3D2548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Blume Jensen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janknecht, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span> </span><span class="NLM_article-title">The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136</span> <span class="citation_source-journal">Curr. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">779</span><span class="NLM_x">â</span> <span class="NLM_lpage">782</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1016%2FS0960-9822%2898%2970302-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=9651683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADyaK1cXktVKqtb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=779-782&author=P.+Blume+Jensenauthor=R.+Janknechtauthor=T.+Hunter&title=The+kit+receptor+promotes+cell+survival+via+activation+of+PI+3-kinase+and+subsequent+Akt-mediated+phosphorylation+of+Bad+on+Ser136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">The Kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136</span></div><div class="casAuthors">Blume-Jensen, Peter; Janknecht, Ralf; Hunter, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">779-782</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Current Biology Ltd.</span>)
        </div><div class="casAbstract">The c-kit-encoded receptor protein tyrosine kinase for stem cell factor (kit/SCF-R) is essential for the development of cells within the hematopoietic, melanogenic and gametogenic lineages.  SCF stimulation induces activation of phosphatidylinositol (PI) 3-kinase, which is required for SCF-induced mitogenesis and cell survival, and for activation of the serine/threonine protein kinase Akt.  Using Kit/SCF-R mutants, the authors found that, in response to SCF, Akt became activated and mediated phosphorylation of Bad, a pro-apoptotic mol., in a PI-3-kinase-dependent manner.  Phosphorylation of Bad was restricted to Ser 112 and Ser 136 in vivo, but only the Akt phosphorylation site Ser 136 was essential for SCF-promoted cell survival.  Furthermore, Bad and Akt interacted and colocalized in intact cells.  A Kit/SCF-R gain-of-function mutant that has increased mitogenic and PI 3-kinase activation potential, due to the absence of the two protein kinase C neg. feedback phosphorylation sites, enhanced both Akt activation and Bad phosphorylation and also resulted in increased cell survival.  Such a mechanism may account for how deregulated PI 3-kinase activity and naturally occurring gain-of-function point mutants of Kit/SCF-R lead to cellular transformation and fatal malignancies in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBKQgC5ys1SLVg90H21EOLACvtfcHk0liv0NMJUKWyvw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXktVKqtb0%253D&md5=fa1e1aacccdcfe75f53045c16ed1dc4d</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=10.1016%2FS0960-9822%2898%2970302-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9822%252898%252970302-1%26sid%3Dliteratum%253Aachs%26aulast%3DBlume%2BJensen%26aufirst%3DP.%26aulast%3DJanknecht%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26atitle%3DThe%2520kit%2520receptor%2520promotes%2520cell%2520survival%2520via%2520activation%2520of%2520PI%25203-kinase%2520and%2520subsequent%2520Akt-mediated%2520phosphorylation%2520of%2520Bad%2520on%2520Ser136%26jtitle%3DCurr.%2520Biol.%26date%3D1998%26volume%3D8%26spage%3D779%26epage%3D782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Masson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronnstrand, L.</span><span> </span><span class="NLM_article-title">Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3</span> <span class="citation_source-journal">Cell Signal.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">1717</span><span class="NLM_x">â</span> <span class="NLM_lpage">1726</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1016%2Fj.cellsig.2009.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=19540337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1GgtrrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=1717-1726&author=K.+Massonauthor=L.+Ronnstrand&title=Oncogenic+signaling+from+the+hematopoietic+growth+factor+receptors+c-Kit+and+Flt3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3</span></div><div class="casAuthors">Masson, Kristina; Roennstrand, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1717-1726</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Signal transduction in response to growth factors is a strictly controlled process with networks of feedback systems, highly selective interactions and finely tuned on-and-off switches.  In the context of cancer, detailed signaling studies have resulted in the development of some of the most frequently used means of therapy, with several well established examples such as the small mol. inhibitors imatinib and dasatinib in the treatment of chronic myeloid leukemia.  Impaired function of receptor tyrosine kinases is implicated in various types of tumors, and much effort is put into mapping the many interactions and downstream pathways.  Here we discuss the hematopoietic growth factor receptors c-Kit and Flt3 and their downstream signaling in normal as well as malignant cells.  Both receptors are members of the same family of tyrosine kinases and crucial mediators of stem-and progenitor-cell proliferation and survival in response to ligand stimuli from the surrounding microenvironment.  Gain-of-function mutations/alterations render the receptors constitutively and ligand-independently activated, resulting in aberrant signaling which is a crucial driving force in tumorigenesis.  Frequently found mutations in c-Kit and Flt3 are point mutations of aspartic acid 816 and 835 resp., in the activation loop of the kinase domains.  Several other point mutations have been identified, but in the case of Flt3, the most common alterations are internal tandem duplications (ITDs) in the juxtamembrane region, reported in approx. 30% of patients with acute myeloid leukemia (AML).  During the last couple of years, the increasing understanding of c-Kit and Flt3 signaling has also revealed the complexity of these receptor systems.  The impact of gain-of-function mutations of c-Kit and Flt3 in different malignancies is well established and shown to be of clin. relevance in both prognosis and therapy.  Many inhibitors of both c-Kit or Flt3 or of their downstream substrates are in clin. trials with encouraging results, and targeted therapy using a combination of such inhibitors is considered a promising approach for future treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBlFdmKXZP3bVg90H21EOLACvtfcHk0lgyzae49kwE8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1GgtrrJ&md5=24e0dfaf3edbe72f82012424c391b422</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2009.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2009.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DMasson%26aufirst%3DK.%26aulast%3DRonnstrand%26aufirst%3DL.%26atitle%3DOncogenic%2520signaling%2520from%2520the%2520hematopoietic%2520growth%2520factor%2520receptors%2520c-Kit%2520and%2520Flt3%26jtitle%3DCell%2520Signal.%26date%3D2009%26volume%3D21%26spage%3D1717%26epage%3D1726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kemmer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGreevey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wait, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Town, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span> </span><span class="NLM_article-title">KIT mutations are common in testicular seminomas</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">305</span><span class="NLM_x">â</span> <span class="NLM_lpage">313</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1016%2FS0002-9440%2810%2963120-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=14695343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsVCmsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2004&pages=305-313&author=K.+Kemmerauthor=C.+L.+Corlessauthor=J.+A.+Fletcherauthor=L.+McGreeveyauthor=A.+Haleyauthor=D.+Griffithauthor=O.+W.+Cummingsauthor=C.+Waitauthor=A.+Townauthor=M.+C.+Heinrich&title=KIT+mutations+are+common+in+testicular+seminomas"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">KIT mutations are common in testicular seminomas</span></div><div class="casAuthors">Kemmer, Kathleen; Corless, Christopher L.; Fletcher, Jonathan A.; McGreevey, Laura; Haley, Andrea; Griffith, Diana; Cummings, Oscar W.; Wait, Cecily; Town, Ajia; Heinrich, Michael C.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">305-313</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Expression of KIT tyrosine kinase is crit. for normal germ cell development and is obsd. in the majority of seminomas.  Activating mutations in KIT are common in gastrointestinal stromal tumors and mastocytosis.  In this study we examd. the frequency and spectrum of KIT mutations in 54 testicular seminomas, 1 ovarian dysgerminoma and 37 nonseminomatous germ cell tumors (NSGCT).  Fourteen seminomas (25.9%) contained exon 17 point mutations including D816V (6 cases), D816H (3 cases), Y823D (2 cases), and single examples of Y823C, N822K, and T801I.  No KIT mutations were found in the ovarian dysgerminoma or the NSGCTs.  In transient transfection assays, mutant isoforms D816V, D816H, Y823D, and N822K were constitutively phosphorylated in the absence of the natural ligand for KIT, stem cell factor (SCF).  In contrast, activation of T801I and wild-type KIT required SCF.  Mutants N822K and Y823D were inhibited by imatinib mesylate (Gleevec, previously STI571) whereas D816V and D816H were both resistant to imatinib mesylate.  Biochem. evidence of KIT activation, as assessed by KIT phosphorylation and KIT assocn. with phosphatidylinositol (PI) 3-kinase in tumor cell lysates, was largely confined to seminomas with a genomic KIT mutation.  These findings suggest that activating KIT mutations may contribute to tumorigenesis in a subset of seminomas, but are not involved in NSGCT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgGTPo5NB007Vg90H21EOLACvtfcHk0lgyzae49kwE8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsVCmsg%253D%253D&md5=d273c18384b9896578b8f21f7d19bcb6</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1016%2FS0002-9440%2810%2963120-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0002-9440%252810%252963120-3%26sid%3Dliteratum%253Aachs%26aulast%3DKemmer%26aufirst%3DK.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DMcGreevey%26aufirst%3DL.%26aulast%3DHaley%26aufirst%3DA.%26aulast%3DGriffith%26aufirst%3DD.%26aulast%3DCummings%26aufirst%3DO.%2BW.%26aulast%3DWait%26aufirst%3DC.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26atitle%3DKIT%2520mutations%2520are%2520common%2520in%2520testicular%2520seminomas%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2004%26volume%3D164%26spage%3D305%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span> </span><span class="NLM_article-title">Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1692</span><span class="NLM_x">â</span> <span class="NLM_lpage">1703</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1200%2FJCO.20.6.1692" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=11896121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD38XivFeit7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=1692-1703&author=M.+C.+Heinrichauthor=C.+D.+Blankeauthor=B.+J.+Drukerauthor=C.+L.+Corless&title=Inhibition+of+KIT+tyrosine+kinase+activity%3A+a+novel+molecular+approach+to+the+treatment+of+KIT-positive+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies</span></div><div class="casAuthors">Heinrich, Michael C.; Blanke, Charles D.; Druker, Brian J.; Corless, Christopher L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1692-1703</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Activation of the KIT tyrosine kinase by somatic mutation has been documented in a no. of human malignancies, including gastrointestinal stromal tumor (GIST), seminoma, acute myelogenous leukemia (AML), and mastocytosis.  In addn., paracrine or auto-crine activation of this kinase has been postulated in numerous other malignancies, including small-cell lung cancer and ovarian cancer.  In this review, we discuss the rationale for and development of KIT tyrosine kinase inhibitors for the treatment of human malignancies.  Studies were identified through a MEDLINE search, review of bibliogs. of relevant articles, and review of abstrs. from national meetings.  Four tyrosine kinase inhibitors that have activity against KIT are currently being used in clin. trials, and one, STI571, has recently been approved by the United States Food and Drug Administration for treating patients with chronic myelogenous leukemia.  The role of KIT inhibitors in treating KIT-pos. malignancies is reviewed.  Targeted therapy to inhibit the kinase activity of KIT is a rationale approach to the treatment of KIT-pos. malignancies.  Two key factors are the potency of a given inhibitor and the relative contribution of KIT activation to the growth of the tumor.  Given our current understanding of KIT activity in human malignancy, the best candidate diseases for treatment with KIT inhibitors are GIST, mastocytosis, seminoma and possibly some cases of AML.  Addnl., KIT inhibitors may play an adjunctive role in diseases such as small-cell lung cancer, in which KIT activation is secondary to ligand binding rather than an acquired mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeOID4WLppJLVg90H21EOLACvtfcHk0lgyzae49kwE8g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivFeit7o%253D&md5=0618c2d38d736b6b33e978f3bce93fd1</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1200%2FJCO.20.6.1692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.20.6.1692%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26atitle%3DInhibition%2520of%2520KIT%2520tyrosine%2520kinase%2520activity%253A%2520a%2520novel%2520molecular%2520approach%2520to%2520the%2520treatment%2520of%2520KIT-positive%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D1692%26epage%3D1703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Nagata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Worobec, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chowdhury, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tannenbaum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalfe, D. D.</span><span> </span><span class="NLM_article-title">Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">10560</span><span class="NLM_x">â</span> <span class="NLM_lpage">10564</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1995&pages=10560-10564&author=H.+Nagataauthor=A.+S.+Worobecauthor=C.+K.+Ohauthor=B.+A.+Chowdhuryauthor=S.+Tannenbaumauthor=Y.+Suzukiauthor=D.+D.+Metcalfe&title=Identification+of+a+point+mutation+in+the+catalytic+domain+of+the+protooncogene+c-kit+in+peripheral+blood+mononuclear+cells+of+patients+who+have+mastocytosis+with+an+associated+hematologic+disorder"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNagata%26aufirst%3DH.%26aulast%3DWorobec%26aufirst%3DA.%2BS.%26aulast%3DOh%26aufirst%3DC.%2BK.%26aulast%3DChowdhury%26aufirst%3DB.%2BA.%26aulast%3DTannenbaum%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DMetcalfe%26aufirst%3DD.%2BD.%26atitle%3DIdentification%2520of%2520a%2520point%2520mutation%2520in%2520the%2520catalytic%2520domain%2520of%2520the%2520protooncogene%2520c-kit%2520in%2520peripheral%2520blood%2520mononuclear%2520cells%2520of%2520patients%2520who%2520have%2520mastocytosis%2520with%2520an%2520associated%2520hematologic%2520disorder%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1995%26volume%3D92%26spage%3D10560%26epage%3D10564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Heinrich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffith, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wait, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zigler, A.</span><span> </span><span class="NLM_article-title">Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">925</span><span class="NLM_x">â</span> <span class="NLM_lpage">932</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2000&pages=925-932&author=M.+Heinrichauthor=D.+Griffithauthor=B.+Drukerauthor=C.+Waitauthor=K.+Ottauthor=A.+Zigler&title=Inhibition+of+c-kit+receptor+tyrosine+kinase+activity+by+STI+571%2C+a+selective+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%26aulast%3DGriffith%26aufirst%3DD.%26aulast%3DDruker%26aufirst%3DB.%26aulast%3DWait%26aufirst%3DC.%26aulast%3DOtt%26aufirst%3DK.%26aulast%3DZigler%26aufirst%3DA.%26atitle%3DInhibition%2520of%2520c-kit%2520receptor%2520tyrosine%2520kinase%2520activity%2520by%2520STI%2520571%252C%2520a%2520selective%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DBlood%26date%3D2000%26volume%3D96%26spage%3D925%26epage%3D932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van den Abbeele, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silverman, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silberman, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiese, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimitrijevic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span> </span><span class="NLM_article-title">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x">, </span> <span class="NLM_fpage">472</span><span class="NLM_x">â</span> <span class="NLM_lpage">480</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1056%2FNEJMoa020461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=12181401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2002&pages=472-480&author=G.+D.+Demetriauthor=M.+von+Mehrenauthor=C.+D.+Blankeauthor=A.+D.+van+den+Abbeeleauthor=B.+Eisenbergauthor=P.+J.+Robertsauthor=M.+C.+Heinrichauthor=D.+A.+Tuvesonauthor=S.+Singerauthor=M.+Janicekauthor=J.+A.+Fletcherauthor=S.+G.+Silvermanauthor=S.+L.+Silbermanauthor=R.+Capdevilleauthor=B.+Kieseauthor=B.+Pengauthor=S.+Dimitrijevicauthor=B.+J.+Drukerauthor=C.+Corlessauthor=C.+D.+Fletcherauthor=H.+Joensuu&title=Efficacy+and+safety+of+imatinib+mesylate+in+advanced+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</span></div><div class="casAuthors">Demetri, George D.; von Mehren, Margaret; Blanke, Charles D.; Van den Abbeele, Annick D.; Eisenberg, Burton; Roberts, Peter J.; Heinrich, Michael C.; Tuveson, David A.; Singer, Samuel; Janicek, Milos; Fletcher, Jonathan A.; Silverman, Stuart G.; Silberman, Sandra L.; Capdeville, Renaud; Kiese, Beate; Peng, Bin; Dimitrijevic, Sasa; Druker, Brian J.; Corless, Christopher; Fletcher, Christopher D. M.; Joensuu, Heikki</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">472-480</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Constitutive activation of KIT receptor tyrosine kinase is crit. in the pathogenesis of gastrointestinal stromal tumors.  Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclin. models and preliminary clin. studies to have activity against such tumors.  We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor.  We assessed antitumor response and the safety and tolerability of the drug.  Pharmacokinetics were assessed in a subgroup of patients.  A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily.  Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for tech. reasons, response could not be evaluated in 7 patients (4.8 percent).  No patient had a complete response to the treatment.  The median duration of response had not been reached after a median follow-up of 24 wk after the onset of response.  Early resistance to imatinib was noted in 20 patients (13.6 percent).  Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common.  Gastrointestinal or intraabdominal hemorrhage occurred in approx. 5 percent of patients.  There were no significant differences in toxic effects or response between the two doses.  Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia.  Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor.  Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVE0HpuuKXXrVg90H21EOLACvtfcHk0ljn5DQ6ZIY56g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtV2nt7s%253D&md5=95c9ea076dd2b0e053ae2061cb3f5d24</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa020461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa020461%26sid%3Dliteratum%253Aachs%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3Dvan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DJanicek%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DSilverman%26aufirst%3DS.%2BG.%26aulast%3DSilberman%26aufirst%3DS.%2BL.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DKiese%26aufirst%3DB.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DCorless%26aufirst%3DC.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DJoensuu%26aufirst%3DH.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520imatinib%2520mesylate%2520in%2520advanced%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2002%26volume%3D347%26spage%3D472%26epage%3D480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mol, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowakowski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McRee, D. E.</span><span> </span><span class="NLM_article-title">Structure of a KIT product complex reveals the basis for kinase transactivation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">31461</span><span class="NLM_x">â</span> <span class="NLM_lpage">31464</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=31461-31464&author=C.+D.+Molauthor=K.+B.+Limauthor=V.+Sridharauthor=H.+Zouauthor=E.+Y.+Chienauthor=B.+C.+Sangauthor=J.+Nowakowskiauthor=D.+B.+Kasselauthor=C.+N.+Croninauthor=D.+E.+McRee&title=Structure+of+a+KIT+product+complex+reveals+the+basis+for+kinase+transactivation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMol%26aufirst%3DC.%2BD.%26aulast%3DLim%26aufirst%3DK.%2BB.%26aulast%3DSridhar%26aufirst%3DV.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChien%26aufirst%3DE.%2BY.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DNowakowski%26aufirst%3DJ.%26aulast%3DKassel%26aufirst%3DD.%2BB.%26aulast%3DCronin%26aufirst%3DC.%2BN.%26aulast%3DMcRee%26aufirst%3DD.%2BE.%26atitle%3DStructure%2520of%2520a%2520KIT%2520product%2520complex%2520reveals%2520the%2520basis%2520for%2520kinase%2520transactivation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D31461%26epage%3D31464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mol, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougan, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheibe, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snell, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, K. P.</span><span> </span><span class="NLM_article-title">Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">31655</span><span class="NLM_x">â</span> <span class="NLM_lpage">31663</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1074%2Fjbc.M403319200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=15123710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlslOrtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=31655-31663&author=C.+D.+Molauthor=D.+R.+Douganauthor=T.+R.+Schneiderauthor=R.+J.+Skeneauthor=M.+L.+Krausauthor=D.+N.+Scheibeauthor=G.+P.+Snellauthor=H.+Zouauthor=B.+C.+Sangauthor=K.+P.+Wilson&title=Structural+basis+for+the+autoinhibition+and+STI-571+inhibition+of+c-Kit+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase</span></div><div class="casAuthors">Mol, Clifford D.; Dougan, Douglas R.; Schneider, Thomas R.; Skene, Robert J.; Kraus, Michelle L.; Scheibe, Daniel N.; Snell, Gyorgy P.; Zou, Hua; Sang, Bi-Ching; Wilson, Keith P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">31655-31663</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The activity of the c-Kit receptor protein-tyrosine kinase is tightly regulated in normal cells, whereas deregulated c-Kit kinase activity is implicated in the pathogenesis of human cancers.  The c-Kit juxtamembrane region is known to have an autoinhibitory function; however the precise mechanism by which c-Kit is maintained in an autoinhibited state is not known.  We report the 1.9-Ã resoln. crystal structure of native c-Kit kinase in an autoinhibited conformation and compare it with active c-Kit kinase.  Autoinhibited c-Kit is stabilized by the juxtamembrane domain, which inserts into the kinase-active site and disrupts formation of the activated structure.  A 1.6-Ã crystal structure of c-Kit in complex with STI-571 (Imatinib or Gleevec) demonstrates that inhibitor binding disrupts this natural mechanism for maintaining c-Kit in an autoinhibited state.  Together, these results provide a structural basis for understanding c-Kit kinase autoinhibition and will facilitate the structure-guided design of specific inhibitors that target the activated and autoinhibited conformations of c-Kit kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWJsKx1IzXQbVg90H21EOLACvtfcHk0ljn5DQ6ZIY56g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlslOrtrc%253D&md5=df6065a62b44e4c2e6b020da0f797ab4</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M403319200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M403319200%26sid%3Dliteratum%253Aachs%26aulast%3DMol%26aufirst%3DC.%2BD.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DSchneider%26aufirst%3DT.%2BR.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DKraus%26aufirst%3DM.%2BL.%26aulast%3DScheibe%26aufirst%3DD.%2BN.%26aulast%3DSnell%26aufirst%3DG.%2BP.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DWilson%26aufirst%3DK.%2BP.%26atitle%3DStructural%2520basis%2520for%2520the%2520autoinhibition%2520and%2520STI-571%2520inhibition%2520of%2520c-Kit%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D31655%26epage%3D31663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanke, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joensuu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Mehren, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandau, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDougall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span> </span><span class="NLM_article-title">Molecular correlates of imatinib resistance in gastrointestinal stromal tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">764</span><span class="NLM_x">â</span> <span class="NLM_lpage">774</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=764-774&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=C.+D.+Blankeauthor=G.+D.+Demetriauthor=H.+Joensuuauthor=P.+J.+Robertsauthor=B.+L.+Eisenbergauthor=M.+von+Mehrenauthor=C.+D.+Fletcherauthor=K.+Sandauauthor=K.+McDougallauthor=W.+B.+Ouauthor=C.+J.+Chenauthor=J.+A.+Fletcher&title=Molecular+correlates+of+imatinib+resistance+in+gastrointestinal+stromal+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DEisenberg%26aufirst%3DB.%2BL.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DSandau%26aufirst%3DK.%26aulast%3DMcDougall%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DW.%2BB.%26aulast%3DChen%26aufirst%3DC.%2BJ.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DMolecular%2520correlates%2520of%2520imatinib%2520resistance%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D764%26epage%3D774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lasota, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corless, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinrich, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debiec Rychter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciot, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardelmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merkelbach Bruse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schildhaus, H. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steigen, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stachura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wozniak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antonescu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daum, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Muro, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miettinen, M.</span><span> </span><span class="NLM_article-title">Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases</span> <span class="citation_source-journal">Mod. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">476</span><span class="NLM_x">â</span> <span class="NLM_lpage">484</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1038%2Fmodpathol.2008.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=18246046" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjs1aku7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=476-484&author=J.+Lasotaauthor=C.+L.+Corlessauthor=M.+C.+Heinrichauthor=M.+Debiec+Rychterauthor=R.+Sciotauthor=E.+Wardelmannauthor=S.+Merkelbach+Bruseauthor=H.+U.+Schildhausauthor=S.+E.+Steigenauthor=J.+Stachuraauthor=A.+Wozniakauthor=C.+Antonescuauthor=O.+Daumauthor=J.+Martinauthor=J.+G.+Del+Muroauthor=M.+Miettinen&title=Clinicopathologic+profile+of+gastrointestinal+stromal+tumors+%28GISTs%29+with+primary+KIT+exon+13+or+exon+17+mutations%3A+a+multicenter+study+on+54+cases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases</span></div><div class="casAuthors">Lasota, Jerzy; Corless, Christopher L.; Heinrich, Michael C.; Debiec-Rychter, Maria; Sciot, Raf; Wardelmann, Eva; Merkelbach-Bruse, Sabine; Schildhaus, Hans-Ulrich; Steigen, Sonja E.; Stachura, Jerzy; Wozniak, Agnieszka; Antonescu, Cristina; Daum, Ondrej; Martin, Javier; del Muro, Javier Garcia; Miettinen, Markku</div><div class="citationInfo"><span class="NLM_cas:title">Modern Pathology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">476-484</span>CODEN:
                <span class="NLM_cas:coden">MODPEO</span>;
        ISSN:<span class="NLM_cas:issn">0893-3952</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms driven by oncogenic, mutational activation of KIT or platelet-derived growth factor receptor Î± (PDGFRA).  GIST-specific KIT or PDGFRA mutations have been linked to tumor location, tumor cell morphol. and clin. behavior.  The purpose of this study was to evaluate the clinicopathol. profile of GISTs that have KIT exon 13 or exon 17 mutations.  Through the collaboration of several GIST research groups, the authors gathered 54 cases from the pre-imatinib era that had such primary mutations.  From the observations and those in the literature, the authors est. that the frequency of these mutations is no higher than 1-2%.  Almost all (32 of 33, 97%) of the KIT exon 13 mutations were the 1945A>G substitution leading to Lys642Glu.  A majority (15 of 21, 71.4%) of the KIT exon 17 mutations were the 2487T>A substitution leading to Asn822Lys.  Demog. and clinicopathol. data were available for 26 and 14 KIT exon 13 and exon 17 mutant GISTs, resp.  Median age and male to female ratio were similar to ones reported in other GIST studies.  Small intestinal tumors were two times more frequent than gastric ones among KIT exon 17 mutants.  Also, intestinal tumors were slightly overrepresented among KIT exon 13 mutants when compared with population-based studies.  The majority of KIT exon 13 or exon 17 mutants had a spindle-cell morphol. and only a few had epithelioid features.  Tumor size varied from 1.2 to 25 cm and av. mitotic rates were 9.5 and 4.2 for KIT exon 13 and exon 17 mutants, resp.  Gastric KIT exon 13 mutant GISTs tend to be slightly larger and more aggressive than gastric GISTs in av., whereas the behavior of small intestinal GISTs with KIT exon 13 mutations does not differ from other small intestinal GISTs.  The latter is also true for all KIT exon 17 mutant GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqL32NFTz6mtrVg90H21EOLACvtfcHk0lh6UGcYTxMLYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjs1aku7c%253D&md5=5cc996a149e1f7decb59b9cd4330961d</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1038%2Fmodpathol.2008.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmodpathol.2008.2%26sid%3Dliteratum%253Aachs%26aulast%3DLasota%26aufirst%3DJ.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DDebiec%2BRychter%26aufirst%3DM.%26aulast%3DSciot%26aufirst%3DR.%26aulast%3DWardelmann%26aufirst%3DE.%26aulast%3DMerkelbach%2BBruse%26aufirst%3DS.%26aulast%3DSchildhaus%26aufirst%3DH.%2BU.%26aulast%3DSteigen%26aufirst%3DS.%2BE.%26aulast%3DStachura%26aufirst%3DJ.%26aulast%3DWozniak%26aufirst%3DA.%26aulast%3DAntonescu%26aufirst%3DC.%26aulast%3DDaum%26aufirst%3DO.%26aulast%3DMartin%26aufirst%3DJ.%26aulast%3DDel%2BMuro%26aufirst%3DJ.%2BG.%26aulast%3DMiettinen%26aufirst%3DM.%26atitle%3DClinicopathologic%2520profile%2520of%2520gastrointestinal%2520stromal%2520tumors%2520%2528GISTs%2529%2520with%2520primary%2520KIT%2520exon%252013%2520or%2520exon%252017%2520mutations%253A%2520a%2520multicenter%2520study%2520on%252054%2520cases%26jtitle%3DMod.%2520Pathol.%26date%3D2008%26volume%3D21%26spage%3D476%26epage%3D484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Longley, B. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalfe, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tharp, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyrrell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heitjan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span> </span><span class="NLM_article-title">Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">1609</span><span class="NLM_x">â</span> <span class="NLM_lpage">1614</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1073%2Fpnas.96.4.1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=9990072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADyaK1MXhsFSqs7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=1609-1614&author=B.+J.+Longleyauthor=D.+D.+Metcalfeauthor=M.+Tharpauthor=X.+Wangauthor=L.+Tyrrellauthor=S.+Z.+Luauthor=D.+Heitjanauthor=Y.+Ma&title=Activating+and+dominant+inactivating+c-KIT+catalytic+domain+mutations+in+distinct+clinical+forms+of+human+mastocytosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis</span></div><div class="casAuthors">Longley, B. Jack Jr.; Metcalfe, Dean D.; Tharp, Michael; Wang, Xiaomei; Tyrrell, Lynda; Lu, Shu-zhuang; Heitjan, David; Ma, Yongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1609-1614</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Human mastocytosis is characterized by increased mast cells.  It usually occurs as a sporadic disease that is often transient and limited in children and persistent or progressive in adults.  The c-KIT protooncogene encodes KIT, a tyrosine kinase that is the receptor for mast cell growth factor.  Because mutated KIT can transform cells, the authors examd. c-KIT in skin lesions of 22 patients with sporadic mastocytosis and 3 patients with familial mastocytosis.  All patients with adult sporadic mastocytosis had somatic c-KIT mutations in codon 816 causing substitution of valine for aspartate and spontaneous activation of mast cell growth factor receptor.  A subset of four pediatric onset cases with clin. unusual disease also had codon 816 activating mutations substituting valine, tyrosine, or phenylalanine for aspartate.  Typical pediatric patients lacked 816 mutations, but limited sequencing showed three of six had a novel dominant inactivating mutation substituting lysine for glutamic acid in position 839, the site of a potential salt bridge that is highly conserved in receptor tyrosine kinases.  No c-KIT mutations were found in the entire coding region of three patients with familial mastocytosis.  The authors conclude that c-KIT somatic mutations substituting valine in position 816 of KIT are characteristic of sporadic adult mastocytosis and may cause this disease.  Similar mutations causing activation of the mast cell growth factor receptor are found in children apparently at risk for extensive or persistent disease.  In contrast, typical pediatric mastocytosis patients lack these mutations and may express inactivating c-KIT mutations.  Familial mastocytosis, however, may occur in the absence of c-KIT coding mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6m1TDiADq27Vg90H21EOLACvtfcHk0lh6UGcYTxMLYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhsFSqs7k%253D&md5=242e0b352a75df6db1178830f26c085f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.4.1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.4.1609%26sid%3Dliteratum%253Aachs%26aulast%3DLongley%26aufirst%3DB.%2BJ.%26aulast%3DMetcalfe%26aufirst%3DD.%2BD.%26aulast%3DTharp%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTyrrell%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DS.%2BZ.%26aulast%3DHeitjan%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DY.%26atitle%3DActivating%2520and%2520dominant%2520inactivating%2520c-KIT%2520catalytic%2520domain%2520mutations%2520in%2520distinct%2520clinical%2520forms%2520of%2520human%2520mastocytosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D1609%26epage%3D1614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Pardanani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentm, P.</span><span> </span><span class="NLM_article-title">Pathogenesis, clinical features, and treatment advances in mastocytosis</span> <span class="citation_source-journal">Best Pract. Res. Clin. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">595</span><span class="NLM_x">â</span> <span class="NLM_lpage">615</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1016%2Fj.beha.2005.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=16781490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD28Xls1aqurY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=595-615&author=A.+Pardananiauthor=C.+Akinauthor=P.+Valentm&title=Pathogenesis%2C+clinical+features%2C+and+treatment+advances+in+mastocytosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Pathogenesis, clinical features, and treatment advances in mastocytosis</span></div><div class="casAuthors">Pardanani, A.; Akin, C.; Valent, P.</div><div class="citationInfo"><span class="NLM_cas:title">Best Practice & Research, Clinical Haematology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">595-615</span>CODEN:
                <span class="NLM_cas:coden">BPRCA5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Systemic mastocytosis (SM) is characterized by the abnormal growth and accumulation of mast cells (MC) in one or more organs.  The interaction between the cytokine stem cell factor (SCF) and its cognate receptor, the c-kit receptor tyrosine kinase (KIT), plays a central role in regulating MC growth and differentiation.  Whereas germline and somatically acquired activating mutations of KIT have been identified in SM, the issue as to whether individual KIT mutation(s) are necessary and sufficient to cause MC transformation remains unclear based on currently available data.  Activating mutations of platelet-derived growth factor receptor-alpha (FIP1 L1-PDGFRA) are identified in a significant no. of SM cases that have assocd. eosinophilia.  To date, as with gastrointestinal stromal tumors, activating mutations of KIT and PDGFRA appear to be alternative and mutually exclusive genetic events in SM.  The World Health Organization has specified criteria for classification of SM into six major subtypes: cutaneous mastocytosis, indolent systemic mastocytosis (ISM), systemic mastocytosis with an assocd. clonal hematol. non-mast-cell disorder (SM-AHNMD), aggressive systemic mastocytosis (ASM), mast cell leukemia, and mast cell sarcoma.  The ability to molecularly classify individual SM cases based on the presence or absence of specific mutations allows for molecularly targeted therapy in a growing no. of cases.  Imatinib mesylate therapy might result in complete remission of SM cases with wild-type KIT, certain KIT mutations, such as F522C, or the FIP1L1-PDGFRA fusion gene, but not of D816V-KIT-bearing SM.  For the latter, interferon-Î± and 2-CdA are potential first- and second-line therapeutic options.  Other drugs under investigation include novel tyrosine kinase inhibitors, as well as NF-ÎºB inhibitors, which might display greater selectivity towards D816V-KIT as compared to wild type KIT.  The pathogenesis of mastocytosis, its major clin. subtypes, and recent treatment advances are discussed in this chapter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5AZRS75zpTrVg90H21EOLACvtfcHk0lh6UGcYTxMLYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xls1aqurY%253D&md5=41da65817b71bbe957e7f12331352791</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.beha.2005.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.beha.2005.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DPardanani%26aufirst%3DA.%26aulast%3DAkin%26aufirst%3DC.%26aulast%3DValentm%26aufirst%3DP.%26atitle%3DPathogenesis%252C%2520clinical%2520features%252C%2520and%2520treatment%2520advances%2520in%2520mastocytosis%26jtitle%3DBest%2520Pract.%2520Res.%2520Clin.%2520Haematol.%26date%3D2006%26volume%3D19%26spage%3D595%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Longley, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyrrell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modlin, I.</span><span> </span><span class="NLM_article-title">Somatic c-KIT activating mutation in urticarial pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm</span> <span class="citation_source-journal">Nature Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">312</span><span class="NLM_x">â</span> <span class="NLM_lpage">314</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1038%2Fng0396-312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=8589724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADyaK28XhvVSgtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1996&pages=312-314&author=B.+J.+Longleyauthor=L.+Tyrrellauthor=S.+Z.+Luauthor=Y.+S.+Maauthor=K.+Langleyauthor=T.+G.+Dingauthor=T.+Duffyauthor=P.+Jacobsauthor=L.+H.+Tangauthor=I.+Modlin&title=Somatic+c-KIT+activating+mutation+in+urticarial+pigmentosa+and+aggressive+mastocytosis%3A+establishment+of+clonality+in+a+human+mast+cell+neoplasm"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm</span></div><div class="casAuthors">Longley, B. Jack; Tyrrell, Lynda; Lu, Shu-Zhuang; Ma, Yong-Sheng; Langley, Keith; Ding, Tie-gang; Duffy, Thomas; Jacobs, Peter; Tang, Laura H.; Modlin, Irvin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">312-14</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Co.</span>)
        </div><div class="casAbstract">Mastocytosis is characterized by accumulations of mast cells in various organs.  Most cases are indolent and confined to the skin, where discrete mast cell infiltrates are assocd. with increased epidermal melanin, a clin. picture known as urticaria pigmentosa (UP).  Other forms of mastocytosis combine UP with aggressive involvement of other organs or with hematol. abnormalities.  It is not known whether all forms of mastocytosis are true neoplasms or whether some might represent reactive hyperplasias.  The c-KIT proto-oncogene encodes a type III receptor tyrosine kinase (KIT) that is crit. to the development and survival of mast cells and melanocytes.  The ligand for KIT (KL) can stimulate mast cell development, proliferation, and mediator release, as well as melanocyte proliferation and pigment prodn.  To det. the role of c-KIT in the pathogenesis of mastocytosis, the authors examd. tissue and cells isolated from a patient with UP and aggressive systemic mastocytosis with massive splenic involvement.  The authors found a mutation that results in constitutive activation and expression of c-KIT in mast cells of both skin and spleen.  This is the first in situ demonstration of an activating c-KIT mutation in neoplastic cells.  It also demonstrates the clonal and neoplastic nature of this form of mastocytosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA_1Vru4XZjbVg90H21EOLACvtfcHk0ljwemrZPAbkgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XhvVSgtb8%253D&md5=c777d63dec18db918a90ccb34ac07c0b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fng0396-312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng0396-312%26sid%3Dliteratum%253Aachs%26aulast%3DLongley%26aufirst%3DB.%2BJ.%26aulast%3DTyrrell%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DS.%2BZ.%26aulast%3DMa%26aufirst%3DY.%2BS.%26aulast%3DLangley%26aufirst%3DK.%26aulast%3DDing%26aufirst%3DT.%2BG.%26aulast%3DDuffy%26aufirst%3DT.%26aulast%3DJacobs%26aufirst%3DP.%26aulast%3DTang%26aufirst%3DL.%2BH.%26aulast%3DModlin%26aufirst%3DI.%26atitle%3DSomatic%2520c-KIT%2520activating%2520mutation%2520in%2520urticarial%2520pigmentosa%2520and%2520aggressive%2520mastocytosis%253A%2520establishment%2520of%2520clonality%2520in%2520a%2520human%2520mast%2520cell%2520neoplasm%26jtitle%3DNature%2520Genet.%26date%3D1996%26volume%3D12%26spage%3D312%26epage%3D314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Bodemer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermine, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">PalmÃ©rini, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grandpeix Guyodo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leventhal, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadj Rabia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasca, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Georgin Lavialle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen Akenine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Launay, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barete, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arock, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catteau, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sans, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stalder, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skowron, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorette, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plantin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordigoni, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lortholary, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Prost, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moussy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sobol, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubreuil, P.</span><span> </span><span class="NLM_article-title">Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations</span> <span class="citation_source-journal">J. Invest. Dermatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">804</span><span class="NLM_x">â</span> <span class="NLM_lpage">815</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2010&pages=804-815&author=C.+Bodemerauthor=O.+Hermineauthor=F.+Palm%C3%A9riniauthor=Y.+Yangauthor=C.+Grandpeix+Guyodoauthor=P.+S.+Leventhalauthor=S.+Hadj+Rabiaauthor=L.+Nascaauthor=S.+Georgin+Lavialleauthor=A.+Cohen+Akenineauthor=J.+M.+Launayauthor=S.+Bareteauthor=F.+Fegerauthor=M.+Arockauthor=B.+Catteauauthor=B.+Sansauthor=J.+F.+Stalderauthor=F.+Skowronauthor=L.+Thomasauthor=G.+Loretteauthor=P.+Plantinauthor=P.+Bordigoniauthor=O.+Lortholaryauthor=Y.+de+Prostauthor=A.+Moussyauthor=H.+Sobolauthor=P.+Dubreuil&title=Pediatric+mastocytosis+is+a+clonal+disease+associated+with+D816V+and+other+activating+c-KIT+mutations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBodemer%26aufirst%3DC.%26aulast%3DHermine%26aufirst%3DO.%26aulast%3DPalm%25C3%25A9rini%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGrandpeix%2BGuyodo%26aufirst%3DC.%26aulast%3DLeventhal%26aufirst%3DP.%2BS.%26aulast%3DHadj%2BRabia%26aufirst%3DS.%26aulast%3DNasca%26aufirst%3DL.%26aulast%3DGeorgin%2BLavialle%26aufirst%3DS.%26aulast%3DCohen%2BAkenine%26aufirst%3DA.%26aulast%3DLaunay%26aufirst%3DJ.%2BM.%26aulast%3DBarete%26aufirst%3DS.%26aulast%3DFeger%26aufirst%3DF.%26aulast%3DArock%26aufirst%3DM.%26aulast%3DCatteau%26aufirst%3DB.%26aulast%3DSans%26aufirst%3DB.%26aulast%3DStalder%26aufirst%3DJ.%2BF.%26aulast%3DSkowron%26aufirst%3DF.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3DLorette%26aufirst%3DG.%26aulast%3DPlantin%26aufirst%3DP.%26aulast%3DBordigoni%26aufirst%3DP.%26aulast%3DLortholary%26aufirst%3DO.%26aulast%3Dde%2BProst%26aufirst%3DY.%26aulast%3DMoussy%26aufirst%3DA.%26aulast%3DSobol%26aufirst%3DH.%26aulast%3DDubreuil%26aufirst%3DP.%26atitle%3DPediatric%2520mastocytosis%2520is%2520a%2520clonal%2520disease%2520associated%2520with%2520D816V%2520and%2520other%2520activating%2520c-KIT%2520mutations%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2010%26volume%3D130%26spage%3D804%26epage%3D815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiNitto, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">English, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greig, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacques, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunney, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quenzer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emmett, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demetri, G. D.</span><span> </span><span class="NLM_article-title">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">1542</span><span class="NLM_x">â</span> <span class="NLM_lpage">1547</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1073%2Fpnas.0812413106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=19164557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=1542-1547&author=K.+S.+Gajiwalaauthor=J.+C.+Wuauthor=J.+Christensenauthor=G.+D.+Deshmukhauthor=W.+Diehlauthor=J.+P.+DiNittoauthor=J.+M.+Englishauthor=M.+J.+Greigauthor=Y.+A.+Heauthor=S.+L.+Jacquesauthor=E.+A.+Lunneyauthor=M.+McTigueauthor=D.+Molinaauthor=T.+Quenzerauthor=P.+A.+Wellsauthor=X.+Yuauthor=Y.+Zhangauthor=A.+Zouauthor=M.+R.+Emmettauthor=A.+G.+Marshallauthor=H.+M.+Zhangauthor=G.+D.+Demetri&title=KIT+kinase+mutants+show+unique+mechanisms+of+drug+resistance+to+imatinib+and+sunitinib+in+gastrointestinal+stromal+tumor+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span></div><div class="casAuthors">Gajiwala, Ketan S.; Wu, Joe C.; Christensen, James; Deshmukh, Gayatri D.; Diehl, Wade; DiNitto, Jonathan P.; English, Jessie M.; Greig, Michael J.; He, You-Ai; Jacques, Suzanne L.; Lunney, Elizabeth A.; McTigue, Michele; Molina, Dave; Quenzer, Terri; Wells, Peter A.; Yu, Xiu; Zhang, Yan; Zou, Aihua; Emmett, Mark R.; Marshall, Alan G.; Zhang, Hui-Min; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1542-1547</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GISTs) exhibit aberrant activation of the receptor tyrosine kinase (RTK) KIT.  The efficacy of the inhibitors imatinib mesylate and sunitinib malate in GIST patients has been linked to their inhibition of these mutant KIT proteins.  However, patients on imatinib can acquire secondary KIT mutations that render the protein insensitive to the inhibitor.  Sunitinib has shown efficacy against certain imatinib-resistant mutants, although a subset that resides in the activation loop, including D816H/V, remains resistant.  Biochem. and structural studies were undertaken to det. the mol. basis of sunitinib resistance.  Our results show that sunitinib targets the autoinhibited conformation of WT KIT and that the D816H mutant undergoes a shift in conformational equil. toward the active state.  These findings provide a structural and enzymol. explanation for the resistance profile obsd. with the KIT inhibitors.  Prospectively, they have implications for understanding oncogenic kinase mutants and for circumventing drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkwFxa-p-iWbVg90H21EOLACvtfcHk0ljwemrZPAbkgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D&md5=dd226c914c6f9a258426c0f4984a5258</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0812413106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0812413106%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DDeshmukh%26aufirst%3DG.%2BD.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DEnglish%26aufirst%3DJ.%2BM.%26aulast%3DGreig%26aufirst%3DM.%2BJ.%26aulast%3DHe%26aufirst%3DY.%2BA.%26aulast%3DJacques%26aufirst%3DS.%2BL.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMolina%26aufirst%3DD.%26aulast%3DQuenzer%26aufirst%3DT.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DA.%26aulast%3DEmmett%26aufirst%3DM.%2BR.%26aulast%3DMarshall%26aufirst%3DA.%2BG.%26aulast%3DZhang%26aufirst%3DH.%2BM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DKIT%2520kinase%2520mutants%2520show%2520unique%2520mechanisms%2520of%2520drug%2520resistance%2520to%2520imatinib%2520and%2520sunitinib%2520in%2520gastrointestinal%2520stromal%2520tumor%2520patients%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D1542%26epage%3D1547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Frost, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrao, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashman, L. K.</span><span> </span><span class="NLM_article-title">Juxtamembrane mutant V560G Kit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816V Kit is resistant</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">1115</span><span class="NLM_x">â</span> <span class="NLM_lpage">1124</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=12481435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmtFamsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=1115-1124&author=M.+J.+Frostauthor=P.+T.+Ferraoauthor=T.+P.+Hughesauthor=L.+K.+Ashman&title=Juxtamembrane+mutant+V560G+Kit+is+more+sensitive+to+Imatinib+%28STI571%29+compared+with+wild-type+c-kit+whereas+the+kinase+domain+mutant+D816V+Kit+is+resistant"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-Kit whereas the kinase domain mutant D816VKit is resistant</span></div><div class="casAuthors">Frost, Michelle J.; Ferrao, Petranel T.; Hughes, Timothy P.; Ashman, Leonie K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1115-1124</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Imatinib (Glivec; STI571) is an ATP-competitive kinase inhibitor of c-Abl, BCR/ABL, c-Kit, and platelet-derived growth factor receptor.  Overexpression or constitutive activation of Kit by mutations have been assocd. with various malignancies.  Mutations in the intracellular juxtamembrane region of Kit (e.g., V560G) are common in gastrointestinal stromal tumors and have been linked to poor prognosis.  Mutations in the kinase domain of Kit (e.g., D816V) have been detected in mastocytosis, acute myeloid leukemia, and germ-cell tumors.  To det. the sensitivity of Kit mutants to Imatinib in the same cellular background, wild-type Kit (WTKit), V560GKit and D816VKit were expressed in FDC-P1 cells.  Growth of FDC(WTKit) was inhibited by Imatinib with GI50 (a concn. of drug at which 50% inhibition of growth occurs) of 0.1-0.2 Î¼M but FDC(V560GKit) were more sensitive to Imatinib with a GI50 of 0.01-0.025 Î¼M and FDC(D816VKit) were resistant to Imatinib with a GI50 greater than 5 Î¼M.  The naturally occurring isoforms of c-Kit did not differ in their sensitivity to Imatinib.  Immunopptn. and Western blot anal. indicated that 1 Î¼M Imatinib reduced phosphorylation of WTKit and completely blocked phosphorylation of V560GKit but did not affect D816VKit phosphorylation.  In signaling studies, addn. of stem cell factor (SCF) induced phosphorylation of ERK and Akt by WTKit, and ERK, Akt and STAT3 by V560GKit, which were all blocked by Imatinib.  Imatinib also blocked the constitutive activation of Akt and STAT3 by V560GKit but had no affect on the constitutive activation of ERK, Akt, and STAT3 by D816VKit.  Overall, these findings demonstrate the increased susceptibility of the Kit juxtamembrane mutant, V560G, and the resistance of the kinase domain mutant, D816V, to Imatinib compared with WTKit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ1dLhDZXIMLVg90H21EOLACvtfcHk0ljauvAiLRbB1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmtFamsQ%253D%253D&md5=21eb56cdb9bc2c99e921ec9bfdb7f9ca</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFrost%26aufirst%3DM.%2BJ.%26aulast%3DFerrao%26aufirst%3DP.%2BT.%26aulast%3DHughes%26aufirst%3DT.%2BP.%26aulast%3DAshman%26aufirst%3DL.%2BK.%26atitle%3DJuxtamembrane%2520mutant%2520V560G%2520Kit%2520is%2520more%2520sensitive%2520to%2520Imatinib%2520%2528STI571%2529%2520compared%2520with%2520wild-type%2520c-kit%2520whereas%2520the%2520kinase%2520domain%2520mutant%2520D816V%2520Kit%2520is%2520resistant%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2002%26volume%3D1%26spage%3D1115%26epage%3D1124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akin, C.</span><span> </span><span class="NLM_article-title">Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">286</span><span class="NLM_x">â</span> <span class="NLM_lpage">291</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2006&pages=286-291&author=N.+P.+Shahauthor=F.+Y.+Leeauthor=R.+Luoauthor=Y.+Jiangauthor=M.+Donkerauthor=C.+Akin&title=Dasatinib+%28BMS-354825%29+inhibits+KITD816V%2C+an+imatinib-resistant+activating+mutation+that+triggers+neoplastic+growth+in+most+patients+with+systemic+mastocytosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DLuo%26aufirst%3DR.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DDonker%26aufirst%3DM.%26aulast%3DAkin%26aufirst%3DC.%26atitle%3DDasatinib%2520%2528BMS-354825%2529%2520inhibits%2520KITD816V%252C%2520an%2520imatinib-resistant%2520activating%2520mutation%2520that%2520triggers%2520neoplastic%2520growth%2520in%2520most%2520patients%2520with%2520systemic%2520mastocytosis%26jtitle%3DBlood%26date%3D2006%26volume%3D108%26spage%3D286%26epage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Lierman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smits, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cools, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dewaele, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debiec Rychter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandenberghe, P.</span><span> </span><span class="NLM_article-title">Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1693</span><span class="NLM_x">â</span> <span class="NLM_lpage">1695</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=1693-1695&author=E.+Liermanauthor=S.+Smitsauthor=J.+Coolsauthor=B.+Dewaeleauthor=M.+Debiec+Rychterauthor=P.+Vandenberghe&title=Ponatinib+is+active+against+imatinib-resistant+mutants+of+FIP1L1-PDGFRA+and+KIT%2C+and+against+FGFR1-derived+fusion+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLierman%26aufirst%3DE.%26aulast%3DSmits%26aufirst%3DS.%26aulast%3DCools%26aufirst%3DJ.%26aulast%3DDewaele%26aufirst%3DB.%26aulast%3DDebiec%2BRychter%26aufirst%3DM.%26aulast%3DVandenberghe%26aufirst%3DP.%26atitle%3DPonatinib%2520is%2520active%2520against%2520imatinib-resistant%2520mutants%2520of%2520FIP1L1-PDGFRA%2520and%2520KIT%252C%2520and%2520against%2520FGFR1-derived%2520fusion%2520kinases%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D1693%26epage%3D1695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Knight, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span> </span><span class="NLM_article-title">Features of selective kinase inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">621</span><span class="NLM_x">â</span> <span class="NLM_lpage">637</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1016%2Fj.chembiol.2005.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=15975507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=621-637&author=Z.+A.+Knightauthor=K.+M.+Shokat&title=Features+of+selective+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Features of Selective Kinase Inhibitors</span></div><div class="casAuthors">Knight, Zachary A.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">621-637</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Summary: Small-mol. inhibitors of protein and lipid kinases have emerged as indispensable tools for studying signal transduction.  Despite the widespread use of these reagents, there is little consensus about the biochem. criteria that define their potency and selectivity in cells.  We discuss some of the features that det. the cellular activity of kinase inhibitors and propose a framework for interpreting inhibitor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAJWhVxtSrCLVg90H21EOLACvtfcHk0ljauvAiLRbB1g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsFGhtrc%253D&md5=ce5b3505a0326b04479172ec05573152</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2005.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2005.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DZ.%2BA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DFeatures%2520of%2520selective%2520kinase%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2005%26volume%3D12%26spage%3D621%26epage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Smyth, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Measuring and interpreting the selectivity of protein kinase inhibitors</span> <span class="citation_source-journal">J. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">â</span> <span class="NLM_lpage">151</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1007%2Fs12154-009-0023-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=19568781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A280%3ADC%252BD1MrkslGqtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=131-151&author=L.+A.+Smythauthor=I.+Collins&title=Measuring+and+interpreting+the+selectivity+of+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Measuring and interpreting the selectivity of protein kinase inhibitors</span></div><div class="casAuthors">Smyth Lynette A; Collins Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of chemical biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">131-51</span>
        ISSN:<span class="NLM_cas:issn">1864-6158</span>.
    </div><div class="casAbstract">Protein kinase inhibitors are a well-established class of clinically useful drugs, particularly for the treatment of cancer.  Achieving inhibitor selectivity for particular protein kinases often remains a significant challenge in the development of new small molecules as drugs or as tools for chemical biology research.  This review summarises the methodologies available for measuring kinase inhibitor selectivity, both in vitro and in cells.  The interpretation of kinase inhibitor selectivity data is discussed, particularly with reference to the structural biology of the protein targets.  Measurement and prediction of kinase inhibitor selectivity will be important for the development of new multi-targeted kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzU9rA5WZcz9FxYDaSSP8XfW6udTcc2ebbDjMLHObbJ7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrkslGqtA%253D%253D&md5=f78ff1202a949a71ffd65e804298c37f</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1007%2Fs12154-009-0023-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12154-009-0023-9%26sid%3Dliteratum%253Aachs%26aulast%3DSmyth%26aufirst%3DL.%2BA.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DMeasuring%2520and%2520interpreting%2520the%2520selectivity%2520of%2520protein%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D2%26spage%3D131%26epage%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Hasinoff, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâHara, K. A.</span><span> </span><span class="NLM_article-title">Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1722</span><span class="NLM_x">â</span> <span class="NLM_lpage">1728</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2008&pages=1722-1728&author=B.+B.+Hasinoffauthor=D.+Patelauthor=K.+A.+O%E2%80%99Hara&title=Mechanisms+of+myocyte+cytotoxicity+induced+by+the+multiple+receptor+tyrosine+kinase+inhibitor+sunitinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHasinoff%26aufirst%3DB.%2BB.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Hara%26aufirst%3DK.%2BA.%26atitle%3DMechanisms%2520of%2520myocyte%2520cytotoxicity%2520induced%2520by%2520the%2520multiple%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520sunitinib%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D74%26spage%3D1722%26epage%3D1728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crespo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">FernÃ¡ndez, A.</span><span> </span><span class="NLM_article-title">Turning promiscuous kinase inhibitors into safer drugs</span> <span class="citation_source-journal">Trends Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">295</span><span class="NLM_x">â</span> <span class="NLM_lpage">301</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=295-301&author=X.+Zhangauthor=A.+Crespoauthor=A.+Fern%C3%A1ndez&title=Turning+promiscuous+kinase+inhibitors+into+safer+drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DCrespo%26aufirst%3DA.%26aulast%3DFern%25C3%25A1ndez%26aufirst%3DA.%26atitle%3DTurning%2520promiscuous%2520kinase%2520inhibitors%2520into%2520safer%2520drugs%26jtitle%3DTrends%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D295%26epage%3D301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Verheul, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinedo, H. M.</span><span> </span><span class="NLM_article-title">Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition</span> <span class="citation_source-journal">Nature Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">475</span><span class="NLM_x">â</span> <span class="NLM_lpage">485</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16e&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1038%2Fnrc2152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16e&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=17522716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16e&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD2sXls1Kjsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=475-485&author=H.+M.+Verheulauthor=H.+M.+Pinedo&title=Possible+molecular+mechanisms+involved+in+the+toxicity+of+angiogenesis+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16eR"><div class="casContent"><span class="casTitleNuber">16e</span><div class="casTitle"><span class="NLM_cas:atitle">Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition</span></div><div class="casAuthors">Verheul, Henk. M. W.; Pinedo, Herbert M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">475-485</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Contrary to initial expectations, angiogenesis inhibitors can cause toxicities in patients with cancer.  The toxicity profiles of these inhibitors reflect the disturbance of growth factor signaling pathways that are important for maintaining homeostasis.  Experiences with angiogenesis inhibitors in clin. trials indicate that short-term toxicities are mostly manageable.  However, these agents will also be given in prolonged treatment strategies, so we need to anticipate possible long-term toxicities.  In addn., understanding the mol. mechanisms involved in the toxicity of angiogenesis inhibition should allow more specific and more potent inhibitors to be developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZf_zBF-HferVg90H21EOLACvtfcHk0lhwFv7axP-G8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1Kjsb4%253D&md5=3754e28af3f27b0c68c08bc9ee129ffd</span></div><a href="/servlet/linkout?suffix=cit16e&amp;dbid=16384&amp;doi=10.1038%2Fnrc2152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2152%26sid%3Dliteratum%253Aachs%26aulast%3DVerheul%26aufirst%3DH.%2BM.%26aulast%3DPinedo%26aufirst%3DH.%2BM.%26atitle%3DPossible%2520molecular%2520mechanisms%2520involved%2520in%2520the%2520toxicity%2520of%2520angiogenesis%2520inhibition%26jtitle%3DNature%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D475%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small moleculeâkinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">â</span> <span class="NLM_lpage">336</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Bendettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule%E2%80%93kinase+interaction+map+for+clinical+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lhwFv7axP-G8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBendetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule%25E2%2580%2593kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNature%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span> </span><span class="NLM_article-title">Discovery of new azaindole-based PI3KÎ± inhibitors: apoptotic and antiangiogenic effect on cancer cells</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">7212</span><span class="NLM_x">â</span> <span class="NLM_lpage">7215</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7212-7215&author=S.+Hongauthor=S.+Leeauthor=B.+Kimauthor=H.+Leeauthor=S.-S.+Hongauthor=S.+Hong&title=Discovery+of+new+azaindole-based+PI3K%CE%B1+inhibitors%3A+apoptotic+and+antiangiogenic+effect+on+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DHong%26aufirst%3DS.-S.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520new%2520azaindole-based%2520PI3K%25CE%25B1%2520inhibitors%253A%2520apoptotic%2520and%2520antiangiogenic%2520effect%2520on%2520cancer%2520cells%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7212%26epage%3D7215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span> </span><span class="NLM_article-title">Design, synthesis and evaluation of 3,5-disubstituted 7-azaindoles as Trk inhibitors with anticancer and anti-angiogenic activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5337</span><span class="NLM_x">â</span> <span class="NLM_lpage">5349</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3002982" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5337-5349&author=S.+Hongauthor=J.+Kimauthor=J.+Seoauthor=K.+Jungauthor=S.-S.+Hongauthor=S.+Hong&title=Design%2C+synthesis+and+evaluation+of+3%2C5-disubstituted+7-azaindoles+as+Trk+inhibitors+with+anticancer+and+anti-angiogenic+activities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1021%2Fjm3002982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3002982%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSeo%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DK.%26aulast%3DHong%26aufirst%3DS.-S.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDesign%252C%2520synthesis%2520and%2520evaluation%2520of%25203%252C5-disubstituted%25207-azaindoles%2520as%2520Trk%2520inhibitors%2520with%2520anticancer%2520and%2520anti-angiogenic%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5337%26epage%3D5349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Knight, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaudhari, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darcy, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donatelli, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luengo, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newlander, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parrish, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ridgers, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarpong, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Aller, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamond, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkins, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardiner, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garver, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gontarek, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kershner, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raha, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherk, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tummino, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wegrzyn, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auger, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhanak, D.</span><span> </span><span class="NLM_article-title">Discovery of GSK2126458, a Highly potent inhibitor of PI3K and the mammalian target of rapamycin</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">39</span><span class="NLM_x">â</span> <span class="NLM_lpage">43</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml900028r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmvF2qtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=39-43&author=S.+D.+Knightauthor=N.+D.+Adamsauthor=J.+L.+Burgessauthor=A.+M.+Chaudhariauthor=M.+G.+Darcyauthor=C.+A.+Donatelliauthor=J.+I.+Luengoauthor=K.+A.+Newlanderauthor=C.+A.+Parrishauthor=L.+H.+Ridgersauthor=M.+A.+Sarpongauthor=S.+J.+Schmidtauthor=G.+S.+Van+Allerauthor=J.+D.+Carsonauthor=M.+A.+Diamondauthor=P.+A.+Elkinsauthor=C.+M.+Gardinerauthor=E.+Garverauthor=S.+A.+Gilbertauthor=R.+R.+Gontarekauthor=J.+R.+Jacksonauthor=K.+L.+Kershnerauthor=L.+Luoauthor=K.+Rahaauthor=C.+S.+Sherkauthor=C.+M.+Sungauthor=D.+Suttonauthor=P.+J.+Tumminoauthor=R.+J.+Wegrzynauthor=K.+R.+Augerauthor=D.+Dhanak&title=Discovery+of+GSK2126458%2C+a+Highly+potent+inhibitor+of+PI3K+and+the+mammalian+target+of+rapamycin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin</span></div><div class="casAuthors">Knight, Steven D.; Adams, Nicholas D.; Burgess, Joelle L.; Chaudhari, Amita M.; Darcy, Michael G.; Donatelli, Carla A.; Luengo, Juan I.; Newlander, Ken A.; Parrish, Cynthia A.; Ridgers, Lance H.; Sarpong, Martha A.; Schmidt, Stanley J.; Van Aller, Glenn S.; Carson, Jeffrey D.; Diamond, Melody A.; Elkins, Patricia A.; Gardiner, Christine M.; Garver, Eric; Gilbert, Seth A.; Gontarek, Richard R.; Jackson, Jeffrey R.; Kershner, Kevin L.; Luo, Lusong; Raha, Kaushik; Sherk, Christian S.; Sung, Chiu-Mei; Sutton, David; Tummino, Peter J.; Wegrzyn, Ronald J.; Auger, Kurt R.; Dhanak, Dashyant</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-43</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase Î± (PI3KÎ±) is a crit. regulator of cell growth and transformation, and its signaling pathway is the most commonly mutated pathway in human cancers.  The mammalian target of rapamycin (mTOR), a class IV PI3K protein kinase, is also a central regulator of cell growth, and mTOR inhibitors are believed to augment the antiproliferative efficacy of PI3K/AKT pathway inhibition. 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide (GSK2126458, 1 (I)) has been identified as a highly potent, orally bioavailable inhibitor of PI3KÎ± and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models.  Compd. 1 is currently being evaluated in human clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBH6_ywCnjCrVg90H21EOLACvtfcHk0ljMkQBvZMKThA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmvF2qtw%253D%253D&md5=72fcca85702dba95529ac03281e0bdbc</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fml900028r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml900028r%26sid%3Dliteratum%253Aachs%26aulast%3DKnight%26aufirst%3DS.%2BD.%26aulast%3DAdams%26aufirst%3DN.%2BD.%26aulast%3DBurgess%26aufirst%3DJ.%2BL.%26aulast%3DChaudhari%26aufirst%3DA.%2BM.%26aulast%3DDarcy%26aufirst%3DM.%2BG.%26aulast%3DDonatelli%26aufirst%3DC.%2BA.%26aulast%3DLuengo%26aufirst%3DJ.%2BI.%26aulast%3DNewlander%26aufirst%3DK.%2BA.%26aulast%3DParrish%26aufirst%3DC.%2BA.%26aulast%3DRidgers%26aufirst%3DL.%2BH.%26aulast%3DSarpong%26aufirst%3DM.%2BA.%26aulast%3DSchmidt%26aufirst%3DS.%2BJ.%26aulast%3DVan%2BAller%26aufirst%3DG.%2BS.%26aulast%3DCarson%26aufirst%3DJ.%2BD.%26aulast%3DDiamond%26aufirst%3DM.%2BA.%26aulast%3DElkins%26aufirst%3DP.%2BA.%26aulast%3DGardiner%26aufirst%3DC.%2BM.%26aulast%3DGarver%26aufirst%3DE.%26aulast%3DGilbert%26aufirst%3DS.%2BA.%26aulast%3DGontarek%26aufirst%3DR.%2BR.%26aulast%3DJackson%26aufirst%3DJ.%2BR.%26aulast%3DKershner%26aufirst%3DK.%2BL.%26aulast%3DLuo%26aufirst%3DL.%26aulast%3DRaha%26aufirst%3DK.%26aulast%3DSherk%26aufirst%3DC.%2BS.%26aulast%3DSung%26aufirst%3DC.%2BM.%26aulast%3DSutton%26aufirst%3DD.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DWegrzyn%26aufirst%3DR.%2BJ.%26aulast%3DAuger%26aufirst%3DK.%2BR.%26aulast%3DDhanak%26aufirst%3DD.%26atitle%3DDiscovery%2520of%2520GSK2126458%252C%2520a%2520Highly%2520potent%2520inhibitor%2520of%2520PI3K%2520and%2520the%2520mammalian%2520target%2520of%2520rapamycin%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D39%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span> </span><span class="NLM_article-title">Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2455</span><span class="NLM_x">â</span> <span class="NLM_lpage">2466</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2455-2466&author=S.+Hongauthor=J.+Kimauthor=J.+H.+Seoauthor=K.+H.+Jungauthor=S.+S.+Hongauthor=S.+Hong&title=Design+and+synthesis+of+imidazopyridine+analogues+as+inhibitors+of+phosphoinositide+3-kinase+signaling+and+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26aulast%3DJung%26aufirst%3DK.%2BH.%26aulast%3DHong%26aufirst%3DS.%2BS.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520imidazopyridine%2520analogues%2520as%2520inhibitors%2520of%2520phosphoinositide%25203-kinase%2520signaling%2520and%2520angiogenesis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2455%26epage%3D2466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span> </span><span class="NLM_article-title">Selectivity enhancement arising from interactions at the PI3K unique pocket</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1379</span><span class="NLM_x">â</span> <span class="NLM_lpage">1383</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1379-1383&author=S.+Hongauthor=J.+Kimauthor=J.+H.+Seoauthor=K.+H.+Jungauthor=S.+S.+Hongauthor=S.+Hong&title=Selectivity+enhancement+arising+from+interactions+at+the+PI3K+unique+pocket"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26aulast%3DJung%26aufirst%3DK.%2BH.%26aulast%3DHong%26aufirst%3DS.%2BS.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DSelectivity%2520enhancement%2520arising%2520from%2520interactions%2520at%2520the%2520PI3K%2520unique%2520pocket%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D1379%26epage%3D1383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Jeong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span> </span><span class="NLM_article-title">Selective and Potent Small-Molecule Inhibitors of Phosphatidylinositol 3-Kinases</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">737</span><span class="NLM_x">â</span> <span class="NLM_lpage">756</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.4155%2Ffmc.14.28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20c&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvFCrsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=737-756&author=Y.+Jeongauthor=D.+Kwonauthor=S.+Hong&title=Selective+and+Potent+Small-Molecule+Inhibitors+of+Phosphatidylinositol+3-Kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20cR"><div class="casContent"><span class="casTitleNuber">20c</span><div class="casTitle"><span class="NLM_cas:atitle">Selective and potent small-molecule inhibitors of PI3Ks</span></div><div class="casAuthors">Jeong, Yujeong; Kwon, Daeil; Hong, Sungwoo</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">737-756</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Class I PI3Ks are composed of four catalytic subunit variants (p110Î±, p110Î², p110Î´ and p110Î³).  The PI3K pathway is among the most frequently activated pathways in many diseases, and has emerged as an attractive target for drug development, in particular for the treatment of many human cancers including breast, prostate, ovarian, gastric, colon and hepatocellular cancers.  One of the challenges in the discovery of drugs that target kinases is designing small-mol. inhibitors that are sufficiently selective to minimize off-target activity and reduce the risk of potential toxicity.  This review explores the current landscape of PI3K-selective inhibitor development and highlights recent advances in achieving selectivity for PI3Ks over other protein kinases, with an emphasis on available structural information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9ZY08eojS4bVg90H21EOLACvtfcHk0ljMkQBvZMKThA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvFCrsb0%253D&md5=f683c444e4bfb9e325a43819617b39d3</span></div><a href="/servlet/linkout?suffix=cit20c&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.28%26sid%3Dliteratum%253Aachs%26aulast%3DJeong%26aufirst%3DY.%26aulast%3DKwon%26aufirst%3DD.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DSelective%2520and%2520Potent%2520Small-Molecule%2520Inhibitors%2520of%2520Phosphatidylinositol%25203-Kinases%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2014%26volume%3D6%26spage%3D737%26epage%3D756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">VendÃ´me, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svinarchuk, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubreuil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auclair, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Bret, M.</span><span> </span><span class="NLM_article-title">Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">6194</span><span class="NLM_x">â</span> <span class="NLM_lpage">6201</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm050231m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6194-6201&author=J.+Vend%C3%B4meauthor=S.+Letardauthor=F.+Martinauthor=F.+Svinarchukauthor=P.+Dubreuilauthor=C.+Auclairauthor=M.+Le+Bret&title=Molecular+modeling+of+wild-type+and+D816V+c-Kit+inhibition+based+on+ATP-competitive+binding+of+ellipticine+derivatives+to+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm050231m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050231m%26sid%3Dliteratum%253Aachs%26aulast%3DVend%25C3%25B4me%26aufirst%3DJ.%26aulast%3DLetard%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DF.%26aulast%3DSvinarchuk%26aufirst%3DF.%26aulast%3DDubreuil%26aufirst%3DP.%26aulast%3DAuclair%26aufirst%3DC.%26aulast%3DLe%2BBret%26aufirst%3DM.%26atitle%3DMolecular%2520modeling%2520of%2520wild-type%2520and%2520D816V%2520c-Kit%2520inhibition%2520based%2520on%2520ATP-competitive%2520binding%2520of%2520ellipticine%2520derivatives%2520to%2520tyrosine%2520kinases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6194%26epage%3D6201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Mol, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nowakowski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McRee, D. E.</span><span> </span><span class="NLM_article-title">Structure of a c-Kit product complex reveals the basis for kinase transactivation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">31461</span><span class="NLM_x">â</span> <span class="NLM_lpage">31464</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1074%2Fjbc.C300186200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=12824176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsVOnsb0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=31461-31464&author=C.+D.+Molauthor=K.+B.+Limauthor=V.+Sridharauthor=H.+Zouauthor=E.+Y.+Chienauthor=B.+C.+Sangauthor=J.+Nowakowskiauthor=D.+B.+Kasselauthor=C.+N.+Croninauthor=D.+E.+McRee&title=Structure+of+a+c-Kit+product+complex+reveals+the+basis+for+kinase+transactivation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of a c-Kit Product Complex Reveals the Basis for Kinase Transactivation</span></div><div class="casAuthors">Mol, Clifford D.; Lim, Kheng B.; Sridhar, Vandana; Zou, Hua; Chien, Ellen Y. T.; Sang, Bi-Ching; Nowakowski, Jacek; Kassel, Daniel B.; Cronin, Ciaran N.; McRee, Duncan E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">31461-31464</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The c-Kit proto-oncogene is a receptor protein-tyrosine kinase assocd. with several highly malignant human cancers.  Upon binding its ligand, stem cell factor (SCF), c-Kit forms an active dimer that autophosphorylates itself and activates a signaling cascade that induces cell growth.  Disease-causing human mutations that activate SCF-independent constitutive expression of c-Kit are found in acute myelogenous leukemia, human mast cell disease, and gastrointestinal stromal tumors.  We report on the phosphorylation state and crystal structure of a c-Kit product complex.  The c-Kit structure is in a fully active form, with ordered kinase activation and phosphate-binding loops.  These results provide key insights into the mol. basis for c-Kit kinase transactivation to assist in the design of new competitive inhibitors targeting activated mutant forms of c-Kit that are resistant to current chemotherapy regimes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv0eZJ9UHNILVg90H21EOLACvtfcHk0lj3r7nRX4XOfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsVOnsb0%253D&md5=f537b5c9903adb6cc057406bd20f0f5a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C300186200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C300186200%26sid%3Dliteratum%253Aachs%26aulast%3DMol%26aufirst%3DC.%2BD.%26aulast%3DLim%26aufirst%3DK.%2BB.%26aulast%3DSridhar%26aufirst%3DV.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChien%26aufirst%3DE.%2BY.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DNowakowski%26aufirst%3DJ.%26aulast%3DKassel%26aufirst%3DD.%2BB.%26aulast%3DCronin%26aufirst%3DC.%2BN.%26aulast%3DMcRee%26aufirst%3DD.%2BE.%26atitle%3DStructure%2520of%2520a%2520c-Kit%2520product%2520complex%2520reveals%2520the%2520basis%2520for%2520kinase%2520transactivation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D31461%26epage%3D31464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Nolen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, G.</span><span> </span><span class="NLM_article-title">Regulation of protein kinases: controlling activity through activation segment conformation</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">661</span><span class="NLM_x">â</span> <span class="NLM_lpage">675</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1016%2Fj.molcel.2004.08.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm500413g&amp;key=15350212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFyhsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=661-675&author=B.+Nolenauthor=S.+Taylorauthor=G.+Ghosh&title=Regulation+of+protein+kinases%3A+controlling+activity+through+activation+segment+conformation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of protein kinases: Controlling activity through activation segment conformation</span></div><div class="casAuthors">Nolen, Brad; Taylor, Susan; Ghosh, Gourisankar</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">661-675</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  There are currently at least 46 unique protein kinase crystal structures, 24 of which are available in an active state.  Here, the authors examine these structures using a structural bioinformatics approach to understand how the conformation of the activation segment controls kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAdRcy6kkUnbVg90H21EOLACvtfcHk0lj3r7nRX4XOfw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFyhsro%253D&md5=e1fc9a323c271a856ccd944a77c83a7f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2004.08.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2004.08.024%26sid%3Dliteratum%253Aachs%26aulast%3DNolen%26aufirst%3DB.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DG.%26atitle%3DRegulation%2520of%2520protein%2520kinases%253A%2520controlling%2520activity%2520through%2520activation%2520segment%2520conformation%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D15%26spage%3D661%26epage%3D675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, L.</span><span> </span><span class="NLM_article-title">LigBuilder: a multi-purpose program for structure-based drug design</span> <span class="citation_source-journal">J. Mol. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">498</span><span class="NLM_x">â</span> <span class="NLM_lpage">516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1007%2Fs0089400060498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVemtLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=498-516&author=R.+Wangauthor=Y.+Gaoauthor=L.+Lai&title=LigBuilder%3A+a+multi-purpose+program+for+structure-based+drug+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">LigBuilder: a multi-purpose program for structure-based drug design</span></div><div class="casAuthors">Wang, Renxiao; Gao, Ying; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling [online computer file]</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">498-516</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">The authors have developed a new multi-purpose program, LigBuilder, for structure-based drug design.  Within the structural constraints of the target protein, LigBuilder builds up ligands step by step using a library of org. fragments.  Various operations, such as growing, linking, and mutation, were implemented to manipulate mol. structures.  The user can choose either growing or linking strategies for ligand construction and a genetic algorithm is adopted to control the whole construction process.  Binding affinities of the ligands are estd. by an empirical scoring function and the bioavailabilities are evaluated by a set of chem. rules.  Using thrombin and dihydrofolate reductase as examples, the authors have demonstrated that LigBuilder is able to generate chem. structures similar to the known ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSJoH1AEzJDbVg90H21EOLACvtfcHk0lhgpUNN9eg5Qg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVemtLo%253D&md5=0edc2bb21366e6fad52fc6b0e1c52552</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2Fs0089400060498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs0089400060498%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DLigBuilder%253A%2520a%2520multi-purpose%2520program%2520for%2520structure-based%2520drug%2520design%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D2000%26volume%3D6%26spage%3D498%26epage%3D516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Wang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, L.</span><span> </span><span class="NLM_article-title">SCORE: A new empirical method for estimating the binding affinity of a proteinâligand complex</span> <span class="citation_source-journal">J. Mol. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">379</span><span class="NLM_x">â</span> <span class="NLM_lpage">394</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm500413g&amp;key=10.1007%2Fs008940050096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm500413g&amp;key=1%3ACAS%3A528%3ADyaK1MXntFSiug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1998&pages=379-394&author=R.+Wangauthor=L.+Liuauthor=L.+Lai&title=SCORE%3A+A+new+empirical+method+for+estimating+the+binding+affinity+of+a+protein%E2%80%93ligand+complex"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">SCORE: A new empirical method for estimating the binding affinity of a protein-ligand complex</span></div><div class="casAuthors">Wang, Renxiao; Liu, Liang; Lai, Luhua; Tang, Youqi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Modeling [Electronic Publication]</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">379-394</span>CODEN:
                <span class="NLM_cas:coden">JMMOFK</span>;
        ISSN:<span class="NLM_cas:issn">0948-5023</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A new method is presented to est. the binding affinity of a protein-ligand complex with known three-dimensional structure.  The method, SCORE, uses an empirical scoring function to describe the binding free energy, which includes terms to account for van der Waals contact, metal-ligand bonding, hydrogen bonding, desolvation effect, and deformation penalty upon the binding process.  The coeffs. of each term are obtained by multivariate regressional anal. of a diverse training set of 170 protein-ligand complexes.  The final scoring function reproduces the binding free energies of the whole training set with a cross-validated deviation of 6.3 kJ/mol.  The predictive ability of the function is further tested by a set of 11 endothiapepsin complexes and the internal consistency of the function is demonstrated in a stepwise procedure named Evolutionary Test.  A major innovation of this method is the introduction of an at. binding score which allows the researcher to inspect and optimize the lead compd. rationally in a structure-based drug design scheme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqImu0miXYf7Vg90H21EOLACvtfcHk0lhgpUNN9eg5Qg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFSiug%253D%253D&md5=057012f22eb084d0c754b7e4ae6cc87f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs008940050096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs008940050096%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DSCORE%253A%2520A%2520new%2520empirical%2520method%2520for%2520estimating%2520the%2520binding%2520affinity%2520of%2520a%2520protein%25E2%2580%2593ligand%2520complex%26jtitle%3DJ.%2520Mol.%2520Model.%26date%3D1998%26volume%3D4%26spage%3D379%26epage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="note"><p class="first last">The IC<sub>50</sub> determinations were performed at the Reaction Biology Corp. (Malvern, PA, USA). POC determinations were performed at the Ambit Bioscience Corp. (San Diego, CA, USA).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T45" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T45','PDB','1T45'); return false;">PDB: 1T45</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i65"><a href="/doi/suppl/10.1021/jm500413g">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_86277"></div></div></div></div></div><hr /></hr><p class="last">Spectra, rescoring of the generated 7-azaindole derivatives, kinase selectivity profiling, and physicochemical properties predicted by Accelrys DB.  This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm500413g/suppl_file/jm500413g_si_001.pdf">jm500413g_si_001.pdf (6.27 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm500413g&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-15%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm500413g%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm500413g" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67996237d88b23f8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
